image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
9bcc43e21971cfe013795a0207dc40f562af160c61da3a6913c8b05b51bbc2a8.png | simple | <table><tr><td><i>MBL2</i></td><td>SCA N = 126 (%)</td><td>FVOE ≥ 1 N = 68 (%)</td><td>FVOE < 1 N = 58 (%)</td><td><i>p</i></td><td>OR</td><td>95%CI</td></tr><tr><td>Promoter SNP −550</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LL</td><td>76 (0.60)</td><td>47 (0.69)</td><td>29 (0.50)</td><td>Reference</td><td></td><td></td></tr><tr><td>HL</td><td>42 (0.33)</td><td>17 (0.25)</td><td>25 (0.43)</td><td>0.0129*</td><td>2.38</td><td>1.10–5.15</td></tr><tr><td>HH</td><td>08 (0.07)</td><td>04 (0.06)</td><td>04 (0.07)</td><td>0.3856</td><td>1.62</td><td>0.37-6.98</td></tr><tr><td>L</td><td>194 (0.77)</td><td>111 (0.82)</td><td>83 (0.72)</td><td>Reference</td><td></td><td></td></tr><tr><td>H</td><td>58 (0.33)</td><td>25 (0.18)</td><td>33 (0.28)</td><td>0.0292*</td><td>1.76</td><td>0.97-3.19</td></tr><tr><td>Promoter SNP −221</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>YY</td><td>86 (0.68)</td><td>42 (0.62)</td><td>44 (0.76)</td><td>Reference</td><td></td><td></td></tr><tr><td>YX</td><td>37 (0.29)</td><td>25 (0.37)</td><td>12 (0.21)</td><td>0.0279*</td><td>0.46</td><td>0.20-1.03</td></tr><tr><td>XX</td><td>03 (0.03)</td><td>01 (0.01)</td><td>02 (0.03)</td><td>0.5256</td><td>1.90</td><td>0.16-21.86</td></tr><tr><td>Y</td><td>209 (0.83)</td><td>109 (0.80)</td><td>100 (0.86)</td><td>Reference</td><td></td><td></td></tr><tr><td>X</td><td>43 (0.17)</td><td>27 (0.20)</td><td>16 (0.14)</td><td>0.1012</td><td>0.64</td><td>0.32-1.13</td></tr><tr><td>Exon 1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>AA</td><td>87 (0.69)</td><td>44 (0.65)</td><td>43 (0.74)</td><td>Reference</td><td></td><td></td></tr><tr><td>AO</td><td>37 (0.29)</td><td>23 (0.34)</td><td>14 (0.24)</td><td>0.1181</td><td>0.62</td><td>0.28-1.36</td></tr><tr><td>OO</td><td>02 (0.02)</td><td>01 (0.01)</td><td>01 (0.02)</td><td>0.7472</td><td>1.02</td><td>0.06-16.90</td></tr><tr><td>A</td><td>211 (0.84)</td><td>111 (0.82)</td><td>100 (0.86)</td><td>Reference</td><td></td><td></td></tr><tr><td>O</td><td>41 (0.16)</td><td>25 (0.18)</td><td>16 (0.14)</td><td>0.1626</td><td>0.71</td><td>0.36-1.14</td></tr><tr><td>Haplotypes of MBL2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>High (HYA + LYA)</td><td>168 (0.67)</td><td>84 (0.62)</td><td>84 (0.72)</td><td>Reference</td><td></td><td></td></tr><tr><td>Intermediate (LXA)</td><td>43 (0.17)</td><td>27 (0.20)</td><td>16 (0.14)</td><td>0.0670</td><td>0.59</td><td>0.29-1.18</td></tr><tr><td>Low (HYO + LYO)</td><td>41 (0.16)</td><td>25 (0.18)</td><td>16 (0.14)</td><td>0.1036</td><td>1.56</td><td>0.77-3.13</td></tr><tr><td>Combined genotypes (diplotypes) of MBL2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>High</td><td>57 (0.45)</td><td>27 (0.40)</td><td>30 (0.52)</td><td>Reference</td><td></td><td></td></tr><tr><td>Intermediate</td><td>57 (0.45)</td><td>31 (0.46)</td><td>26 (0.45)</td><td>0.2268</td><td>1.31</td><td>0.61–2.82</td></tr><tr><td>Low</td><td>12 (0.10)</td><td>10 (0.14)</td><td>02 (0.03)</td><td>0.0229**</td><td>5.55</td><td>1.11–27.66</td></tr></table> |
6a49b81ab7e7f7f8f9543b9389e68213f6ea0b3fa0595dbc05b4afc1a7da6e19.png | simple | <table><tr><td>Mineral intake per day</td><td>RDA [11]</td><td>Fast finishers</td><td>Slow finishers</td></tr><tr><td>Calcium (mg.day<sup>−1</sup>)</td><td>1,000 mg (M, F)</td><td>848.7 ± 137.6</td><td>872.4 ± 260.5</td></tr><tr><td>Phosphorus (mg.day<sup>−1</sup>)</td><td>700 mg (M, F)</td><td>1,859.3 ± 781.4*</td><td>717.9 ± 200.2</td></tr><tr><td>Iron (mg.day<sup>−1</sup>)</td><td>8 mg (M), 18 mg (F)</td><td>8.1 ± 3.6</td><td>5.8 ± 2.0</td></tr><tr><td>Sodium (mg.day<sup>−1</sup>)</td><td>1,500 mg (M, F)</td><td>343.2 ± 38.4</td><td>3,769.4 ± 1,764.1*</td></tr><tr><td>Potassium (mg.day<sup>−1</sup>)</td><td>4,700 mg (M, F)</td><td>1,747.2 ± 845.4*</td><td>531.5 ± 152.3</td></tr><tr><td>Magnesium (mg.day<sup>−1</sup>)</td><td>420 mg (M), 320 mg (F)</td><td>852.6 ± 407.7*</td><td>215.2 ± 73.9</td></tr><tr><td>Copper (mg.day<sup>−1</sup>)</td><td>0.9 mg (M, F)</td><td>3.8 ± 1.8*</td><td>0.9 ± 0.3</td></tr><tr><td>Manganese (mg.day<sup>−1</sup>)</td><td>2.3 mg (M), 1.8 mg (F)</td><td>3.3 ± 1.5</td><td>4.8 ± 1.6</td></tr></table> |
edd6f2ce71f9a3210df314e090d0a95f2a47d6a25ccf2495b3bb7e644652372e.png | simple | <table><tr><td>INVERSION</td><td>SIZE (Mb)</td><td>GENOMIC DISORDER/REARRANGEMENT</td><td>REFERENCE</td></tr><tr><td>inv(3)(q29)</td><td>1.9</td><td>3q29 microdeletion syndrome</td><td>[29]</td></tr><tr><td>inv(5)(q35)</td><td>1.3</td><td>Sotos syndrome</td><td>[30]</td></tr><tr><td>inv(7)(q11.23)</td><td>1.8</td><td>Williams-Beuren syndrome</td><td>[31]</td></tr><tr><td>inv(8)(p23)</td><td>4.7</td><td>8p23 microdeletion syndrome</td><td>[32]</td></tr><tr><td>inv(15)(q11q13)</td><td>4</td><td>Angelman syndrome</td><td>[12]</td></tr><tr><td>inv(15)(q13.3)</td><td>2</td><td>15q13.3 deletion syndrome</td><td>[33]</td></tr><tr><td>inv(17)(q12)</td><td>1.5</td><td>RCAD syndrome</td><td>[29]</td></tr><tr><td>inv(17)(q21.31)</td><td>0.9</td><td>17q21.21 deletion syndrome</td><td>[34]</td></tr></table> |
b5850e3dc88d721dc6aa8ed71648e42d1227da7e85f0bb6bde00c710415697c1.png | simple | <table><tr><td>Type of Nasal-Spray Container (group)</td><td>Positive Cultures (No.)</td><td>Negative Cultures (No.)</td><td>Total</td></tr><tr><td>1 (Cap-off)</td><td>3</td><td>63</td><td>66</td></tr><tr><td>2 (Cap-on)</td><td>1</td><td>65</td><td>66</td></tr><tr><td>3 (Control)</td><td>0</td><td>66</td><td>66</td></tr><tr><td>Total</td><td>4</td><td>194</td><td>198</td></tr></table> |
79184ea42a1d1d718e947a1d2e4908d33fb029911bf1b410a00b48596a2f5994.png | complex | <table><tr><td></td><td colspan="3">Smoking cohort</td><td colspan="3">All clients/comparisons</td></tr><tr><td rowspan="2">Characteristics</td><td>Comparisons (<i>n</i> = 7701)</td><td>Clients (<i>n</i> = 2595)</td><td><i>p-</i>value</td><td>Controls (<i>n</i> = 33,384)</td><td>Clients (<i>n</i> = 8986)</td><td rowspan="2"><i>p-</i>value</td></tr><tr><td>%</td><td>%</td><td></td><td>%</td><td>%</td></tr><tr><td>Age, less than 18 years</td><td>28.9</td><td>24.2</td><td><0.01</td><td>18.6</td><td>22.1</td><td><0.01</td></tr><tr><td colspan="7">Race/ethnicity</td></tr><tr><td> White</td><td>75.3</td><td>75.2</td><td></td><td>50.9</td><td>50.3</td><td></td></tr><tr><td> Black</td><td>12.9</td><td>13.8</td><td></td><td>25.3</td><td>25.9</td><td></td></tr><tr><td> Hispanic</td><td>10.5</td><td>10.2</td><td></td><td>20.9</td><td>21.3</td><td></td></tr><tr><td> Other</td><td>1.4</td><td>0.8</td><td>0.08</td><td>2.9</td><td>2.6</td><td>0.22</td></tr><tr><td>Unmarried</td><td>93.8</td><td>92.5</td><td>0.03</td><td>89.8</td><td>88.9</td><td>0.01</td></tr><tr><td>Education, less than high school</td><td>36.7</td><td>38.2</td><td>0.19</td><td>30.5</td><td>31.2</td><td>0.20</td></tr><tr><td>TANF Receipt</td><td>57.1</td><td>54.0</td><td>0.01</td><td>49.6</td><td>50.4</td><td>0.18</td></tr><tr><td>Foodstamp Receipt</td><td>59.8</td><td>60.1</td><td>0.76</td><td>48.9</td><td>47.2</td><td><0.01</td></tr></table> |
23872d321a89650197ab4f4601f24562cbe208850026143ec569fb91149b6803.png | complex | <table><tr><td></td><td colspan="2">Test A versus B</td><td colspan="2">Test B versus C</td></tr><tr><td></td><td>Medially loaded</td><td>Laterally loaded</td><td>Medially loaded</td><td>Laterally loaded</td></tr><tr><td>Proximal migration</td><td>0.04</td><td>0.04</td><td>0.04</td><td>0.04</td></tr><tr><td>Varus rotation</td><td>0.2</td><td>0.3</td><td>0.04</td><td>0.04</td></tr><tr><td>Flexion tilt</td><td>0.9</td><td>0.1</td><td>0.04</td><td>0.04</td></tr></table> |
0684fd1020cd9625d00a81afc9651d59ff18b153698c74d0739a91a1534e38e9.png | simple | <table><tr><td>Macronutrient</td><td>Source</td><td>Content at 20 kcal/fl oz (g/L)</td><td>Content at 30 kcal/fl oz (g/L)</td></tr><tr><td>Protein equivalent</td><td>100% free L-amino acids</td><td>20.3</td><td>30.1</td></tr><tr><td>Carbohydrate</td><td>100% corn syrup solids</td><td>72.3</td><td>107.0</td></tr><tr><td>Fat</td><td>38% high-oleic safflower oil, 33% medium chain triglycerides, 29% soy oil</td><td>32.2</td><td>47.6</td></tr></table> |
cd2d4be3b097a55bb9decb6134f4ee12d1364e13b8832d455263995f98076102.png | complex | <table><tr><td>Concordance</td><td colspan="2">Coder 1(YS)</td><td colspan="2">Coder 2 (AV)</td></tr><tr><td>0 (non found)</td><td>16 (1.7%)</td><td></td><td>4 (0.4%)</td><td></td></tr><tr><td>1 (partly concordant)</td><td>127 (13%)</td><td></td><td>114 (11.7%)</td><td></td></tr><tr><td> 1a. target (SNOMED CT) more specific than source (KSH97-P)</td><td></td><td>77 (60%)</td><td></td><td>75 (65%)</td></tr><tr><td> 1b. target less specific than source</td><td></td><td>25 (20%)</td><td></td><td>20 (18%)</td></tr><tr><td> 1c. imprecise but neither more nor less specific'</td><td></td><td>25 (20%)</td><td></td><td>19 (17%)</td></tr><tr><td>2 (completely concordant)</td><td>829 (85.3%)</td><td></td><td>854 (87.9%)</td><td></td></tr><tr><td>Total</td><td>972 (100%)</td><td>127 (100%)</td><td>972 (100%)</td><td>114 (100%)</td></tr></table> |
19d6d83c70b90e886805aa038e8f689639348755b669aa24edf11616f642e0aa.png | complex | <table><tr><td rowspan="2">The maximum level of non-compliance, with the seasonality adjustment</td><td colspan="5">The maximum level of non-compliance, without the seasonality adjustment</td><td rowspan="2">Total (with seasonal adjustments)</td></tr><tr><td>Always compliant</td><td>At least one first warning</td><td>At least one second warning</td><td>At least one third warning</td><td>Liable for suspension</td></tr><tr><td colspan="7">Calculation method 1</td></tr><tr><td> Always compliant</td><td>13426</td><td>524</td><td>60</td><td>0</td><td>0</td><td>14010</td></tr><tr><td> At least one first warning</td><td>0</td><td>607</td><td>101</td><td>13</td><td>0</td><td>721</td></tr><tr><td> At least one second warning</td><td>0</td><td>0</td><td>496</td><td>95</td><td>11</td><td>602</td></tr><tr><td> At least one third warning</td><td>0</td><td>0</td><td>0</td><td>444</td><td>103</td><td>547</td></tr><tr><td> Liable for suspension</td><td>0</td><td>0</td><td>0</td><td>0</td><td>860</td><td>860</td></tr><tr><td> Total (without seasonal adjustments)</td><td>13426</td><td>1131</td><td>657</td><td>552</td><td>974</td><td>16740</td></tr><tr><td colspan="7">Calculation method 2</td></tr><tr><td> Always compliant</td><td>13616</td><td>393</td><td>48</td><td>0</td><td>0</td><td>14057</td></tr><tr><td> At least one first warning</td><td>0</td><td>542</td><td>87</td><td>14</td><td>0</td><td>643</td></tr><tr><td> At least one second warning</td><td>0</td><td>0</td><td>513</td><td>84</td><td>9</td><td>606</td></tr><tr><td> At least one third warning</td><td>0</td><td>0</td><td>0</td><td>479</td><td>101</td><td>580</td></tr><tr><td> Liable for suspension</td><td>0</td><td>0</td><td>0</td><td>0</td><td>854</td><td>854</td></tr><tr><td> Total (without seasonal adjustments)</td><td>13616</td><td>935</td><td>648</td><td>577</td><td>964</td><td>16740</td></tr></table> |
97d54a9f1b2b9dae53741818115518fd151e36f2fd3a73c8584f7c15ad5c499d.png | simple | <table><tr><td>RPKM interval</td><td>Expression level</td><td>D1</td><td>D4</td><td>D6</td></tr><tr><td>0-0.1</td><td>no</td><td>17,765 (27.08 %)</td><td>22,483 (34.28 %)</td><td>22,843 (34.83 %)</td></tr><tr><td>0.1-3.57</td><td>low</td><td>29, 146 (44.44 %)</td><td>29,935 (45.64 %)</td><td>28,720 (43.79 %)</td></tr><tr><td>3.57-15</td><td>medium</td><td>10,459 (15.95 %)</td><td>8,031 (12.24 %)</td><td>8,273 (12.61 %)</td></tr><tr><td>15-60</td><td>high</td><td>6, 176 (9.42 %)</td><td>3,822 (5.83 %)</td><td>4,182 (6.38 %)</td></tr><tr><td>>60</td><td>very high</td><td>2,045 (3.12 %)</td><td>1,320 (2.01 %)</td><td>1,573 (2.40 %)</td></tr></table> |
ff40f998a1ed0b9e96c691301d759d12b7769dda7836fcab6798e7599bd4987b.png | simple | <table><tr><td>Groups</td><td>ALT (U/L)</td><td>AST (U/L)</td><td>LDH (U/L)</td><td>T-BIL (mg/L)</td></tr><tr><td>Sham (Control)</td><td>292.43 ± 32.41</td><td>428.39 ± 34.66</td><td>859.34 ± 94.36</td><td>75.39 ± 8.12</td></tr><tr><td>Model</td><td>580.52 ± 51.96<sup>#</sup></td><td>738.11 ± 75.63<sup>#</sup></td><td>1404.65 ± 168.74<sup>#</sup></td><td>83.94 ± 9.53</td></tr><tr><td>LV-NC</td><td>577.21 ± 61.14</td><td>784.7 ± 47.85</td><td>1553.19 ± 125.83</td><td>84.38 ± 10.46</td></tr><tr><td>LV-sh4-1BB1</td><td>333.26 ± 39.92*</td><td>457.7 ± 43.61*</td><td>942.81 ± 83.17*</td><td>76.84 ± 8.43</td></tr></table> |
2c19c63114f554e833c707127cdd2e58d0ebf7f18a45ab39533af75a1418dba2.png | complex | <table><tr><td>Subsystem</td><td>Instrument</td><td>Signal</td><td>Task</td><td>Measurements</td></tr><tr><td rowspan="2">Respiratory</td><td rowspan="2">Phonatory Aerodynamic System (PAS), <i>KAYPentax </i></td><td rowspan="2">Aerodynamic</td><td>/pa/, /pi/</td><td>Maximum subglottal pressure</td></tr><tr><td>Bamboo passage</td><td>Speech duration, pausing pattern (e.g., number of pauses, pause duration, pausing frequency)</td></tr><tr><td>Phonatory</td><td>Compact flash recorder, professional quality microphone, <i>Countryman E6</i>, Phonatory Aerodynamic System, <i>KAYPentax </i></td><td>Acoustic, aerodynamic</td><td>“Normal” and “high pitch” phonation of /a/</td><td>Phonation duration, maximum F0, jitter, shimmer, NHR, SPL, laryngeal airway resistance</td></tr><tr><td rowspan="2">Articulatory</td><td>Eagle Digital System, <i>Motion Analysis Corp. </i></td><td>Kinematic</td><td>“Buy Bobby a puppy”“Say /aCa/ again” </td><td>Maximum/minimum velocities of lips and jaw</td></tr><tr><td>Microphone</td><td>Acoustic</td><td>Repeat /ba/ as clear and as fast as possible on one breath</td><td>Number, duration, and rate of syllable repetitions</td></tr><tr><td rowspan="2">Resonatory</td><td>Nasometer, <i>Model 6400</i>, <i>KAYPentax </i></td><td>Acoustic</td><td>“Mama made a lemon jam” “Buy Bobby a puppy” </td><td>Nasalance</td></tr><tr><td>Phonatory Aerodynamic System, <i>KAYPentax </i></td><td>Aerodynamic</td><td>/pa/, /pi/, /ma/, /mi/, “hamper”</td><td>Intraoral air pressure and nasal airflow in syllables, time lag between /m/ and /p/ in “hamper”</td></tr></table> |
b13bedd1629ea13e3fa13656bf27b22d9824025da15621a83b9d90fb10545863.png | simple | <table><tr><td></td><td>Ocular manifestation first group (<i>n</i> = 18)</td><td>Extraocular manifestation first group (<i>n</i> = 21)</td><td><i>P</i> value</td></tr><tr><td>Mean age</td><td>57.4 ± 15.3</td><td>54.1 ± 12.0</td><td>0.45</td></tr><tr><td>Female/male ratio</td><td>17/1 (94.4%)</td><td>18/3 (85.7%)</td><td>0.61</td></tr><tr><td>BHL<sup>a</sup> in radiography</td><td>15 (83.3%)</td><td>19 (90.5%)</td><td>0.65</td></tr><tr><td>Increased ACE<sup>b</sup></td><td>13 (72.2%)</td><td>16 (76.2%)</td><td>0.78</td></tr><tr><td>ACE<sup>b</sup> level</td><td>82.4 ± 46.5</td><td>72.6 ± 36.0</td><td>0.47</td></tr><tr><td>Ocular complications</td><td>4 (22.2%)</td><td>5 (23.8%)</td><td>0.61</td></tr><tr><td>Visual acuity at last visit</td><td>0.83 ± 0.19</td><td>0.90 ± 0.14</td><td>0.15</td></tr><tr><td>Ocular involvement</td><td></td><td></td><td></td></tr><tr><td> Mutton-fat KP<sup>c</sup></td><td>16 (88.9%)</td><td>14 (66.7%)</td><td>0.10</td></tr><tr><td> Angle change</td><td>2 (11.1%)</td><td>3 (14.3%)</td><td>0.58</td></tr><tr><td> Vitreous opacity</td><td>5 (27.8%)</td><td>5 (23.8%)</td><td>0.53</td></tr><tr><td> Nodular phlebitis</td><td>13 (72.2%)</td><td>13 (61.9%)</td><td>0.37</td></tr><tr><td> Multiple choroidal lesions</td><td>7 (38.9%)</td><td>6 (28.6%)</td><td>0.36</td></tr><tr><td> Optic disc lesion</td><td>3 (16.7%)</td><td>5 (23.8%)</td><td>0.44</td></tr><tr><td> Bilaterality</td><td>16 (88.9%)</td><td>13 (61.9%)</td><td>0.07</td></tr><tr><td>Systemic treatment</td><td>16 (88.9%)</td><td>12 (57.1%)</td><td>0.037</td></tr><tr><td> Immunosuppression</td><td>10 (55.6%)</td><td>4 (19.0%)</td><td>0.018</td></tr></table> |
1bccf15cebb81e9aa22679ea8eae89db82adf8d2caa0ee945891d5d109eedc08.png | complex | <table><tr><td></td><td colspan="3">ALL</td><td colspan="3">Egypt</td><td colspan="3">Germany</td></tr><tr><td></td><td>n</td><td>Positive LR</td><td>Negative LR</td><td>n</td><td>Positive LR</td><td>Negative LR</td><td>n</td><td>Positive LR</td><td>Negative LR</td></tr><tr><td colspan="10">Visual detection</td></tr><tr><td> advanced occlusal</td><td>94</td><td>7.09 (5.6–8.9)</td><td>0.39 (0.3–0.5)</td><td>55</td><td>5.0 (4.3–5.8)</td><td>0.29 (0.2–0.4)</td><td>50</td><td>12.5 (9.2–16.9)</td><td>0.58 (0.5–0.7)</td></tr><tr><td> all occlusal</td><td>67</td><td>3.46 (2.8–4.3)</td><td>0.19 (0.15–0.25)</td><td>51</td><td>3.73 (3.1–4.4)</td><td>0.18 (0.14–0.24)</td><td>12</td><td>5.56 (3.7–8.5)</td><td>0.56 (0.46–0.68)</td></tr><tr><td colspan="10">Radiographic detection</td></tr><tr><td> advanced occlusal</td><td>44</td><td>4.90 (3.7–6.5)</td><td>0.53 (0.46–0.62)</td><td>38</td><td>5.96 (3.7–6.6)</td><td>0.51 (0.44–0.60)</td><td>36</td><td>5.87 (4.3–8.0)</td><td>0.54 (0.46–0.63)</td></tr><tr><td> all occlusal</td><td>14</td><td>1.74 (1.3–2.4)</td><td>0.79 (0.65–0.96)</td><td>11</td><td>2.02 (1.4–2.9)</td><td>0.75 (0.60–0.94)</td><td>9</td><td>2.36 (1.4–4.1)</td><td>0.76 (0.58–0.99)</td></tr><tr><td> advanced proximal</td><td>22</td><td>9.82 (7.3–13.3)</td><td>0.58 (0.52–0.65)</td><td>22</td><td>9.82 (7.3–13.3)</td><td>0.58 (0.52–0.65)</td><td>22</td><td>9.82 (7.3–13.3)</td><td>0.58 (0.52–0.65)</td></tr><tr><td> all proximal</td><td>38</td><td>4.30 (3.4–5.5)</td><td>0.63 (0.56–0.72)</td><td>31</td><td>5.34 (4.2–6.8)</td><td>0.65 (0.57–0.74)</td><td>34</td><td>4.89 (3.9–6.2)</td><td>0.65 (0.57–0.73)</td></tr></table> |
5f2ffd8f2b00e645c14030443ab8739ea7b3206e46257a7e5786186692bd0bd0.png | complex | <table><tr><td>Variable</td><td>Sub-category</td><td><i>n</i></td><td>GWG up to 28 Weeks (<i>n</i> = 105) Mean (SD)</td><td>95% CI</td><td><i>p</i>-Value</td><td>Total GWG (<i>n</i> = 119) Mean (SD)</td><td>95% CI</td><td><i>p</i>-Value</td></tr><tr><td>All</td><td>-</td><td></td><td>6.33 (2.85)</td><td>5.78–6.89</td><td>-</td><td>9.30 (3.72)</td><td>8.63–9.98</td><td>-</td></tr><tr><td rowspan="3">Education level</td><td>None/primary</td><td>16</td><td>5.72 (2.80)</td><td>4.20–7.24</td><td rowspan="3">0.519</td><td>7.34 (3.72)</td><td>5.51–9.17</td><td rowspan="3">0.072</td></tr><tr><td>Secondary</td><td>99</td><td>6.46 (2.92)</td><td>5.85–7.07</td><td>9.64 (3.71)</td><td>8.90–10.37</td></tr><tr><td>Higher</td><td>2</td><td>5.13 (0.11)</td><td>1.84–8.42</td><td>8.60 (0.57)</td><td>3.42–13.78</td></tr><tr><td rowspan="5">Income level (LKR (Sri Lankan rupee))</td><td><9000</td><td>5</td><td>6.67 (2.57)</td><td>3.33–10.00</td><td rowspan="5">0.978</td><td>9.08 (4.91)</td><td>5.75–12.41</td><td rowspan="5">0.474</td></tr><tr><td>9000–13,999</td><td>20</td><td>6.09 (2.62)</td><td>4.73–7.46</td><td>8.30 (3.44)</td><td>6.64–9.96</td></tr><tr><td>14,000–19,999</td><td>32</td><td>6.27 (3.35)</td><td>5.26–7.27</td><td>9.42 (3.23)</td><td>8.11–10.74</td></tr><tr><td>20,000–31,999</td><td>45</td><td>6.52 (2.77)</td><td>5.60–7.45</td><td>9.23 (4.21)</td><td>8.12–10.34</td></tr><tr><td>≥32,000</td><td>16</td><td>6.04 (2.44)</td><td>4.30–7.79</td><td>10.70 (3.31)</td><td>8.77–12.61</td></tr><tr><td rowspan="3">Area of residence</td><td>Urban</td><td>9</td><td>4.53 (3.49)</td><td>2.40–6.66</td><td rowspan="3">0.167</td><td>7.44 (3.93)</td><td>4.97–9.92</td><td rowspan="3">0.306</td></tr><tr><td>Sub-urban</td><td>52</td><td>6.68 (3.33)</td><td>5.86–7.50</td><td>9.28 (3.99)</td><td>8.25–10.31</td></tr><tr><td>Rural</td><td>55</td><td>6.18 (2.15)</td><td>5.37–7.00</td><td>9.52 (3.46)</td><td>8.52–10.52</td></tr><tr><td rowspan="2">History of LBW deliveries</td><td>Yes</td><td>22</td><td>5.33 (3.03)</td><td>4.14–6.52</td><td rowspan="2">0.062</td><td>8.04 (3.36)</td><td>6.48–9.59</td><td rowspan="2">0.077</td></tr><tr><td>No</td><td>97</td><td>6.60 (2.76)</td><td>5.99–7.21</td><td>9.60 (3.76)</td><td>8.85–10.33</td></tr><tr><td rowspan="2">History of miscarriage or abortion</td><td>Yes</td><td>32</td><td>6.47 (2.75)</td><td>5.43–7.51</td><td rowspan="2">0.759</td><td>8.87 (3.75)</td><td>7.56–10.17</td><td rowspan="2">0.442</td></tr><tr><td>No</td><td>87</td><td>6.28 (2.91)</td><td>5.62–6.94</td><td>9.46 (3.77)</td><td>8.67–10.25</td></tr><tr><td rowspan="2">Hyperemesis gravidarum <sup>a</sup></td><td>Yes</td><td>20</td><td>6.34 (3.21)</td><td>5.03–7.65</td><td rowspan="2">0.978</td><td>9.04 (4.20)</td><td>7.37–10.70</td><td rowspan="2">0.730</td></tr><tr><td>No</td><td>97</td><td>6.32 (2.80)</td><td>5.70–6.93</td><td>9.36 (3.67)</td><td>8.60–10.12</td></tr><tr><td rowspan="2">Parity</td><td>Primiparous</td><td>40</td><td>6.89 (2.39)</td><td>5.86–7.92</td><td rowspan="2">0.208</td><td>10.00(4.00)</td><td>8.84–11.16</td><td rowspan="2">0.146</td></tr><tr><td>Multiparous</td><td>79</td><td>6.11 (3.00)</td><td>5.46–6.76</td><td>8.95 (3.54)</td><td>8.12–9.77</td></tr><tr><td rowspan="4">Pre-pregnancy BMI category <sup>b</sup></td><td>Underweight</td><td>23</td><td>8.43 (2.94) <sup>1</sup></td><td>7.24–9.62</td><td rowspan="4"><0.001 *</td><td>12.00(4.07) <sup>1</sup></td><td>10.58–13.43</td><td rowspan="4"><0.001 *</td></tr><tr><td>Normal</td><td>69</td><td>6.18 (2.26) <sup>2</sup></td><td>5.51–6.85</td><td>9.10 (3.12) <sup>2</sup></td><td>8.27–9.92</td></tr><tr><td>Overweight</td><td>20</td><td>5.73 (3.38) <sup>2,3</sup></td><td>4.60–6.86</td><td>7.89 (3.81) <sup>2</sup></td><td>6.37–9.42</td></tr><tr><td>Obese</td><td>7</td><td>2.76 (0.97) <sup>3</sup></td><td>0.44–5.08</td><td>6.50 (3.30) <sup>2</sup></td><td>3.92–9.08</td></tr><tr><td rowspan="2">Energy intake <sup>c</sup></td><td><EER</td><td>21</td><td>5.57 (3.04)</td><td>4.32–6.82</td><td rowspan="2">0.188</td><td>8.05 (3.44)</td><td>6.44–9.67</td><td rowspan="2">0.083</td></tr><tr><td>≥EER</td><td>93</td><td>6.51 (2.85)</td><td>5.87–7.16</td><td>9.62 (3.80)</td><td>8.86–10.39</td></tr><tr><td rowspan="3">Carbohydrate intake (g/day)</td><td>229–429</td><td>25</td><td>5.97 (3.08)</td><td>4.78–7.15</td><td rowspan="3">0.798</td><td>8.03 (3.60)</td><td>6.56–9.50</td><td rowspan="3">0.089</td></tr><tr><td>430–629</td><td>58</td><td>6.41 (2.99)</td><td>5.60–7.23</td><td>10.00 (3.68)</td><td>9.03–10.96</td></tr><tr><td>630–829</td><td>31</td><td>6.45 (2.63)</td><td>5.29–7.61</td><td>9.16 (3.88)</td><td>7.84–10.49</td></tr><tr><td rowspan="2">Protein intake <sup>d</sup></td><td><RDA</td><td>21</td><td>5.49 (3.21)</td><td>4.24–6.74</td><td rowspan="2">0.141</td><td>7.81 (3.56)</td><td>6.20–9.41</td><td rowspan="2">0.039 *</td></tr><tr><td>≥RDA</td><td>93</td><td>6.53 (2.80)</td><td>5.89–7.18</td><td>9.68 (3.74)</td><td>8.92–10.44</td></tr><tr><td rowspan="2">Sex of the newborn</td><td>Male</td><td>53</td><td>6.44 (2.78)</td><td>5.63–7.25</td><td rowspan="2">0.552</td><td>9.23 (3.31)</td><td>8.25–10.21</td><td rowspan="2">0.976</td></tr><tr><td>Female</td><td>53</td><td>6.10 (2.75)</td><td>5.28–6.91</td><td>9.21 (3.86)</td><td>8.23–10.19</td></tr></table> |
bdc4cf8b41fa9d68198806eed335d6843b51373b9945dff840f9be0677546974.png | complex | <table><tr><td>Outcomes</td><td>Transferred (n = 82)</td><td>Non-transferred (n = 288)</td><td><i>P</i>value</td></tr><tr><td>Mortality, n (%)</td><td>35 (42.7)</td><td>150 (52.1)</td><td>0.13</td></tr><tr><td>Kidney status among survivors, n (%)</td><td></td><td></td><td></td></tr><tr><td>Full recovery</td><td>6 (12.8)</td><td>46 (33.3)</td><td rowspan="3">0.02</td></tr><tr><td>Partial recovery</td><td>20 (42.6)</td><td>42 (30.4)</td></tr><tr><td>Renal replacement therapy-dependent</td><td>21 (44.7)</td><td>50 (36.2)</td></tr></table> |
1347c66903ef75bf4e193c85c3fa81256965dc2ed37bca560953cfa32becaa99.png | complex | <table><tr><td> </td><td colspan="3">Univariate</td><td colspan="3">Multivariate</td></tr><tr><td>Variable</td><td>HR</td><td>95% CI</td><td>P</td><td>HR</td><td>95% CI</td><td>P</td></tr><tr><td>Gender F/M</td><td>1.35</td><td>0.80-2.25</td><td>0.26</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Age < 60/≥60 yr</td><td>1.59</td><td>0.95-2.67</td><td>0.08</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Tumor site</td><td>–</td><td>–</td><td>0.17</td><td>–</td><td>–</td><td>–</td></tr><tr><td>body/fundus</td><td>0.47</td><td>0.20-1.09</td><td>0.078</td><td>–</td><td>–</td><td>–</td></tr><tr><td>antrum/fundus, body</td><td>0.57</td><td>0.29 -1.13</td><td>0.11</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Tumor size < 5/ ≥5 cm</td><td>1.72</td><td>1.02-2.90</td><td>0.043</td><td>–</td><td>–</td><td>0.57</td></tr><tr><td>grade Well/Poorly</td><td>0.57</td><td>0.26-1.27</td><td>0.17</td><td>–</td><td>–</td><td>–</td></tr><tr><td>T stage</td><td>–</td><td>–</td><td>0.004</td><td>–</td><td>–</td><td>0.019</td></tr><tr><td>T3/T2</td><td>1.60</td><td>0.66-3.89</td><td>0.30</td><td>0.83</td><td>0.33–2.12</td><td>0.70</td></tr><tr><td>T4/T2,T3</td><td>3.36</td><td>1.38–8.15</td><td>0.007</td><td>1.86</td><td>0.73–4.70</td><td>0.19</td></tr><tr><td>N stage N0,N1/N2,N3</td><td>2.87</td><td>1.57–5.21</td><td>0.001</td><td>–</td><td>–</td><td>0.12</td></tr><tr><td>Vascular−/+</td><td>1.23</td><td>0.65-2.34</td><td>0.52</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Perineural−/+</td><td>1.32</td><td>0.71-2.43</td><td>0.38</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Margin−/+</td><td>1.29</td><td>0.72-2.31</td><td>0.40</td><td>–</td><td>–</td><td>–</td></tr><tr><td>TNM stage I,II/III,IV</td><td>4.05</td><td>2.04– 8.03</td><td><0.001</td><td>2.99</td><td>1.45–6.16</td><td>0.003</td></tr><tr><td>hK6−/+</td><td>2.88</td><td>1.40-5.92</td><td>0.004</td><td>2.66</td><td>1.25–5.63</td><td>0.011</td></tr></table> |
b0e103d37cc857f10a166b776acb11a3317ea2b3e7e05c145b1329649f4fa73e.png | complex | <table><tr><td rowspan="2">Drowning</td><td rowspan="2">No of cases</td><td colspan="2">Testing rates</td></tr><tr><td>Alcohol(%)</td><td>Medicinal drugs(%)</td></tr><tr><td>Unintentional (V90, V92, W65-W74)</td><td>1746</td><td>100%</td><td>91.5%</td></tr><tr><td><i>Boating-related (V90, V92)</i></td><td><i>303</i></td><td><i>100%</i></td><td><i>91.1%</i></td></tr><tr><td><i>Non-boating (W65-W74)</i></td><td><i>1443</i></td><td><i>100%</i></td><td><i>91.6%</i></td></tr></table> |
56acf4310f0d93b5a99092df9db2a4d4423052530ecf7b6602dac41072a7b5ad.png | simple | <table><tr><td>Variable</td><td>Mean (SD)</td></tr><tr><td>Total energy (kJ)</td><td>7709.0 (2320.4)</td></tr><tr><td>Total soy product (g)</td><td>45.0 (33.8)</td></tr><tr><td>Tofu (g)</td><td>20.8 (22.0)</td></tr><tr><td>Tofu products (g)</td><td>3.0 (5.8)</td></tr><tr><td>Fermented soybeans (g)</td><td>10.2 (13.3)</td></tr><tr><td>Boiled soybeans (g)</td><td>4.1 (9.4)</td></tr><tr><td>Miso (g)</td><td>1.7 (5.3)</td></tr><tr><td>Miso soup (g)</td><td>5.2 (4.6)</td></tr><tr><td>Soy protein (g)</td><td>4.6 (3.5)</td></tr><tr><td>Isoflavone (mg)</td><td>26.8 (21.7)</td></tr><tr><td>Daidzein (mg)</td><td>10.1 (8.2)</td></tr><tr><td>Genistein (mg)</td><td>16.7 (13.5)</td></tr></table> |
0d3adbb8cae521efd2915d7dcb568a15d3cb2e43c5589e01524177744006dfe8.png | complex | <table><tr><td>Perceived stress (PS) owing to the following items in Indistinct organisation and conflicts</td><td colspan="2">High stress perception</td><td colspan="2">No/Low stress perception</td></tr><tr><td></td><td>% (95% CI)</td><td>n</td><td>% (95% CI)</td><td>n</td></tr><tr><td>PS owing to increased work-load</td><td>38 (33 – 43)</td><td>160</td><td>62 (57 – 67)</td><td>264</td></tr><tr><td>PS owing to unclear goals at workplace</td><td>14 (11 – 18)</td><td>60</td><td>86 (82 – 89)</td><td>364</td></tr><tr><td>PS owing to unclear work assignments</td><td>7 (4 – 9)</td><td>28</td><td>93 (91 – 95)</td><td>396</td></tr><tr><td>PS owing to unclear leadership</td><td>3 (1 – 5)</td><td>12</td><td>97 (95 – 99)</td><td>412</td></tr><tr><td>PS owing to conflicts at work</td><td>23 (19 – 27)</td><td>98</td><td>77 (73 – 81)</td><td>326</td></tr><tr><td>PS owing to involved in conflicts at work</td><td>12 (9 – 15)</td><td>49</td><td>88 (85 – 91)</td><td>375</td></tr><tr><td>PS owing to supervisor not solved the conflicts</td><td>17 (13 – 21)</td><td>71</td><td>83 (79 – 87)</td><td>353</td></tr><tr><td>Perceived stress (PS) owing to the following items in Individual demands and commitment</td><td></td><td></td><td></td><td></td></tr><tr><td>PS owing to high demands on oneself at work</td><td>29 (25 – 34)</td><td>125</td><td>71 (66 – 75)</td><td>299</td></tr><tr><td>PS owing to engaged in one's work</td><td>17 (14 – 21)</td><td>72</td><td>83 (79 – 86)</td><td>352</td></tr><tr><td>PS owing to think about work after working-day</td><td>25 (21 – 29)</td><td>106</td><td>75 (71 – 79)</td><td>318</td></tr><tr><td>PS owing to hard to set limits</td><td>44 (39 – 49)</td><td>187</td><td>56 (51 – 61)</td><td>237</td></tr><tr><td>PS owing to high responsibility for one's work</td><td>29 (25 – 34)</td><td>123</td><td>71 (66 – 75)</td><td>301</td></tr><tr><td>PS owing to work over-time/stress</td><td>24 (20 – 28)</td><td>102</td><td>76 (72 – 80)</td><td>322</td></tr><tr><td>PS owing to sleep disturbance on account of work</td><td>26 (22 – 31)</td><td>112</td><td>74 (69 – 78)</td><td>312</td></tr></table> |
d22d22b0fe9dbcf0cb646b63fb50de05634a2bcba7f46c44a2cc4c2f0097ed75.png | complex | <table><tr><td>At-genome</td><td colspan="4">Dt-genome</td></tr><tr><td></td><td>A</td><td>T</td><td>C</td><td>G</td></tr><tr><td>A</td><td>0</td><td>190,935</td><td>132,443</td><td>409,059</td></tr><tr><td>T</td><td>190,468</td><td>0</td><td>407,605</td><td>132,678</td></tr><tr><td>C</td><td>117,349</td><td>363,240</td><td>0</td><td>86,903</td></tr><tr><td>G</td><td>363,609</td><td>117,194</td><td>87,509</td><td>0</td></tr></table> |
5b36afe4ae942a242a59113f85e1283ea54d3d8c188efe2147bae95d1d54fd1f.png | simple | <table><tr><td></td><td>CWH43</td><td>YDR056C</td><td>ROT2</td><td>ADP1</td><td>SCT1</td><td>PEP1</td></tr><tr><td>CWH43</td><td>No Data</td><td>1.43</td><td>-1.29</td><td>No Data</td><td>0.08</td><td>1.31</td></tr><tr><td>YDR056C</td><td>1.43</td><td>No Data</td><td>1.39</td><td>1.23</td><td>0.81</td><td>0.23</td></tr><tr><td>ROT2</td><td>-1.29</td><td>1.39</td><td>No Data</td><td>0.74</td><td>0.31</td><td>-0.87</td></tr><tr><td>ADP1</td><td>No Data</td><td>1.23</td><td>0.74</td><td>No Data</td><td>0.25</td><td>-0.64</td></tr><tr><td>SCT1</td><td>0.08</td><td>0.81</td><td>0.31</td><td>0.25</td><td>No Data</td><td>No Data</td></tr><tr><td>PEP1</td><td>1.31</td><td>0.23</td><td>-0.87</td><td>-0.64</td><td>No Data</td><td>No Data</td></tr></table> |
53b88c1e4fcca4d7a5b11fc94160bc6cd21f408294602a828ab23c9a6c2a0f10.png | simple | <table><tr><td></td><td>MHPA</td><td>PKU</td></tr><tr><td>Number patients</td><td>41</td><td>100</td></tr><tr><td>Gender – Male</td><td>20</td><td>47</td></tr><tr><td>Gender – Female</td><td>21</td><td>53</td></tr><tr><td>Average Age</td><td>9y 7 m</td><td>17y 10 m</td></tr><tr><td>Under 18 years</td><td>35</td><td>57</td></tr><tr><td>zBMI – obese + overweight</td><td>3</td><td>34</td></tr><tr><td>zBMI – normal</td><td>33</td><td>61</td></tr><tr><td>zBMI – underweight</td><td>5</td><td>5</td></tr><tr><td>WC - obese + overweight</td><td>7</td><td>45</td></tr><tr><td>WC - normal</td><td>30</td><td>50</td></tr><tr><td>WC - underweight</td><td>4</td><td>5</td></tr><tr><td>AC - obese + overweight</td><td>5</td><td>21</td></tr><tr><td>AC - normal</td><td>21</td><td>27</td></tr><tr><td>AC - underweight</td><td>4</td><td>15</td></tr><tr><td>Early Diagnostic</td><td>40</td><td>85</td></tr><tr><td>BH4 treatment</td><td>0</td><td>17</td></tr><tr><td>Adequated Diet adherence</td><td>40</td><td>80</td></tr><tr><td>Phe Tol (mg/day)</td><td>1889.6 ± 831.9</td><td>481.1 ± 376.3</td></tr><tr><td>Phe median (μmol/L)</td><td>238.6 ± 93.2</td><td>397.3 ± 281.9</td></tr><tr><td>Total Cholesterol (mg/dL)</td><td>164.2 ± 21.9</td><td>149.9 ± 31.5</td></tr><tr><td>HDL (mg/dL)</td><td>55.8 ± 12.6</td><td>49.8 ± 11.9</td></tr><tr><td>LDL (mg/dL)</td><td>92.1 ± 17.2</td><td>82.1 ± 24.7</td></tr><tr><td>ApoA (mg/dL)</td><td>160.7 ± 26.4</td><td>144.1 ± 25.9</td></tr><tr><td>ApoB (mg/dL)</td><td>75.5 ± 17.6</td><td>65.9 ± 19.1</td></tr><tr><td>LDL/ApoB</td><td>1.26 ± 0.16</td><td>1.22 ± 0.19</td></tr><tr><td>Triglycerids (mg/dL)</td><td>79.2 ± 36.2</td><td>91.7 ± 45.7</td></tr><tr><td>Homocystein (μmol/L)</td><td>5.9 ± 2.4</td><td>5.9 ± 3.3</td></tr><tr><td>Systolic BP (mmHg)</td><td>105.5 ± 12</td><td>114.9 ± 14.4</td></tr><tr><td>Diastolic BP (mmHg)</td><td>65.7 ± 10.5</td><td>69.3 ± 13.7</td></tr><tr><td>B12 (pg/mL)</td><td>584.9 ± 205.6</td><td>664.5 ± 333.6</td></tr><tr><td>Zinc (μg/dL)</td><td>82.4 ± 33.1</td><td>81.2 ± 21.5</td></tr><tr><td>Copper (μg/dL)</td><td>86 ± 22.5</td><td>78.4 ± 21.3</td></tr><tr><td>Zinc/Copper</td><td>1.01 ± 0.46</td><td>1.11 ± 0.45</td></tr></table> |
6aa1aab750542bf6766362f638516bb7f920a0584f81c9b523b271ffe3276b1c.png | simple | <table><tr><td>Trait</td><td>Average heterozygosity</td><td>Rotation 1</td><td>Rotation 2</td><td>Rotation 3</td><td>Rotation 4</td></tr><tr><td>Age</td><td>0.02</td><td>0.14</td><td>0.16</td><td>0.07</td><td>0.06</td></tr><tr><td>Smoke</td><td>−0.01</td><td>−0.04</td><td>−0.05</td><td>0.04</td><td>0.01</td></tr><tr><td>Q1</td><td>0.16</td><td>−0.15</td><td>−0.07</td><td>0.05</td><td>−0.19</td></tr><tr><td>Q2</td><td>0.05</td><td>−0.01</td><td>0.01</td><td>−0.04</td><td>−0.05</td></tr><tr><td>Q4</td><td>−0.06</td><td>−0.09</td><td>−0.12</td><td>−0.07</td><td>−0.03</td></tr><tr><td>Q1A</td><td>0.17</td><td>−0.21</td><td>−0.12</td><td>0.02</td><td>−0.24</td></tr><tr><td>Q1B</td><td>0.02</td><td>0.00</td><td>−0.01</td><td>−0.01</td><td>0.00</td></tr><tr><td>Q4A</td><td>−0.10</td><td>0.06</td><td>0.02</td><td>−0.02</td><td>0.06</td></tr><tr><td>Affected</td><td>0.14</td><td>0.02</td><td>0.09</td><td>0.07</td><td>−0.05</td></tr></table> |
0f79e274f68232318fcc533e9a2e30356cdab7328b085d82f010f9dbbe98606d.png | complex | <table><tr><td></td><td>Non-musicians</td><td>Musicians</td><td>Pianists</td><td>String players</td></tr><tr><td><i>n</i></td><td>16</td><td>15</td><td>7</td><td>8</td></tr><tr><td>Male/Female</td><td>6/10</td><td>9/6</td><td>4/3</td><td>5/3</td></tr><tr><td>Age (years)</td><td>23.81 (2.14)</td><td>24.13 (2.35)</td><td>24.29 (3.40)</td><td>24.00 (1.60)</td></tr><tr><td colspan="5">AGE OF ONSET (YEARS)</td></tr><tr><td>Mean (<i>SD</i>)</td><td>–</td><td>5.47 (1.25)</td><td>5.57 (1.62)</td><td>5.38 (0.92)</td></tr><tr><td>Range</td><td>–</td><td>4–8</td><td>4–8</td><td>4–6</td></tr><tr><td colspan="5">FORMAL TRAINING (YEARS)</td></tr><tr><td>Mean (<i>SD</i>)</td><td>–</td><td>11.40 (3.33)</td><td>10.00 (3.00)</td><td>12.63 (3.29)</td></tr><tr><td>Range</td><td>–</td><td>6–16</td><td>6–14</td><td>6–16</td></tr><tr><td colspan="5">CURRENT PRACTICE (H/WEEK)</td></tr><tr><td>Mean (<i>SD</i>)</td><td>–</td><td>6.60 (7.21)</td><td>4.00 (5.69)</td><td>8.88 (7.97)</td></tr><tr><td>Range</td><td>–</td><td>0–25</td><td>0–15</td><td>2–25</td></tr><tr><td colspan="5">ELECTROPHYSIOLOGY</td></tr><tr><td>1mV L (%)</td><td>45.38 (7.36)</td><td>46.67 (6.38)</td><td>49.00 (6.71)</td><td>44.63 (5.71)</td></tr><tr><td>1mV R (%)</td><td>47.50 (7.47)</td><td>47.07 (5.46)</td><td>49.14 (4.14)</td><td>45.25 (6.07)</td></tr><tr><td>IHI LR (%)</td><td>38.34 (24.57)<sup>*</sup><sup>+</sup></td><td>54.37 (15.49)</td><td>48.53 (16.34)</td><td>59.47 (13.67)</td></tr><tr><td>IHI RL (%)</td><td>45.22 (20.66)</td><td>43.82 (19.80)</td><td>42.56 (18.81)</td><td>44.93 (21.86)</td></tr></table> |
6cc498e1e5a65ac4ab621bb87eebdc4c750d8ae49569aeb7f4d8357090bed192.png | simple | <table><tr><td>Variables</td><td>Adnexal Torsion (<i>n</i> = 17)</td><td>Control (<i>n</i> = 34)</td><td><i>p</i></td></tr><tr><td>Acute onset pain (<8 h)</td><td>11 (64.7%)</td><td>16 (47.1%)</td><td>0.23</td></tr><tr><td>Cyst diameter > 5cm</td><td>14 (82.4%)</td><td>14 (41.2%)</td><td><0.001</td></tr><tr><td>Peritoneal signs</td><td>9 (52.9%)</td><td>13 (38.2%)</td><td>0.32</td></tr><tr><td>Nausea and vomiting</td><td>6 (35.3%)</td><td>3 (8.8%)</td><td>0.04</td></tr><tr><td>Negative flow in Doppler</td><td>8 (47.1%)</td><td>2 (5.8%)</td><td>0.001</td></tr><tr><td>Leukocytosis (WBC ≥ 12 × 10<sup>3</sup>) (cells/mm<sup>3</sup>) 10 (71.4%)</td><td>8 (47.1%)</td><td>6 (17.6%)</td><td>0.04</td></tr><tr><td>Elevated CRP (≥8 mg/L)</td><td>5 (29.4%)</td><td>4 (11.7%)</td><td>0.14</td></tr><tr><td>* Elevated D-dimer</td><td>13 (76.5%)</td><td>3 (8.8%)</td><td>0.001</td></tr></table> |
9e24d0656c0b9b536590e873d9ca86ee7ef144d13b9ba7ac6ebe76b9ba48720b.png | simple | <table><tr><td></td><td>Drug class</td><td>Ovarian cancer indication</td><td>Black box warnings</td><td>Warnings and precautions</td></tr><tr><td>Bevacizumab [33]</td><td>VEGF inhibitor; anti-angiogenesis</td><td>Platinum-resistant recurrent disease• In combination with paclitaxel, PLD, or topotecan with no more than 2 prior lines of chemotherapyPlatinum-sensitive recurrent disease• In combination with carboplatin and paclitaxel, or carboplatin and gemcitabine; followed by single-agent bevacizumab</td><td>• Gastrointestinal perforations• Surgery and wound healing complications• Hemorrhage</td><td>• Perforation or fistula• Arterial and venous thromboembolic events• Hypertension• Posterior reversible encephalopathy syndrome• Proteinuria• Infusion reactions• Embryo-fetal toxicity• Ovarian failure</td></tr><tr><td>Niraparib [36]</td><td>PARP inhibitor</td><td>Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapy</td><td>None</td><td>• Myelodysplastic syndrome/acute myeloid leukemia• Bone marrow suppression• Cardiovascular effects (blood pressure and heart rate)• Embryo-fetal toxicity</td></tr><tr><td>Olaparib [35]</td><td>PARP inhibitor</td><td>Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapyTreatment of deleterious or suspected deleterious germline <i>BRCA</i>-mutated disease with ≥3 prior lines of chemotherapy; requires FDA-approved companion diagnostic test</td><td>None</td><td>• Myelodysplastic syndrome/acute myeloid leukemia• Pneumonitis• Embryo-fetal toxicity</td></tr><tr><td>Rucaparib [34]</td><td>PARP inhibitor</td><td>Monotherapy in patients with deleterious <i>BRCA</i> mutations treated with two or more prior chemotherapies; requires companion diagnostic test</td><td>None</td><td>• Myelodysplastic syndrome/acute myeloid leukemia• Embryo-fetal toxicity</td></tr></table> |
c1a51a288f058854a3b561e8202d0b09634a57cca7695209c1498a9ef3fbedea.png | complex | <table><tr><td></td><td colspan="2">Inhibited Temperament</td><td colspan="2">Uninhibited Temperament</td><td><i>p </i>value</td></tr><tr><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td></td></tr><tr><td>Temperament</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Retrospective</td><td>3.0</td><td>.32</td><td>1.5</td><td>.22</td><td>.0001</td></tr><tr><td> Current</td><td>3.1</td><td>.55</td><td>1.7</td><td>.14</td><td>.0001</td></tr><tr><td>Demographics</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Age</td><td>22.20</td><td>3.62</td><td>21.30</td><td>2.45</td><td>NS</td></tr><tr><td> Gender (% Male)</td><td>40%</td><td></td><td>40%</td><td></td><td>NS</td></tr><tr><td> Handedness (% Right)</td><td>80%</td><td></td><td>100%</td><td></td><td>NS</td></tr><tr><td> Ethnicity</td><td></td><td></td><td></td><td></td><td>.07</td></tr><tr><td>% Caucasian</td><td>50%</td><td></td><td>70%</td><td></td><td></td></tr><tr><td>% African-American</td><td>10%</td><td></td><td>30%</td><td></td><td></td></tr><tr><td>% Asian</td><td>40%</td><td></td><td>0%</td><td></td><td></td></tr></table> |
188f3cca216504a641e8261b233d491ee60023d2b3fd715790af532b3147d892.png | complex | <table><tr><td>SF-36 domains</td><td colspan="3">ASA</td><td colspan="3">Scheduled surgery</td><td colspan="3">Magnitude</td></tr><tr><td></td><td>I/II</td><td>III/IV</td><td>p<sup>a</sup></td><td>Yes</td><td>No</td><td>P</td><td>Major</td><td>Mediun/minor</td><td>p<sup>a</sup></td></tr><tr><td>Physical function</td><td>65</td><td>45</td><td><0.001</td><td>55</td><td>55</td><td><i>0.842</i></td><td>55</td><td>50</td><td><i>0.626</i></td></tr><tr><td>Role physical</td><td>50</td><td>25</td><td><0.001</td><td>44</td><td>38</td><td><i>0.534</i></td><td>44</td><td>38</td><td><i>0.350</i></td></tr><tr><td>Bodily pain</td><td>62</td><td>52</td><td><i>0.118</i></td><td>52</td><td>52</td><td><i>0.180</i></td><td>52</td><td>52</td><td><i>0.286</i></td></tr><tr><td>General health</td><td>50</td><td>40</td><td>0.001</td><td>45</td><td>55</td><td><i>0.533</i></td><td>45</td><td>45</td><td><i>0.330</i></td></tr><tr><td>Vitality</td><td>42</td><td>27</td><td><0.001</td><td>33</td><td>29</td><td><i>0.204</i></td><td>33</td><td>33</td><td><i>0.408</i></td></tr><tr><td>Social function</td><td>63</td><td>50</td><td>0.006</td><td>63</td><td>63</td><td><i>0.999</i></td><td>63</td><td>50</td><td><i>0.121</i></td></tr><tr><td>Role emotional</td><td>67</td><td>42</td><td><0.001</td><td>50</td><td>50</td><td><i>0.733</i></td><td>50</td><td>50</td><td><i>0.313</i></td></tr><tr><td>Mental health</td><td>56</td><td>44</td><td>0.001</td><td>48</td><td>48</td><td><i>0.837</i></td><td>48</td><td>48</td><td><i>0.939</i></td></tr></table> |
be22d4269b12e6740279c2931a31ab00bcfb4e6f0b2292fc017aeefe090bbf82.png | simple | <table><tr><td>Authors</td><td>Specimen bone</td><td>Yield strength (<i>Re</i>)[MPa]</td><td>Ult. tensile strength (<i>σ</i><sub><i>ult</i></sub>)[MPa]</td><td>Elongation at break (<i>ε</i><sub><i>ult</i></sub>)[%]</td></tr><tr><td>(Yamada 1970)</td><td>Femur</td><td></td><td>109</td><td>1.35</td></tr><tr><td>(Reilly and Burstein 1975)</td><td>Femur</td><td>114</td><td>135</td><td>3.1</td></tr><tr><td>(Vinz 1975)</td><td>Femur for adults (avg. 30 years)</td><td></td><td>106</td><td>0.26</td></tr><tr><td>(Evans 1976)</td><td>Tibia (avg. 41.5 years)</td><td></td><td>106</td><td>1.76</td></tr><tr><td>(Evans 1976)</td><td>Tibia (avg. 72 years)</td><td></td><td>84</td><td>1.56</td></tr><tr><td>(McCalden et al. 1993)(Ott 2007, Ott et al. 2010)</td><td>Femur (avg. between [20–102] years)</td><td>71</td><td>98</td><td>2.4</td></tr><tr><td>(MatWeb, 2016)</td><td>Femur</td><td></td><td>135</td><td>3.1</td></tr></table> |
f0b8cee2155601fd69aaf313ddfd15086afdbd8e0499999f560a921088beac32.png | complex | <table><tr><td>Subgroups</td><td>No. of studies</td><td>HR (95% CI)</td><td><i>I</i><sup>2</sup> (<i>P</i> value)</td></tr><tr><td colspan="4">Population</td></tr><tr><td> Children</td><td>6</td><td>5.62 (3.75–8.42)</td><td>3.2% (0.40)</td></tr><tr><td> Mixed adult and children</td><td>2</td><td>3.60 (1.72–7.51)</td><td>65.2% (0.09)</td></tr><tr><td colspan="4">Design</td></tr><tr><td> Prospective</td><td>5</td><td>5.33 (2.88–9.86)</td><td>57.6% (0.05)</td></tr><tr><td> Retrospective</td><td>3</td><td>4.59 (2.89–7.27)</td><td>0 (0.73)</td></tr><tr><td colspan="4">Detection method</td></tr><tr><td> PCR</td><td>6</td><td>4.97 (2.93–8.44)</td><td>49.2% (0.08)</td></tr><tr><td> FC</td><td>2</td><td>4.77 (3.31–6.87)</td><td>0 (0.70)</td></tr><tr><td colspan="4">Adjustment</td></tr><tr><td> Adjusted</td><td>4</td><td>4.56 (2.64–7.88)</td><td>48.9% (0.12)</td></tr><tr><td> Crude</td><td>4</td><td>5.18 (2.94–9.11)</td><td>24.4% (0.27)</td></tr></table> |
509300182d4a7b205e6cae213006d46c4252de84e3284c68c4278f57f1f0c3cf.png | complex | <table><tr><td rowspan="2">Factor</td><td rowspan="2">Responsive</td><td rowspan="2">Unresponsive</td><td rowspan="2"><i>p</i>-Value</td><td rowspan="2">OR</td><td colspan="2">95% CI of OR</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td>Gender, males</td><td>21 (40.4%)</td><td>11 (28.9%)</td><td>0.265</td><td>1.663</td><td>0.680</td><td>4.063</td></tr><tr><td>Age, years</td><td>46.75 ± 12.95</td><td>41.68 ± 17.3</td><td>0.117</td><td>1.023</td><td>0.994</td><td>1.053</td></tr><tr><td>Duration of eye symptoms, months</td><td>8.75 [4–12]<sup>a</sup></td><td>24 [12–75]</td><td>0.011</td><td>0.984</td><td>0.971</td><td>0.996</td></tr><tr><td>Smoking history</td><td>28 (53.8%)</td><td>19 (50%)</td><td>0.718</td><td>1.167</td><td>0.505</td><td>2.696</td></tr><tr><td>Family history of TAO</td><td>9 (17.3%)</td><td>12 (31.6%)</td><td>0.118</td><td>0.453</td><td>0.168</td><td>1.223</td></tr><tr><td>History of impaired thyroid function</td><td>44 (84.6%)</td><td>36 (94.7%)</td><td>0.149</td><td>0.306</td><td>0.061</td><td>1.530</td></tr><tr><td>Pretreatment CAS</td><td>4 [3–4]</td><td>2 [1–3]</td><td>0.001</td><td>1.653</td><td>1.214</td><td>2.250</td></tr><tr><td>Restoration of euthyroidism</td><td>19 (36.5%)</td><td>6 (15.8%)</td><td>0.026</td><td>3.272</td><td>1.150</td><td>9.315</td></tr></table> |
bb8c7374bc6b3e1c38865e82f2c1211943988e6f0b196ef12aa265472d3717f8.png | complex | <table><tr><td>Parameters</td><td colspan="3">Seminal leukocytes (X 10<sup>6</sup> WBC/mL)</td></tr><tr><td></td><td>No leukocytes</td><td>0.1 – 1 WBC</td><td>> 1 WBC</td></tr><tr><td>Concentration (X 10<sup>6</sup>/mL)</td><td>53.04 ± 56.76</td><td>69.04 ± 80.72</td><td>39.35 ± 39.98</td></tr><tr><td>Motility (%)</td><td>48.37 ± 17.42</td><td>47.33 ± 25.74</td><td>49.23 ± 19.56</td></tr><tr><td>Normal morphology (%)</td><td>3.42 ± 3.12</td><td>3.56 ± 3.16</td><td>4.14 ± 3.79</td></tr><tr><td>ROS (RLU/ sec)</td><td>116.7 (49; 550.3)</td><td>944.8 (127; 3315.4)<sup>a</sup></td><td>61286.8 (6905; 234876)<sup>a,b</sup></td></tr><tr><td>DNA damage (%)</td><td>19.89 ± 17.31</td><td>26.47 ± 19.64<sup>a</sup></td><td>24.60 ± 17.47</td></tr></table> |
837747ffde4aaf18044e103373ed9870cdd999e57e42fd0aacf6a5f1dc7926d1.png | complex | <table><tr><td></td><td colspan="3">Percentile GroupsGlobal Improved (%)</td><td></td></tr><tr><td>Variable</td><td>Lowest tertile</td><td>Middle tertile</td><td>Highest tertile</td><td>Fisher's Exact Test</td></tr><tr><td>Patellar Length Ratio (PLR)</td><td>3(25)</td><td>5(38.5)</td><td>4(30.8)</td><td><i>p =</i> 0.907</td></tr><tr><td><i>Bisect Offset (BO)</i></td><td><i>8(66.7)</i></td><td><i>1(7.7)</i></td><td><i>3(23.1)</i></td><td><i>p =</i> <i>0.007</i></td></tr><tr><td>Patellar Tilt Angle (PTA)</td><td>5(41.7)</td><td>5(38.5)</td><td>2(15.4)</td><td><i>p =</i> 0.323</td></tr><tr><td>Trochlear Inclination (TI) (Lateral)</td><td>4(33.3)</td><td>3(23.1)</td><td>5(38.5)</td><td><i>p =</i> 0.757</td></tr><tr><td>Trochlear Inclination (TI) (Medial)</td><td>2(16.7)</td><td>6(46.2)</td><td>4(30.8)</td><td><i>p =</i> 0.383</td></tr><tr><td>Trochlear Angle (TA)</td><td>3(25)</td><td>5(38.5)</td><td>4(30.8)</td><td><i>p =</i> 0.907</td></tr><tr><td>Sulcus Angle (SA)</td><td>4(33.3)</td><td>4(30.8)</td><td>4(30.8)</td><td><i>p =</i> 1</td></tr><tr><td>Lateral Patellofemoral Angle (LPFA)</td><td>2(16.7)</td><td>6(46.2)</td><td>4(30.8)</td><td><i>p =</i> 0.383</td></tr><tr><td>Congruence Angle (CA)</td><td>5(41.7)</td><td>5(38.5)</td><td>2(15.4)</td><td><i>p =</i> 0.323</td></tr><tr><td><i>Patellar Lateral Subluxation Distance (PSD)</i></td><td><i>7(63.6)</i></td><td><i>4(33.3)</i></td><td><i>1(8.3)</i></td><td><i>p =</i> <i>0.023</i></td></tr><tr><td>Lateral Patellar Displacement (LPD)</td><td>3(27.3)</td><td>5(41.7)</td><td>4(33.3)</td><td><i>p =</i> 0.903</td></tr></table> |
509aaa92dadf9b8b9d351af41fa7b383411f7b7769f9762cc45180d482bafdb3.png | complex | <table><tr><td>Characteristic</td><td>Total (n:12)</td></tr><tr><td colspan="2">Demographic characteristics</td></tr><tr><td>Age, median (range)</td><td>32 (21–56)</td></tr><tr><td>Men, number</td><td>9</td></tr><tr><td colspan="2">Epidemiological characteristics and risk factors</td></tr><tr><td>Foreigners, number<sup>a</sup></td><td>1</td></tr><tr><td>MSM/men, ratio</td><td>9/9 </td></tr><tr><td>High-risk sexual behaviour<sup>b</sup>, number</td><td>9</td></tr><tr><td>Contact with infected individuals, number<sup>c</sup></td><td>3</td></tr><tr><td>Travelled in the 2 months before symptom onset, number</td><td>0</td></tr><tr><td>Cases who used drugs<sup>d</sup>, number</td><td>5</td></tr><tr><td>Cases with severe hepatitis<sup>e</sup>, number</td><td>2</td></tr><tr><td>Cases which were hospitalised, number</td><td>4</td></tr><tr><td colspan="2">Sexually transmitted co-infections</td></tr><tr><td>HIV, number</td><td>5</td></tr><tr><td>HBV, number</td><td>1</td></tr><tr><td>HCV, number</td><td>0</td></tr><tr><td>Syphilis, number</td><td>2</td></tr><tr><td colspan="2">Liver function tests </td></tr><tr><td>ALT, median (range)</td><td>3,609 (1,615–5,904)</td></tr><tr><td>Total bilirubin, median (range)</td><td>8.6 (4–21)</td></tr><tr><td>INR, median (range)</td><td>1.4 (1.2–2.0)</td></tr></table> |
561c0d96f344f2b9ceae01fe407c53374e5293e4cf76c708036c93d00808c044.png | simple | <table><tr><td>Speciation Mode</td><td>Synopsis</td><td>References</td></tr><tr><td>Point mutation</td><td>Speciation whereby each individual in the metacommunity has an equal probability of producing an offspring of a new species. Produces many rare species with lifetimes unrealistically short</td><td>Hubbell (2001)</td></tr><tr><td>Random fission</td><td>Speciation occurs through a population randomly dividing into two distinct species. Produces species with lifetimes unrealistically long</td><td>Hubbell and Lake (2003), Hubbell (2005), Etienne and Haegeman (2011)</td></tr><tr><td>Peripheral isolate</td><td>Divergence follows the isolation of populations. Newly arisen species have abundances drawn from a normal distribution</td><td>Hubbell and Lake (2003), Hubbell (2005)</td></tr><tr><td>Generalized speciation</td><td>A generalized neutral community model incorporating numerous modes</td><td>Haegeman and Etienne (2009)</td></tr><tr><td>Protracted speciation</td><td>Speciation is a gradual, drawn out process. Results in a new predicted metacommunity SAD (termed the “difference logseries”)</td><td>Rosindell et al. (2010)</td></tr></table> |
a848b685b34f51341f23ac9d508107cd11996180c7bd99efec8e47552012fcc9.png | simple | <table><tr><td></td><td>a) AUC for “highly suspected drugs“</td><td>b) AUC for “highly suspected drugs“ or “suspected drugs“</td></tr><tr><td>Univariable CLR</td><td>0.836</td><td>0.871</td></tr><tr><td>Multivariable CLR</td><td>0.741</td><td>0.775</td></tr><tr><td>Lasso</td><td>0.862</td><td>0.861</td></tr><tr><td>Elastic net</td><td>0.868</td><td>0.909</td></tr><tr><td>Bolasso</td><td>0.804</td><td>0.813</td></tr><tr><td>Sublasso</td><td>0.815</td><td>0.823</td></tr><tr><td>Random lasso</td><td>0.820</td><td>0.847</td></tr><tr><td>Firth correction</td><td>0.852</td><td>0.928</td></tr><tr><td>Case-control<sup>a</sup></td><td>0.947</td><td>0.809</td></tr></table> |
8a227f3e79e3d07c9191df794067ee4c3e3742473e6587cdfe40663f46077d3a.png | complex | <table><tr><td rowspan="2">Integrins</td><td colspan="2">OS</td><td colspan="2">RFS</td></tr><tr><td>Log-rank P</td><td>Cox P*</td><td>Log-rank P</td><td>Cox P*</td></tr><tr><td>ITGA1</td><td>0.861</td><td>0.438</td><td>0.793</td><td>0.471</td></tr><tr><td>ITGA2</td><td>0.241</td><td>0.762</td><td>0.305</td><td>0.727</td></tr><tr><td>ITGA2B</td><td>0.230</td><td>0.064</td><td>0.172</td><td>0.032</td></tr><tr><td>ITGA3</td><td>0.209</td><td>0.217</td><td>0.721</td><td>0.997</td></tr><tr><td>ITGA4</td><td>0.138</td><td>0.327</td><td>0.069</td><td>0.095</td></tr><tr><td>ITGA5</td><td>0.013</td><td>0.041</td><td>0.003</td><td>0.006</td></tr><tr><td>ITGA6</td><td>0.885</td><td>0.337</td><td>0.377</td><td>0.089</td></tr><tr><td>ITGA7</td><td>0.126</td><td>0.169</td><td>0.438</td><td>0.407</td></tr><tr><td>ITGA8</td><td>0.579</td><td>0.826</td><td>0.877</td><td>0.784</td></tr><tr><td>ITGA9</td><td>0.481</td><td>0.813</td><td>0.094</td><td>0.072</td></tr><tr><td>ITGA10</td><td>0.509</td><td>0.567</td><td>0.308</td><td>0.510</td></tr><tr><td>ITGAE</td><td>0.528</td><td>0.464</td><td>0.906</td><td>0.913</td></tr><tr><td>ITGAL</td><td>0.803</td><td>0.913</td><td>0.562</td><td>0.672</td></tr><tr><td>ITGAM</td><td>0.463</td><td>0.677</td><td>0.439</td><td>0.777</td></tr><tr><td>ITGAV</td><td>0.411</td><td>0.172</td><td>0.825</td><td>0.692</td></tr><tr><td>ITGAX</td><td>0.877</td><td>0.079</td><td>0.517</td><td>0.879</td></tr><tr><td>ITGB1</td><td>0.403</td><td>0.822</td><td>0.340</td><td>0.846</td></tr><tr><td>ITGB2</td><td>0.902</td><td>0.654</td><td>0.514</td><td>0.298</td></tr><tr><td>ITGB3</td><td>0.614</td><td>0.154</td><td>0.042</td><td>0.064</td></tr><tr><td>ITGB4</td><td>0.716</td><td>0.983</td><td>0.735</td><td>0.407</td></tr><tr><td>ITGB5</td><td>0.016</td><td>0.048</td><td>0.069</td><td>0.042</td></tr><tr><td>ITGB6</td><td>0.434</td><td>0.928</td><td>0.625</td><td>0.768</td></tr><tr><td>ITGB7</td><td>0.451</td><td>0.635</td><td>0.523</td><td>0.591</td></tr><tr><td>ITGB8</td><td>0.945</td><td>0.919</td><td>0.615</td><td>0.760</td></tr></table> |
415b8b11df37dc2e21dff7b3ba049db56b8faa86a5eb0f8715610e704ca0d2b1.png | complex | <table><tr><td></td><td colspan="2">Stunting <i>n</i> = 3886</td><td colspan="2">Wasting <i>n</i> = 3886</td><td colspan="2">Underweight <i>n</i> = 3886</td><td colspan="2">Overweight <i>n</i> = 4302</td><td colspan="2">Anemia <i>n</i> = 3798</td></tr><tr><td></td><td><i>p</i>-Value</td><td>OR ** (95% CI)</td><td><i>p</i>-Value</td><td>OR ** (95% CI)</td><td><i>p</i>-Value</td><td>OR ** (95% CI)</td><td><i>p</i>-Value</td><td>OR ** (95% CI)</td><td><i>p</i>-Value</td><td>OR ** (95% CI)</td></tr><tr><td>Age in months *</td><td><0.001</td><td>1.22 (1.16–1.28)</td><td>Ns.</td><td>-</td><td><0.001</td><td>1.23 (1.16–1.29)</td><td><0.001</td><td>0.77 (0.69–0.86)</td><td><0.001</td><td>0.66 (0.63–0.70)</td></tr><tr><td>Gender (ref = female) *</td><td>Ns.</td><td>-</td><td>Ns.</td><td>-</td><td>Ns.</td><td>-</td><td>0.031</td><td>1.76 (1.05–2.94)</td><td>Ns.</td><td>-</td></tr><tr><td>Wealth index</td><td><0.001</td><td>0.83 (0.78–0.89)</td><td>0.015</td><td>0.89 (0.82–0.98)</td><td><0.001</td><td>0.84 (0.7–0.90)</td><td>0.038</td><td>1.22 (1.01–1.47)</td><td><0.001</td><td>0.85 (0.79–0.91)</td></tr><tr><td>Living area (ref = rural)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.034</td><td>0.77 (0.60–0.98)</td></tr><tr><td>BMI of mother</td><td><0.001</td><td>0.63 (0.52–0.78)</td><td><0.001</td><td>0.56 (0.41–0.76)</td><td><0.001</td><td>0.49 (0.40–0.60)</td><td>-</td><td>-</td><td>0.017</td><td>0.81 (0.6–0.96)</td></tr><tr><td>Low birth weight (ref = normal birth weight)</td><td><0.001</td><td>2.12 (1.51–2.98)</td><td><0.001</td><td>2.30 (1.49–3.55)</td><td><0.001</td><td>2.59 (1.83–3.66)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Wasting</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.039</td><td>1.35 (1.02–1.78)</td></tr><tr><td>Stunting</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td><0.001</td><td>1.46 (1.22–1.75)</td></tr></table> |
433e8545e435a6e1b74b50cf918b2e04e7d169551bae1671b8989ebbde1e26a8.png | simple | <table><tr><td>Category</td><td>Previous Methods [12]</td><td>Proposed Method</td></tr><tr><td>Number of classes</td><td>24</td><td>64</td></tr><tr><td>Number of USD images</td><td>15,000</td><td>61,240</td></tr><tr><td>False recognition rate (%)</td><td>0.12</td><td>0.114</td></tr><tr><td>Reject rate (%)</td><td>0.58</td><td>0</td></tr></table> |
73f96f05ab94de906904ab689a3df10af80d19c05b013075f7f4d9fdbc1f7618.png | simple | <table><tr><td>Z‐score</td><td>G/G</td><td>A/C</td><td>C/A</td><td>U/U</td><td>U/C</td><td>C/U</td><td>A/A</td><td>C/C</td><td>G/A</td><td>A/G</td></tr><tr><td>G/G</td><td>0.00</td><td>1.26</td><td>1.47</td><td>1.56</td><td>4.67</td><td>5.70</td><td>8.46</td><td>9.42</td><td>9.42</td><td>10.43</td></tr><tr><td>A/C</td><td>−1.26</td><td>0.00</td><td>0.22</td><td>0.30</td><td>3.42</td><td>4.46</td><td>7.25</td><td>8.23</td><td>8.23</td><td>9.26</td></tr><tr><td>C/A</td><td>−1.47</td><td>−0.22</td><td>0.00</td><td>0.09</td><td>3.21</td><td>4.25</td><td>7.04</td><td>8.03</td><td>8.03</td><td>9.06</td></tr><tr><td>U/U</td><td>1.56</td><td>−0.30</td><td>−0.09</td><td>0.00</td><td>3.12</td><td>4.17</td><td>6.96</td><td>7.95</td><td>7.95</td><td>8.98</td></tr><tr><td>U/C</td><td>−4.67</td><td>−3.42</td><td>−3.21</td><td>−3.12</td><td>0.00</td><td>1.05</td><td>3.90</td><td>4.92</td><td>4.92</td><td>5.99</td></tr><tr><td>C/U</td><td>5.70</td><td>−4.46</td><td>−4.25</td><td>−4.17</td><td>−1.05</td><td>0.00</td><td>2.86</td><td>3.89</td><td>3.89</td><td>4.97</td></tr><tr><td>A/A</td><td>−8.46</td><td>−7.25</td><td>−7.04</td><td>−6.96</td><td>−3.90</td><td>−2.86</td><td>0.00</td><td>1.04</td><td>1.04</td><td>2.15</td></tr><tr><td>C/C</td><td>−9.42</td><td>−8.23</td><td>−8.03</td><td>−7.95</td><td>−4.92</td><td>−3.89</td><td>−1.04</td><td>0.00</td><td>0.00</td><td>1.11</td></tr><tr><td>G/A</td><td>−9.42</td><td>−8.23</td><td>−8.03</td><td>−7.95</td><td>−4.92</td><td>−3.89</td><td>−1.04</td><td>0.00</td><td>0.00</td><td>1.11</td></tr><tr><td>A/G</td><td>−10.43</td><td>−9.26</td><td>−9.06</td><td>−8.98</td><td>−5.99</td><td>−4.97</td><td>−2.15</td><td>−1.11</td><td>−1.11</td><td>0.00</td></tr></table> |
3138e99af953d59af1cdf4766ae72900c1bc84401a8ffb85ae7afb576adf60dd.png | simple | <table><tr><td>Surf</td><td>Type</td><td>Radius (mm)</td><td>Thickness (mm)</td><td>Glass</td><td>Semidiameter (mm)</td><td>Conic</td></tr><tr><td>OBJ</td><td>Standard</td><td>15</td><td>10</td><td></td><td>10.143393</td><td>0</td></tr><tr><td>1</td><td>Standard</td><td>75.638249</td><td>0.228611</td><td>E48R</td><td>1.467268</td><td>0</td></tr><tr><td>2</td><td>Even Asphere</td><td>0.730586</td><td>0.375833</td><td></td><td>0.998383</td><td>−0.7580</td></tr><tr><td>3</td><td>Even Asphere</td><td>0.677934</td><td>1.181807</td><td>CAF2</td><td>0.908234</td><td>−1.5743</td></tr><tr><td>4</td><td>Standard</td><td>−1.704216</td><td>0.173513</td><td></td><td>0.692586</td><td>0</td></tr><tr><td>STO</td><td>Standard</td><td>Infinity</td><td>0.055548</td><td></td><td>0.380945</td><td>0</td></tr><tr><td>6</td><td>Standard</td><td>15.517551</td><td>0.530639</td><td>CAF2</td><td>0.441318</td><td>0</td></tr><tr><td>7</td><td>Standard</td><td>−1.085120</td><td>0.367124</td><td></td><td>0.619864</td><td>0</td></tr><tr><td>8</td><td>Even Asphere</td><td>−3.065604</td><td>0.285170</td><td>COC</td><td>0.714128</td><td>14.9694</td></tr><tr><td>9</td><td>Even Asphere</td><td>1.970309</td><td>1.236203</td><td></td><td>1.097346</td><td>−43.1582</td></tr><tr><td>IMA</td><td></td><td>Infinity</td><td>—</td><td></td><td>2.328690</td><td>0</td></tr></table> |
411a3bbe135fb1d53d0da50edcc50fcea8481ec8b21b4bc17490fcffd75b8f59.png | complex | <table><tr><td></td><td>Mean (SD) or N</td><td>Mean (SD) or N</td><td>P value</td></tr><tr><td></td><td>Methylphenidate slow release (N = 28)</td><td>Placebo (N = 28)</td><td></td></tr><tr><td>Age (years)</td><td>35.6(10.8)</td><td>34.7(11.5)</td><td>ns</td></tr><tr><td>Gender, n</td><td>8</td><td>7</td><td rowspan="3">ns</td></tr><tr><td>• Female</td><td>20</td><td>21</td></tr><tr><td>• Male</td><td></td><td></td></tr><tr><td>Marital status, n</td><td></td><td></td><td rowspan="4">ns</td></tr><tr><td>• Single</td><td>18</td><td>19</td></tr><tr><td>• Married</td><td>6</td><td>5</td></tr><tr><td>• Divorced</td><td>4</td><td>4</td></tr><tr><td>Level of education, n</td><td></td><td></td><td rowspan="5">ns</td></tr><tr><td>• Illiterate</td><td>2</td><td>1</td></tr><tr><td>• Primary school</td><td>16</td><td>17</td></tr><tr><td>• High school diploma</td><td>8</td><td>9</td></tr><tr><td>• University degree</td><td>2</td><td>1</td></tr><tr><td>Smoking, n</td><td>25</td><td>26</td><td>ns</td></tr><tr><td>Use of methadone</td><td>12</td><td>11</td><td>ns</td></tr><tr><td>Employed, n</td><td>5</td><td>7</td><td>ns</td></tr><tr><td>Years of methamphetamine use</td><td>13.3(8.5)</td><td>12.8(9.1)</td><td>ns</td></tr><tr><td>Days of methamphetamine use (past month)</td><td>10.2(8.7)</td><td>10.4(8.8)</td><td>ns</td></tr><tr><td>Route of methamphetamine use, n</td><td></td><td></td><td rowspan="5">ns</td></tr><tr><td>• Smoking</td><td>23</td><td>22</td></tr><tr><td>• Nasal</td><td>3</td><td>2</td></tr><tr><td>• Injection</td><td>1</td><td>1</td></tr><tr><td>• Oral</td><td>1</td><td>3</td></tr><tr><td>Addiction severity index composite score</td><td></td><td></td><td rowspan="8">ns</td></tr><tr><td>• Medical</td><td>0.25(0.31)</td><td>0.28(0.26)</td></tr><tr><td>• Employment</td><td>0.22(017)</td><td>0.24(0.19)</td></tr><tr><td>• Alcohol</td><td>0.15(0.10)</td><td>0.14(0.13)</td></tr><tr><td>• Drug</td><td>0.28(0.1)</td><td>0.29(0.12)</td></tr><tr><td>• Legal</td><td>0.08(0.17)</td><td>0.07(0.16)</td></tr><tr><td>• Family/Social</td><td>0.22(0.23)</td><td>0.19(0.20)</td></tr><tr><td>• Psychiatric</td><td>0.24(0.25)</td><td>0.22(0.23</td></tr></table> |
b0964228c279e197cea63f5b2db1c6de6ba7b780341289444ceafaae596ef30e.png | simple | <table><tr><td>City</td><td>Number of Stations</td><td>2008</td><td>2009</td><td>2010</td><td>2011</td></tr><tr><td>Kochi</td><td>7</td><td>43</td><td>42</td><td>36</td><td>38</td></tr><tr><td>Kozhikode</td><td>2</td><td>34</td><td>32</td><td>42</td><td>46</td></tr><tr><td>Thrissur</td><td>1</td><td>–</td><td>–</td><td>31</td><td>33</td></tr><tr><td>Mallapuram</td><td>1</td><td>–</td><td>–</td><td>39</td><td>30</td></tr><tr><td>Trivandrum</td><td>4</td><td>67</td><td>61</td><td>56</td><td>58</td></tr><tr><td>Kollam</td><td>2</td><td>–</td><td>–</td><td>47</td><td>53</td></tr></table> |
a4505a97d96c392abbe693fec348c0b57c321efe0687d52e450a5d26a7b2a0f1.png | complex | <table><tr><td rowspan="3">MRI</td><td colspan="2">Surgical pathology</td><td rowspan="3">Sensitivitya, % (n)</td><td rowspan="3">Specificityb, % (n)</td><td rowspan="3">POS predictionc value, % (n)</td><td rowspan="3">NEG predictiond value, % (n)</td><td rowspan="3">Accuracye, % (n)</td><td rowspan="3">κ</td><td rowspan="3">P-value</td></tr><tr><td>POS</td><td>NEG</td></tr><tr><td>T1</td><td></td><td></td><td>60 (3/5)</td><td>96 (24/25)</td><td>75 (3/4)</td><td>92.33 (24/26)</td><td>90 (27/30)</td><td>0.61</td><td><0.001</td></tr><tr><td> POS</td><td>3</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> NEG</td><td>2</td><td>24</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>T2</td><td></td><td></td><td>83.3 (5/6)</td><td>87.5 (21/24)</td><td>62.5 (5/8)</td><td>95.4 (21/22)</td><td>86.7 (26/30)</td><td>0.71</td><td><0.001</td></tr><tr><td> POS</td><td>5</td><td>3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> NEG</td><td>1</td><td>21</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>T3</td><td></td><td></td><td>90 (9/10)</td><td>90 (18/20)</td><td>81.8 (9/11)</td><td>94.7 (18/19)</td><td>90 (27/30)</td><td>0.78</td><td><0.001</td></tr><tr><td> POS</td><td>9</td><td>2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> NEG</td><td>1</td><td>18</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>T4</td><td></td><td></td><td>87.5 (7/8)</td><td>100 (22/22)</td><td>100 (7/7)</td><td>95.7 (22/23)</td><td>96.7 (29/30)</td><td>0.91</td><td><0.001</td></tr><tr><td> POS</td><td>7</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> NEG</td><td>1</td><td>22</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> |
b37c14a5cd4b9d7971d96a3b9891cc07fd79b589e25ef6496114e8b81adb6260.png | complex | <table><tr><td rowspan="2">Clinicopathologicalcharacteristics</td><td colspan="2">KRAS/BRAF gene</td><td rowspan="2"><i>P</i>-value</td></tr><tr><td>Mutation(<i>n</i> = 11)</td><td>Wild-type(<i>n</i> = 21)</td></tr><tr><td>Age (years)</td><td></td><td></td><td>0.106</td></tr><tr><td>< 45</td><td>1 (9.10%)</td><td>9 (42.86%)</td><td></td></tr><tr><td>≥ 45</td><td>10 (90.90%)</td><td>12 (57.14%)</td><td></td></tr><tr><td>FIGO stage</td><td></td><td></td><td>1.000</td></tr><tr><td> I/II</td><td>3 (27.27%)</td><td>7 (33.33%)</td><td></td></tr><tr><td> III/IV</td><td>8 (72.73%)</td><td>14 (66.67%)</td><td></td></tr><tr><td>CA125 (U/ml)</td><td></td><td></td><td>1.000</td></tr><tr><td>≤ 35 U/mL</td><td>0 (0.00%)</td><td>1 (4.76%)</td><td></td></tr><tr><td>> 35 U/mL</td><td>11 (100.00%)</td><td>20 (95.24%)</td><td></td></tr><tr><td>Tumor size(cm)</td><td></td><td></td><td>0.442</td></tr><tr><td>< 10</td><td>5 (45.45%)</td><td>6 (28.57%)</td><td></td></tr><tr><td>≥ 10</td><td>6 (54.55%)</td><td>15 (71.43%)</td><td></td></tr><tr><td>Laterality</td><td></td><td></td><td>0.053</td></tr><tr><td> Unilateral</td><td>7 (63.64%)</td><td>5 (23.81%)</td><td></td></tr><tr><td> Bilateral</td><td>4 (36.36%)</td><td>16 (76.19%)</td><td></td></tr><tr><td>Cytology</td><td></td><td></td><td>0.703</td></tr><tr><td> Negative</td><td>8 (72.73%)</td><td>13 (61.90%)</td><td></td></tr><tr><td> Positive</td><td>3 (27.27%)</td><td>8 (38.10%)</td><td></td></tr><tr><td>Ascites</td><td></td><td></td><td>0.441</td></tr><tr><td> Absent</td><td>2 (18.18%)</td><td>7 (33.33%)</td><td></td></tr><tr><td> Present</td><td>9 (81.82%)</td><td>14 (66.67%)</td><td></td></tr><tr><td>Ovarian surface involvement</td><td></td><td></td><td>0.815</td></tr><tr><td> No</td><td>3 (27.27%)</td><td>8 (38.10%)</td><td></td></tr><tr><td> Yes</td><td>7 (63.64%)</td><td>11 (52.38%)</td><td></td></tr><tr><td> Unknown</td><td>1 (9.10%)</td><td>2 (9.52%)</td><td></td></tr><tr><td>Metastases</td><td></td><td></td><td>1.000</td></tr><tr><td> No</td><td>3 (27.27%)</td><td>7 (33.33%)</td><td></td></tr><tr><td> Yes</td><td>8 (72.73%)</td><td>14 (66.67%)</td><td></td></tr><tr><td>Lymph node involvement</td><td></td><td></td><td>0.392</td></tr><tr><td> No</td><td>1 (9.10%)</td><td>1 (4.76%)</td><td></td></tr><tr><td> Yes</td><td>2 (18.18%)</td><td>1 (4.76%)</td><td></td></tr><tr><td> Unknown</td><td>8 (72.73%)</td><td>19 (90.48%)</td><td></td></tr></table> |
f7ff19ff1233450785bc0788cab1d83a2d5af34d7b7ce840b7d06f9fe51f0de1.png | simple | <table><tr><td>Authors</td><td>Date</td><td>Condition<sup>a</sup>and sample size</td><td>Exploration-insight gain</td><td>Experiential gain</td><td>Action gain</td></tr><tr><td>Current study</td><td></td><td>Ullman dream group. (<i>n</i> = 11)</td><td>8.17 (0.54)</td><td>7.28 (1.94)</td><td>5.78 (1.04)</td></tr><tr><td>Heaton et al.</td><td>1998</td><td>Therapist-facilitated, following Hill (1996). (<i>n</i> = 25)</td><td>8.03 (0.73)</td><td>7.06 (1.50)</td><td>6.98 (1.07)<sup>**</sup></td></tr><tr><td></td><td></td><td>Self-guided, following Hill (1996) as adapted by Hill et al. (1996). (<i>n</i> = 25)</td><td>6.61 (1.35)<sup>**</sup></td><td>6.76 (1.74)</td><td>5.99 (1.11)</td></tr><tr><td>Hill et al.</td><td>1998</td><td>Participants elaborate on image details in dream, following only the Exploration Stage of the Hill (1996) model. (<i>n</i> = 17)</td><td>4.61 (1.71)<sup>**</sup></td><td>Not reported</td><td>Not reported</td></tr><tr><td></td><td></td><td>Participants provide associations to images, following only the Exploration Stage of the Hill (1996) model. (<i>n</i> = 17)</td><td>6.48 (1.35)<sup>**</sup></td><td>Not reported</td><td>Not reported</td></tr><tr><td></td><td></td><td>Participants elaborate on image details and provide associations. Following only the Exploration Stage of the Hill (1996) model. (<i>n</i> = 17)</td><td>5.84 (1.76)<sup>**</sup></td><td>Not reported</td><td>Not reported</td></tr><tr><td>Zack and Hill</td><td>1998</td><td>Used Hill (1996) model. (<i>n</i> = 38)</td><td>7.67 (1.10)</td><td>7.09 (1.42)</td><td>6.34 (1.74)</td></tr><tr><td>Rochlen et al.</td><td>1999</td><td>Pre-study discussion of benefits of dream contemplation. Participants encouraged to use strategies to boost dream recall prior to study following Hill (1996). (<i>n</i> = 14)</td><td>7.48 (1.48)</td><td>7.00 (1.70)</td><td>6.03 (1.41)</td></tr><tr><td></td><td></td><td>Involved an introduction to Hill model and participation in two sessions of the group procedure prior to study following Hill (1996). (<i>n</i> = 14)</td><td>8.04 (0.96)</td><td>6.79 (1.97)</td><td>7.01 (1.34)<sup>*</sup></td></tr><tr><td></td><td></td><td>Pre-study discussion of theoretical perspectives regarding counseling prior to study following Hill (1996). (<i>n</i> = 14)</td><td>7.92 (0.82)</td><td>7.32 (1.48)</td><td>6.79 (1.22)<sup>*</sup></td></tr><tr><td>Hill et al.</td><td>2000</td><td>Dream condition, following Hill (1996). (<i>n</i> = 7)</td><td>8.08 (0.52)</td><td>7.43 (0.97)</td><td>7.54 (0.49)<sup>**</sup></td></tr><tr><td></td><td></td><td>Control condition: Recent loss focussed on, not a dream (<i>n</i> = 7)<sup>b</sup></td><td>6.63 (0.76)<sup>**</sup></td><td>6.59 (0.99)</td><td>6.12 (0.82)</td></tr><tr><td>Wonnell and Hill</td><td>2000</td><td>Hill (1996) followed, action stage omitted (<i>n</i> = 23)</td><td>7.88 (1.06)</td><td>Not reported</td><td>6.10 (1.24)</td></tr><tr><td></td><td></td><td>Hill (1996) followed, including Action stage (<i>n</i> = 20)</td><td>7.99 (1.00)</td><td>Not reported</td><td>6.98 (1.45)<sup>*</sup></td></tr><tr><td>Hill et al.</td><td>2001</td><td>Followed Hill (1996). (<i>n</i> = 105)</td><td>7.77 (1.20)</td><td>Not reported</td><td>Not reported</td></tr><tr><td>Hill et al.</td><td>2003</td><td>Participants type dream and computer-generated voice asks questions, following Hill (1996). (<i>n</i> = 39)</td><td>6.72 (1.27)<sup>**</sup></td><td>Not reported</td><td>6.12 (1.73)</td></tr><tr><td></td><td></td><td>Therapist empathy: Followed Hill (1996) but therapists did not offer interpretations or provide action suggestions. (<i>n</i> = 26)</td><td>7.75 (0.85)</td><td>Not reported</td><td>6.60 (1.16)</td></tr><tr><td></td><td></td><td>Therapist empathy + input: Followed Hill (1996), at least one therapist interpretation and one action idea offered to participants. (<i>n</i> = 29)</td><td>7.93 (0.93)</td><td>Not reported</td><td>6.81 (1.05)<sup>**</sup></td></tr><tr><td>All Hill studies</td><td></td><td>Weighted mean (SD) of all Hill dream conditions<sup>c</sup></td><td>7.40 (1.15)</td><td>7.03 (1.56)</td><td>6.51 (1.34)</td></tr></table> |
b1c15e658add76d37f42e5a865e7fa99a59a9b060a9662c7ae5598c7dc62bb78.png | complex | <table><tr><td rowspan="2">Study intervention</td><td rowspan="2">N</td><td colspan="2">Darunavir C<sub>trough,ss</sub>, ng/mL</td><td colspan="2">Elvitegravir C<sub>trough,ss</sub>, ng/mL</td><td rowspan="2">Refs.</td></tr><tr><td>Median/mean</td><td>Range</td><td>Median/mean</td><td>Range</td></tr><tr><td>DRV/rtv, pre-switch</td><td>5</td><td>981 (median)932 (mean)</td><td>667–1150</td><td>––</td><td>–</td><td></td></tr><tr><td>E/C/F/TDF + DRV</td><td>9</td><td>482 (median)490 (mean)</td><td>96–848</td><td>184 (median)200 (mean)</td><td><80–435</td><td></td></tr><tr><td rowspan="2">DRV/rtv 800/100 mg</td><td>335<sup>a</sup></td><td>2041 (median)</td><td>368–7242</td><td>–</td><td>–</td><td>[22]</td></tr><tr><td>119</td><td>1820 (mean)</td><td>IQR 1470–2460</td><td>–</td><td>–</td><td>[23]</td></tr><tr><td rowspan="3">DRV/cobi 800/150 mg</td><td>298<sup>a</sup></td><td>2150 (mean)</td><td>SD 1320</td><td>–</td><td>–</td><td>[25]</td></tr><tr><td>59</td><td>1311 (mean)</td><td>SD 969</td><td>–</td><td>–</td><td>[25]</td></tr><tr><td>32</td><td>1319 (mean)</td><td>288–3641</td><td>–</td><td>–</td><td>[24]</td></tr><tr><td rowspan="2">E/C/F/TDF (no DRV)</td><td>419<sup>a</sup></td><td>–</td><td>–</td><td>451 (mean)</td><td>58–2341</td><td>[26]</td></tr><tr><td>32</td><td>–</td><td>–</td><td>250 (mean)</td><td>30–762</td><td>[24]</td></tr><tr><td rowspan="2">E/C/F/TDF + DRV</td><td>24</td><td>1294 (mean)</td><td>163–3641</td><td>234 (mean)</td><td>92–432</td><td>[24]</td></tr><tr><td>8</td><td>273 (median)<sup>b</sup></td><td>164–501 (IQR)<sup>b</sup></td><td>–</td><td>–</td><td>[12]</td></tr><tr><td>E/C/F/TAF + DRV</td><td>15</td><td>1250 (mean)</td><td>NA</td><td>464 (mean)</td><td>NA</td><td>[36]</td></tr></table> |
8feee3039258f9b5e92570ac4e1731e3e09877aa567c55b400799e879bc45f85.png | complex | <table><tr><td rowspan="2">Characteristics</td><td colspan="4">Serum fibrinogen levels, g/l</td><td rowspan="2"><i>p</i>-value</td></tr><tr><td>Q1 (1.7–2.8)</td><td>Q2 (2.8–3.3)</td><td>Q3 (3.3–3.9)</td><td>Q4 (3.9–8.2)</td></tr><tr><td>Patients (n)</td><td>171</td><td>167</td><td>167</td><td>165</td><td></td></tr><tr><td>At time of biopsy</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Female (n [%])</td><td>95 (55.6)</td><td>100 (59.9)</td><td>99 (59.3)</td><td>87 (52.7)</td><td>0.515</td></tr><tr><td>Age (mean [SD], years)</td><td>32.3 (8.3)</td><td>36.4 (11.2)</td><td>38.4 (11.4)</td><td>41.9 (13.9)</td><td>< 0.001</td></tr><tr><td>BMI (mean [SD], kg/m<sup>2</sup>)</td><td>22.0 (2.9)</td><td>23.00 (3.2)</td><td>23.12 (3.3)</td><td>24.0 (3.8)</td><td>< 0.001</td></tr><tr><td>TC (mean [SD], g/l)</td><td>4.4 (0.9)</td><td>4.9 (1.1)</td><td>5.1 (1.1)</td><td>5.7 (1.7)</td><td>< 0.001</td></tr><tr><td>TG (median [IQR], g/l)</td><td>1.2 [0.9, 1.6]</td><td>1.5 [1.1, 2.3]</td><td>1.6 [1.1, 2.2]</td><td>1.9 [1.3, 2.5]</td><td>< 0.001</td></tr><tr><td>HDL-C (mean [SD], g/l)</td><td>1.2 (0.3)</td><td>1.2(0.3)</td><td>1.1 (0.3)</td><td>1.1 (0.3)</td><td>0.521</td></tr><tr><td>LDL-C (mean [SD], g/l)</td><td>2.6 (0.7)</td><td>2.9 (0.9)</td><td>3.0 (0.8)</td><td>3.4 (1.3)</td><td>< 0.001</td></tr><tr><td>Scr (median [IQR], mmol/l)</td><td>73 [59, 90]</td><td>73 [59, 96]</td><td>83 [63, 113]</td><td>98 [75, 138]</td><td>< 0.001</td></tr><tr><td>Upro (median [IQR], g/24 h)</td><td>0.8 [0.4, 1.2]</td><td>1.0 [0.6, 1.6]</td><td>1.4 [0.9, 2.9]</td><td>2.7 [1.5, 4.8]</td><td>< 0.001</td></tr><tr><td>eGFR (mean [SD], ml/min/1.73 m<sup>2</sup>)</td><td>105 (25.2)</td><td>99 (25.5)</td><td>86 (30.8)</td><td>71 (31.9)</td><td>< 0.001</td></tr><tr><td>ALB (mean [SD], g/l)</td><td>40.3 (6.7)</td><td>40.0 (6.7)</td><td>38.1 (7.3)</td><td>34.2 (8.3)</td><td>< 0.001</td></tr><tr><td>UA (median [IQR], mmol/l)</td><td>342 [274, 404]</td><td>355 [289, 414]</td><td>355 [305, 440]</td><td>382 [327, 446]</td><td>< 0.001</td></tr><tr><td>Hb (mean [SD], g/l)</td><td>125.1 (19.3)</td><td>130.3 (17.0)</td><td>125.5 (18.5)</td><td>121.6 (19.5)</td><td>< 0.001</td></tr><tr><td>SBP (mean [SD], mmHg)</td><td>124.96 (15.8)</td><td>130.41 (21.3)</td><td>132.29 (16.9)</td><td>137.98 (19.8)</td><td>< 0.001</td></tr><tr><td>DBP (mean [SD], mmHg)</td><td>77.25 (10.3)</td><td>81.34 (12.1)</td><td>81.58 (12.4)</td><td>84.61 (12.0)</td><td>< 0.001</td></tr><tr><td>Oxford classification</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>M1 (n [%])</td><td>60 (35.9)</td><td>72 (43.4)</td><td>75 (45.7)</td><td>94 (57.7)</td><td>0.001</td></tr><tr><td>E1 (n [%])</td><td>55 (32.9)</td><td>38 (22.9)</td><td>51 (30.9)</td><td>48 (29.4)</td><td>0.206</td></tr><tr><td>S1 (n [%])</td><td>129 (77.2)</td><td>124 (75.2)</td><td>134 (81.2)</td><td>119 (73.0)</td><td>0.338</td></tr><tr><td>T (n [%])</td><td></td><td></td><td></td><td></td><td>< 0.001</td></tr><tr><td> T0</td><td>130 (77.8)</td><td>119 (71.3)</td><td>89 (53.9)</td><td>81 (49.7)</td><td></td></tr><tr><td> T1</td><td>30 (18.0)</td><td>38 (22.8)</td><td>54 (32.7)</td><td>39 (23.9)</td><td></td></tr><tr><td> T2</td><td>7 (4.2)</td><td>10 (6.0)</td><td>22 (13.3)</td><td>43 (26.4)</td><td></td></tr><tr><td>C1 (n [%])</td><td>79 (46.5)</td><td>65 (38.9)</td><td>82 (49.1)</td><td>86 (52.8)</td><td>0.077</td></tr><tr><td>Follow-up</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Follow-up time (median [IQR], months)</td><td>41.0 [20.0, 66.5]</td><td>34.0 [19.5, 55.5]</td><td>34.0 [16.0, 57.5]</td><td>35.0 [20.0, 64.0]</td><td>0.034</td></tr><tr><td>Primary endpoint (n [%])</td><td>3 (1.8)</td><td>9 (5.4)</td><td>29 (17.4)</td><td>49 (29.7)</td><td>< 0.001</td></tr><tr><td>ESRD (n [%])</td><td>2 (1.2)</td><td>1 (0.6)</td><td>10 (6.0)</td><td>17 (10.3)</td><td>< 0.001</td></tr><tr><td>Treated with ACEIs (n [%])</td><td>65 (38.0)</td><td>54 (32.3)</td><td>66 (39.5)</td><td>57 (34.5)</td><td>0.509</td></tr><tr><td>Treated with ARBs (n [%])</td><td>148 (86.5)</td><td>148 (88.6)</td><td>147 (88.0)</td><td>133 (80.6)</td><td>0.136</td></tr><tr><td>Immunosuppressant therapy</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Glucocorticoids (n [%])</td><td>65 (38.0)</td><td>79 (47.3)</td><td>95 (56.9)</td><td>98 (59.4)</td><td>< 0.001</td></tr><tr><td> Cyclophosphamide (n [%])</td><td>6 (3.5)</td><td>3 (1.8)</td><td>14 (8.4)</td><td>25 (15.2)</td><td>< 0.001</td></tr><tr><td> OtherIM (n [%])</td><td>36 (21.1)</td><td>44 (26.3)</td><td>48 (28.7)</td><td>61 (37.0)</td><td>0.012</td></tr></table> |
5b9208fdac8347c9dcb39391271eceb450249adfdedc7d4d85fe9fb0073a9e82.png | complex | <table><tr><td colspan="2">Uveoscleral outflow (<i>μ</i>L min<sup>−1</sup>)</td></tr><tr><td>Bimatoprost</td><td>1.37* ± 0.27</td></tr><tr><td>Vehicle</td><td>0.96 ± 0.20</td></tr></table> |
0551be8260ed5eadc09eeb3b46e83007b3abf88c68fbd5b5af07c94b45e3ae63.png | simple | <table><tr><td>Immunohistochemistry stains</td><td>Esophageal tumor</td><td>Liver biopsy (neoplastic cells)</td><td>Bladder biopsy (neoplastic cells)</td><td><i>Primary </i>bladder cancer</td></tr><tr><td>CK7</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>CK20</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>CDX-2</td><td>+</td><td>+</td><td>+</td><td>−</td></tr><tr><td>GATA-3</td><td>−</td><td>−</td><td>−</td><td>+</td></tr><tr><td>Uroplakin</td><td>−</td><td>−</td><td>−</td><td>+</td></tr></table> |
d591ae195dedd01bcf823a1e7aa35238c4e94e434ca17685a24ef5f72488a7da.png | complex | <table><tr><td>Sequence</td><td colspan="3">Dialysate Potassium</td></tr><tr><td></td><td>1st tertile</td><td>2nd tertile</td><td>3th tertile</td></tr><tr><td>1</td><td>K-1</td><td>K</td><td>K+1</td></tr><tr><td>2</td><td>K-1</td><td>K+1</td><td>K</td></tr><tr><td>3</td><td>K</td><td>K-1</td><td>K+1</td></tr><tr><td>4</td><td>K</td><td>K+1</td><td>K-1</td></tr><tr><td>5</td><td>K+1</td><td>K</td><td>K-1</td></tr><tr><td>6</td><td>K+1</td><td>K-1</td><td>K</td></tr></table> |
d86c20763ac4dd24e39c93e5b6fea673b084e8689933e1b4821b1d63fe8b4f01.png | simple | <table><tr><td>Comparison groups</td><td>averages</td><td>df</td><td><i>t</i></td><td><i>P</i></td></tr><tr><td>TE-genes vs non TE-genes</td><td>0.82 vs 0.76</td><td>14800</td><td>7.4</td><td>1.2e-13</td></tr><tr><td>TE-exons vs non TE-genes</td><td>0.96 vs 0.76</td><td>14386</td><td>9.4</td><td>6.8e-21</td></tr><tr><td>Alu-exons vs other TE-exons</td><td>1.01 vs 0.95</td><td>345</td><td>1.9</td><td>6.2e-2</td></tr><tr><td>Alu-exons vs non TE-genes</td><td>1.01 vs 0.76</td><td>14106</td><td>8.2</td><td>3.9e-16</td></tr></table> |
a5a583ef85ca3c8d83127798852d35a912daf6b3e8be26d94bd66e4cbc84daed.png | simple | <table><tr><td>LncRNA</td><td>Expression</td><td>Mechanism</td><td>Target</td><td>Reference</td></tr><tr><td>AK058003</td><td>Upregulation</td><td>Hypoxia;Methylation in the CpG islands</td><td>SNCG</td><td>[59]</td></tr><tr><td>AK123072</td><td>Upregulation</td><td>Hypoxia;Methylation in the CpG islands</td><td>EGFR</td><td>[60]</td></tr><tr><td>HOTTIP</td><td>Upregulation</td><td>Methylation in the CpG islands;H3K4 methylation</td><td>HoxA13</td><td>[61, 62]</td></tr><tr><td>HOXA11-AS</td><td>Upregulation</td><td>DNA methylation;Histone modification; miR-1297</td><td>E2F1; P21; E-cadherin; EZH2</td><td>[63, 64]</td></tr><tr><td>HOTAIR</td><td>Upregulation</td><td>H3K27 trimethylation; miR-34a</td><td>C-Met; Snail</td><td>[68–70]</td></tr><tr><td>MALAT1</td><td>Upregulation</td><td>H3 histone acetylation</td><td>EGFL7</td><td>[36, 71]</td></tr><tr><td>GClnc1</td><td>Upregulation</td><td>Histone modification</td><td>SOD2</td><td>[72]</td></tr><tr><td>LINC00673</td><td>Upregulation</td><td>SP1; Histone modification</td><td>KLF2; LATS2</td><td>[73]</td></tr><tr><td>AGAP2-AS1</td><td>Upregulation</td><td>SP1; Histone modification</td><td>P21; E-cadherin</td><td>[74]</td></tr><tr><td>ZFAS1</td><td>Upregulation</td><td>Histone modification</td><td>NDK2; KLF2</td><td>[75]</td></tr><tr><td>PVT1</td><td>Upregulation</td><td>Histone modification</td><td>p15; p16</td><td>[70]</td></tr><tr><td>LINC00668</td><td>Upregulation</td><td>E2F1; Histone methylation</td><td>p15; p16; p21; p27; p57</td><td>[76, 77]</td></tr><tr><td>TUG1</td><td>Upregulation</td><td>Histone methylation</td><td>P57</td><td>[78]</td></tr><tr><td>LINC00152</td><td>Upregulation</td><td>Histone methylation</td><td>p15; p21</td><td>[79]</td></tr><tr><td>FEZF1-AS1</td><td>Upregulation</td><td>H3K4 methylation</td><td>p21</td><td>[80]</td></tr><tr><td>ANRIL</td><td>Upregulation</td><td>Histone modification;miR-99a/miR-449a</td><td>p15INK4B; p16INK4A; mTOR; CDK6</td><td>[83–85]</td></tr><tr><td>SPRY4-IT1</td><td>Downregulation</td><td>DNA methylation</td><td>SPRY4-IT1</td><td>[87]</td></tr><tr><td>LOC100130476</td><td>Downregulation</td><td>Methylation in the CpG islands</td><td>LOC100130476</td><td>[88]</td></tr><tr><td>GAS5</td><td>Downregulation</td><td>Promoter methylation</td><td>GAS5</td><td>[89, 90]</td></tr><tr><td>FENDRR</td><td>Downregulation</td><td>Histone deacetylation</td><td>FENDRR</td><td>[90, 91, 92]</td></tr><tr><td>MEG3</td><td>Downregulation</td><td>Promoter methylation; miR-148a</td><td>MEG3; RUNX3</td><td>[93, 94,95–97]</td></tr></table> |
d3c440ad1eb1966bb4651cd35164f16ba9cb86a0e7c937d5e735697cf6aa724e.png | complex | <table><tr><td>ROI</td><td>hemisphere</td><td>x</td><td>y</td><td>z</td><td>t-statistic</td></tr><tr><td rowspan="2">HF</td><td>left</td><td>−30</td><td>−36</td><td>−6</td><td>3.64</td></tr><tr><td>right</td><td>33</td><td>−36</td><td>−9</td><td>3.73</td></tr><tr><td rowspan="2">PHC</td><td>left</td><td>−21</td><td>−42</td><td>9</td><td>4.87</td></tr><tr><td>right</td><td>30</td><td>−39</td><td>6</td><td>6.81</td></tr><tr><td rowspan="2">Rsp</td><td>left</td><td>−9</td><td>−48</td><td>12</td><td>3.97</td></tr><tr><td>right</td><td>9</td><td>−51</td><td>12</td><td>3.89</td></tr><tr><td rowspan="2">PCC</td><td>left</td><td>−12</td><td>−54</td><td>24</td><td>5.12</td></tr><tr><td>right</td><td>12</td><td>−51</td><td>24</td><td>5.16</td></tr><tr><td rowspan="2">AMPFC</td><td>left</td><td>−9</td><td>51</td><td>−6</td><td>3.24</td></tr><tr><td>right</td><td>9</td><td>48</td><td>−3</td><td>3.72</td></tr><tr><td>pIPL</td><td>left</td><td>−39</td><td>−75</td><td>33</td><td>3.58</td></tr></table> |
8735170869f3dc8570d9500269c2c1650b9b904d33eaa98ea189171d48483061.png | complex | <table><tr><td colspan="2">Variable</td><td>Spearman’s rho</td><td>p</td></tr><tr><td colspan="2">Age</td><td>-0.08</td><td><0.05</td></tr><tr><td colspan="2">Hours of self-regulated learning</td><td> </td><td> </td></tr><tr><td rowspan="2"> </td><td>Term time</td><td>-0.10</td><td><0.05</td></tr><tr><td>Revision period</td><td>-0.10</td><td><0.01</td></tr><tr><td colspan="2">Research activity</td><td>-0.17</td><td><0.01</td></tr><tr><td colspan="2">Teaching activity</td><td>-0.13</td><td><0.01</td></tr><tr><td colspan="2">Employment</td><td>0.10</td><td><0.05</td></tr><tr><td colspan="2">Care for family</td><td>0.10</td><td><0.05</td></tr></table> |
a432f73bc0ad651189280722403ac9bf4c9b3fb0a817e0e0d6b3aad7c7e1cf55.png | simple | <table><tr><td> </td><td>K-Cd (μg/g ww)</td><td>Age</td><td>Sex</td><td>Weight</td><td>Menopause</td><td>S-Ca, ionized (mmol/l)</td><td>24-h urinary flow rate (ml/h)</td><td>Overnight urinary flow rate (ml/h)</td><td>S-25(OH)D3 (ng/ml)</td><td>24-h U-Ca (mmol/h)</td><td>24-h U-Ca (mmol/mmol creatinine)</td><td>ON U-Ca (mmol/h)</td><td>ON U-Ca (mmol/mmol creatinine)</td></tr><tr><td>K-Cd, μg/g ww</td><td> </td><td>0.28**</td><td>0.24*</td><td>-0.27**</td><td>0.33**</td><td>0.06</td><td>-0.09</td><td>0.09</td><td>0.14</td><td>-0.06</td><td>0.27*</td><td>0.05</td><td>0.27**</td></tr><tr><td>Age</td><td>0.33**</td><td> </td><td>-0.10</td><td>-0.009</td><td>0.44**</td><td>-0.22*</td><td>-0.29**</td><td>0.08</td><td>0.13</td><td>0.006</td><td>0.25*</td><td>0.14</td><td>0.23*</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td>-0.57**</td><td>0.49**</td><td>0.06</td><td>0.07</td><td>-0.12</td><td>0.09</td><td>-0.41**</td><td>0.16</td><td>-0.27**</td><td>0.15</td></tr><tr><td>Weight</td><td>-0.10</td><td>0.04</td><td> </td><td> </td><td>-0.32**</td><td>0.15</td><td>-0.09</td><td>0.06</td><td>-0.22*</td><td>0.23*</td><td>-0.30**</td><td>0.17</td><td>-0.25*</td></tr><tr><td>Menopause</td><td>0.31*</td><td>0.77**</td><td> </td><td>-0.08</td><td> </td><td>-0.13</td><td>-0.13</td><td>-0.03</td><td>0.08</td><td>-0.14</td><td>0.29**</td><td>0.05</td><td>0.34**</td></tr><tr><td>S-Ca, ionized, mmol/l</td><td>0.17</td><td>-0.15</td><td> </td><td>0.21</td><td>-0.22</td><td> </td><td>0.05</td><td>0.12</td><td>-0.06</td><td>0.21</td><td>0.30**</td><td>0.22*</td><td>0.26**</td></tr><tr><td>24-h urinary flow rate, ml/h</td><td>-0.02</td><td>-0.25</td><td> </td><td>-0.01</td><td>-0.23</td><td>0.06</td><td> </td><td>0.43**</td><td>0.13</td><td>-0.01</td><td>-0.06</td><td>-0.06</td><td>-0.07</td></tr><tr><td>Overnight urinary flow rate, ml/h</td><td>0.25</td><td>-0.04</td><td> </td><td>-0.11</td><td>0.05</td><td>0.15</td><td>0.52**</td><td> </td><td>0.02</td><td>0.005</td><td>0.06</td><td>0.30**</td><td>0.16</td></tr><tr><td>S-25(OH)D3, ng/ml</td><td>0.07</td><td>0.05</td><td> </td><td>-0.08</td><td>0.05</td><td>-0.003</td><td>0.19</td><td>0.08</td><td> </td><td>-0.22</td><td>-0.11</td><td>-0.01</td><td>0.08</td></tr><tr><td>24-h U-Ca, mmol/h</td><td>0.29*</td><td>0.19</td><td> </td><td>-0.10</td><td>0.17</td><td>0.24</td><td>0.11</td><td>0.08</td><td>-0.07</td><td> </td><td>0.62**</td><td>0.63**</td><td>0.46**</td></tr><tr><td>24-h U-Ca, mmol/mmol creatinine</td><td>0.35*</td><td>0.36*</td><td> </td><td>-0.26</td><td>0.28</td><td>0.31*</td><td>-0.03</td><td>0.14</td><td>-0.07</td><td>0.82**</td><td> </td><td>0.47**</td><td>0.72**</td></tr><tr><td>ON U-Ca, mmol/h</td><td>0.37**</td><td>0.25</td><td> </td><td>-0.19</td><td>0.33*</td><td>0.19</td><td>0.04</td><td>0.31*</td><td>0.25</td><td>0.56**</td><td>0.57**</td><td> </td><td>0.77**</td></tr><tr><td>ON U-Ca, mmol/mmol creatinine</td><td>0.37**</td><td>0.29*</td><td> </td><td>-0.27*</td><td>0.36**</td><td>0.25</td><td>-0.03</td><td>0.21</td><td>0.22</td><td>0.57**</td><td>0.70**</td><td>0.91**</td><td> </td></tr></table> |
4e1ba97990cb2db764854040dc229a4929515d3e2685caaae0a1e05135e91392.png | complex | <table><tr><td></td><td colspan="6">Genotype frequency (%)</td></tr><tr><td>Year</td><td>2012</td><td>2013</td><td>2014</td><td>2015</td><td>2016</td><td>2017</td></tr><tr><td>Clear</td><td>70.6</td><td>48.1</td><td>61.6</td><td>68.8</td><td>65.1</td><td>71.6</td></tr><tr><td>Carrier</td><td>23.5</td><td>41.5</td><td>31.5</td><td>25.4</td><td>29.5</td><td>25.7</td></tr><tr><td>Homozygous</td><td>5.9</td><td>10.4</td><td>6.8</td><td>5.8</td><td>5.4</td><td>2.7</td></tr><tr><td>Total no. of dogs</td><td>34</td><td>212</td><td>146</td><td>138</td><td>129</td><td>74</td></tr></table> |
02d255b25c52b25fece1f956a0039ee9d9ab2cb2fd53c6ea724c7d753e4f4b89.png | simple | <table><tr><td>Disease for which steroids were prescribed</td><td>Number of patients</td><td>Steroids used</td><td>Use of Cyclosporin</td><td>Oral or topical therapy</td><td>Time period for which the steroid therapy lasted</td><td>Prescribed dosage of steroid</td><td>Time since PSC developed</td></tr><tr><td>Renal transplantation</td><td>21</td><td>WY/CY</td><td>5 mg/day</td><td>Oral</td><td>>2–4 years</td><td>5–10 mg/day</td><td>Not recorded</td></tr><tr><td>Asthma</td><td>08</td><td>WY/DE/DP</td><td>-</td><td>Oral</td><td>>2–4 years</td><td>10 mg/day</td><td>Not recorded</td></tr><tr><td>Lung disease</td><td>02</td><td>WY/DE</td><td>-</td><td>Oral</td><td>>2 years</td><td>7–10 mg/day</td><td>Not recorded</td></tr><tr><td>Arthritis</td><td>03</td><td>OP/DP</td><td>-</td><td>Oral</td><td>>2–3 years</td><td>10 mg/day</td><td>Not recorded</td></tr><tr><td>Allergy</td><td>16</td><td>WY/DE/DP/OP</td><td>-</td><td>Oral/topical</td><td>>2–3 years</td><td>10 mg/day</td><td>Not recorded</td></tr></table> |
050a74988683dccee31aafb51169b38d264f09b60ecd21ae4dccab4a0536138a.png | simple | <table><tr><td></td><td>Preoperatively</td><td>After ICRS implantation</td><td>After IOL implantation</td><td><i>P value</i></td></tr><tr><td>M</td><td>−5.35 ± 5.09<sup>∗</sup></td><td>−3.45 ± 3.88<sup>∗∗</sup></td><td>−0.59 ± 0.80</td><td><0.0001</td></tr><tr><td>J<sub>0</sub></td><td>−0.40 ± 0.92<sup>∗</sup></td><td>−0.32 ± 0.63<sup>∗∗</sup></td><td>−0.07 ± 0.40</td><td><i>P</i> = 0.009</td></tr><tr><td>J<sub>45</sub></td><td>0.17 ± 1.13</td><td>0.23 ± 0.40<sup>∗∗</sup></td><td>−0.09 ± 0.57</td><td><i>P</i> = 0.02</td></tr><tr><td>B</td><td>6.28 ± 4.08<sup>∗</sup></td><td>4.17 ± 3.15<sup>∗∗</sup></td><td>0.94 ± 0.74</td><td><0.0001</td></tr></table> |
2f34c89e33c935ff71cdaf677a6fdd61b0185876f108eb9bb1f2285d58322842.png | complex | <table><tr><td colspan="4">Cellular component</td></tr><tr><td>GOid</td><td>Function</td><td>Type</td><td>Level</td></tr><tr><td>GO:0030176</td><td>integral to endoplasmic reticulum membrane</td><td>component</td><td>7</td></tr><tr><td>GO:0001518</td><td>voltage-gated sodium channel complex</td><td>component</td><td>6</td></tr><tr><td>GO:0005891</td><td>voltage-gated calcium channel complex</td><td>component</td><td>6</td></tr><tr><td>GO:0008023</td><td>transcription elongation factor complex</td><td>component</td><td>6</td></tr><tr><td>GO:0005667</td><td>transcription factor complex</td><td>component</td><td>6</td></tr><tr><td colspan="4">Molecular Function</td></tr><tr><td>GO:0008332</td><td>low voltage-gated calcium channel activity</td><td>function</td><td>9</td></tr><tr><td>GO:0005248</td><td>voltage-gated sodium channel activity</td><td>function</td><td>8</td></tr><tr><td>GO:0005245</td><td>voltage-gated calcium channel activity</td><td>function</td><td>8</td></tr><tr><td>GO:0005262</td><td>calcium channel activity</td><td>function</td><td>7</td></tr><tr><td>GO:0005272</td><td>sodium channel activity</td><td>function</td><td>7</td></tr><tr><td colspan="4">Biological Process</td></tr><tr><td>GO:0006814</td><td>sodium ion transport</td><td>process</td><td>9</td></tr><tr><td>GO:0006816</td><td>calcium ion transport</td><td>process</td><td>9</td></tr><tr><td>GO:0030029</td><td>actin filament-based process</td><td>process</td><td>9</td></tr></table> |
b90f5e4359ff1bcf3bfd3732f4f602b55cc11a65f2ba87876ea2d292cb15bad1.png | simple | <table><tr><td></td><td><i>n</i></td><td><i>%</i></td></tr><tr><td>Males</td><td>19</td><td>95</td></tr><tr><td>Female</td><td>1</td><td>5</td></tr><tr><td>Stable angina</td><td>9</td><td>45</td></tr><tr><td>Non-STEMI or unstable angina</td><td>5</td><td>25</td></tr><tr><td>STEMI</td><td>6</td><td>30</td></tr><tr><td>Median age</td><td>50</td><td></td></tr><tr><td>Mean age</td><td>51</td><td></td></tr><tr><td>White</td><td>12</td><td>60</td></tr><tr><td>Indian/coloured</td><td>7</td><td>35</td></tr><tr><td>Black</td><td>1</td><td>5</td></tr><tr><td>Family history of CAD</td><td>7</td><td>35</td></tr><tr><td>Diabetes mellitus</td><td>4</td><td>20</td></tr><tr><td>Hypertension</td><td>8</td><td>40</td></tr><tr><td>Dyslipidiamia</td><td>7</td><td>35</td></tr><tr><td>Co-existent obstructive CAD</td><td>11</td><td>55</td></tr></table> |
28a57c0d1ec0191085b6873010874ae17b1052eca18902693fb372c3ec831cd5.png | simple | <table><tr><td>ICD-10 Code</td><td>Cause</td><td>Number</td><td>Percentage of deaths</td></tr><tr><td></td><td>Natural causes - total</td><td>155</td><td>80.3</td></tr><tr><td>O00-O99</td><td>Obstetric death</td><td>61</td><td>31.6</td></tr><tr><td>C00-C97</td><td>Cancer</td><td>40</td><td>20.7</td></tr><tr><td>R96-R99</td><td>Unknown/ill-defined</td><td>18</td><td>9.3</td></tr><tr><td>I00-I09,I11,I13,I20-I51</td><td>Heart disease</td><td>5</td><td>2.6</td></tr><tr><td>I60-I69</td><td>Cerebrovascular disease</td><td>4</td><td>2.1</td></tr><tr><td>J00-J99</td><td>Respiratory</td><td>4</td><td>2.1</td></tr><tr><td>B20-B24</td><td>HIV</td><td>2</td><td>1.0</td></tr><tr><td>Remaining natural causes</td><td>Other natural</td><td>21</td><td>10.9</td></tr><tr><td></td><td>External causes - total</td><td>38</td><td>19.7</td></tr><tr><td>V01-V99, Y85</td><td>Accidental transport deaths</td><td>14</td><td>7.3</td></tr><tr><td>X85-Y09, Y87.1</td><td>Assault</td><td>9</td><td>4.7</td></tr><tr><td>X60-X84, Y87.0</td><td>Suicide</td><td>7</td><td>3.6</td></tr><tr><td>Y37</td><td>War and terror</td><td>3</td><td>1.6</td></tr><tr><td>W00-W19</td><td>Accidental falls</td><td>2</td><td>1.0</td></tr><tr><td>Y10-Y34</td><td>Undetermined intent</td><td>2</td><td>1.0</td></tr><tr><td>W20-X59, Y86</td><td>Other accidents</td><td>1</td><td>0.5</td></tr></table> |
5c67b4590b63d3874ffc9e0535238d69816d2ffc7dd670ccf81ece993f3470e8.png | simple | <table><tr><td>Term<sup>a</sup></td><td>GO Gene Count</td><td>GO Slim</td><td>GO Slim Gene Count</td></tr><tr><td>cellular ion homeostasis</td><td>9</td><td>cellular process</td><td>9</td></tr><tr><td>regulation of biological quality</td><td>27</td><td>regulation of biological quality</td><td>27</td></tr><tr><td>defense response</td><td>22</td><td></td><td></td></tr><tr><td>response to stimulus</td><td>48</td><td></td><td></td></tr><tr><td>response to chemical stimulus</td><td>22</td><td></td><td></td></tr><tr><td>immune system process</td><td>19</td><td></td><td></td></tr><tr><td>response to stress</td><td>34</td><td></td><td></td></tr><tr><td>immune response</td><td>14</td><td></td><td></td></tr><tr><td>regulation of response to stimulus</td><td>12</td><td></td><td></td></tr><tr><td>response to external stimulus</td><td>26</td><td></td><td></td></tr><tr><td>response to bacterium</td><td>7</td><td></td><td></td></tr><tr><td>response to wounding</td><td>20</td><td>response to stimulus</td><td>49</td></tr><tr><td>regulation of immune response</td><td>9</td><td></td><td></td></tr><tr><td>regulation of defense response</td><td>7</td><td></td><td></td></tr><tr><td>inflammatory response</td><td>16</td><td></td><td></td></tr><tr><td>blood coagulation</td><td>6</td><td></td><td></td></tr><tr><td>innate immune response</td><td>10</td><td></td><td></td></tr><tr><td>positive regulation of defense</td><td>5</td><td></td><td></td></tr><tr><td>response</td><td>9</td><td></td><td></td></tr><tr><td>humoral immune response</td><td>6</td><td></td><td></td></tr><tr><td>complement activation, classical pathway</td><td></td><td></td><td></td></tr><tr><td>transition metal ion transport</td><td>5</td><td>transport</td><td>5</td></tr></table> |
b8ffd8c1eeccb74f282f085a71845c410b30c4d8dfacbe0cc8fce35831b1b6bd.png | simple | <table><tr><td></td><td>Elderly MD subjects (<i>n</i> = 30)</td><td>Younger MD subjects (<i>n</i> = 32)</td><td><i>P</i> value</td></tr><tr><td>Years since first vertigo</td><td>2.7 ± 2.3</td><td>3.4 ± 1.8</td><td>0.08</td></tr><tr><td>Hearing loss affected ear</td><td>64.7 ± 8.1 db</td><td>48.2 ± 10.9 db</td><td>0.001</td></tr><tr><td>Hearing loss unaffected ear</td><td>18.2 ± 4.5 db</td><td>16.3 ± 3.3 db</td><td>0.04</td></tr><tr><td>N° of crises in the last 6 months</td><td>6.5 ± 3.7</td><td>10.4 ± 5.5</td><td>0.002</td></tr></table> |
ec5e45b705b03b5dd50ef14c3dc54de797e88be5fe15e0515af30402f7386674.png | complex | <table><tr><td> </td><td>Clinical group</td><td>Genotype</td><td>Pre-S2 S tart codon</td><td colspan="6">Deletions</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>Region</td><td colspan="2">Nucleotides</td><td colspan="2">Amino acids</td><td>Region and functions affected</td></tr><tr><td>ID</td><td> </td><td> </td><td> </td><td> </td><td>Size</td><td>Position</td><td>Size</td><td>position</td><td> </td></tr><tr><td>SDAC024</td><td>CR</td><td>D</td><td>ATG</td><td>Pre-S2</td><td>21</td><td>35-55<sup>a</sup></td><td>7</td><td>16-22<sup>a</sup></td><td> </td></tr><tr><td>SDAC048</td><td>CR</td><td>D</td><td>ATG</td><td>Pre-S1</td><td>72</td><td>2998-3069</td><td>24</td><td>51-74</td><td>S promoter, Transactivator domain</td></tr><tr><td>SDAC083</td><td>CR</td><td>D</td><td>ATG</td><td>Pre-S2</td><td>21</td><td>35-55</td><td>7</td><td>16-22</td><td> </td></tr><tr><td>SDAC097</td><td>CR</td><td>D</td><td><i>GTG</i><sup>b</sup></td><td>Pre-S 2</td><td>9</td><td>45- 53</td><td>3</td><td>19-21</td><td> </td></tr><tr><td>SDAC098</td><td>CH</td><td>D</td><td>ATG</td><td>Pre-S1</td><td>18</td><td>3129-3146</td><td>6</td><td>94-99</td><td>Hsc70 binding site, CCAAT binding factor (CBF) binding site, Cytosolic anchorage determinant (CAD)</td></tr><tr><td>SDAC112</td><td>ASC</td><td>D</td><td>ATG</td><td>Pre-S2</td><td>6</td><td>49-54</td><td>2</td><td>20-21</td><td> </td></tr><tr><td>SDAC118</td><td>CR</td><td>D</td><td>ATG</td><td>Pre-S2</td><td>54</td><td>4-57</td><td>18</td><td>5 to 22</td><td>pHSA binding site, Viral secretion</td></tr><tr><td>SDAC107</td><td>CR</td><td>D</td><td><i>ATA</i></td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>SDAC090</td><td>CR</td><td>D</td><td><i>ATA</i></td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>SDAC058</td><td>CR</td><td>E</td><td>ATG</td><td>Pre-S2</td><td>9</td><td>58-66<sup>c</sup></td><td>3</td><td>20-22<sup>c</sup></td><td>Transactivator domain</td></tr><tr><td>SDAC059</td><td>HCC</td><td>E</td><td><i>GTG</i></td><td>Pre-S2</td><td>12</td><td>52-63</td><td>4</td><td>18-21</td><td>Transactivator domain</td></tr><tr><td>SDAC088</td><td>HCC</td><td>E</td><td>ATG</td><td>Pre-S2</td><td>12</td><td>52-63</td><td>4</td><td>18-21</td><td>Transactivator domain</td></tr><tr><td>SDAC095</td><td>HCC</td><td>E</td><td>ATG</td><td>Pre-S2</td><td>15</td><td>52-66</td><td>5</td><td>18-22</td><td>Transactivator domain</td></tr><tr><td>SDAC067</td><td>ASC</td><td>E</td><td><i>GTG</i></td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>SDAC113</td><td>ASC</td><td>A</td><td><i>ACA</i></td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table> |
a59d74249d7e9af2809f5d4a1b5bf898255d63989293cc72f167df9034219a27.png | simple | <table><tr><td>Category</td><td>Blue LED</td><td>UV LED</td><td>White light</td></tr><tr><td>Bark, Bract,</td><td>Lint has higher</td><td>-</td><td>Lint has higher red, green,</td></tr><tr><td>Brown leaf,</td><td>red and green</td><td>-</td><td>and blue reflectance</td></tr><tr><td>Green leaf,</td><td>fl. emission</td><td>-</td><td></td></tr><tr><td>Stem</td><td></td><td>-</td><td></td></tr><tr><td>Hull</td><td>Lint has higher</td><td>-</td><td>Lint has higher red, green,</td></tr><tr><td></td><td>green fl.</td><td>-</td><td>and blue reflectance</td></tr><tr><td></td><td>emission</td><td>-</td><td></td></tr><tr><td>Paper</td><td>-</td><td>Lint has lower red, green</td><td>Lint has lower red, green</td></tr><tr><td></td><td>-</td><td>and blue fl. emission</td><td>and blue reflectance</td></tr><tr><td>Plastic bag</td><td>-</td><td>Lint has higher green and</td><td>Lint has higher red and</td></tr><tr><td></td><td>-</td><td>blue fl. emission</td><td>green reflectance</td></tr><tr><td>Plastic bale</td><td>-</td><td>Lint has higher green and</td><td>Lint has higher blue</td></tr><tr><td>Packaging</td><td>-</td><td>blue fl. emission</td><td>reflectance</td></tr><tr><td>Seed coat (Inner),</td><td>-</td><td>Lint has higher green and</td><td>Lint has higher red, green,</td></tr><tr><td>Seed coat (Outer),</td><td>-</td><td>blue fl. emission</td><td>and blue reflectance</td></tr><tr><td>Seed, Twine</td><td>-</td><td></td><td></td></tr></table> |
e6ae188228ecf948f6371cc2f6439532ab9075b104d75fcbe4602c6020273626.png | complex | <table><tr><td rowspan="2">Target species</td><td colspan="4">MIC (μg mL<sup>−1</sup>)</td></tr><tr><td>1</td><td>2</td><td>Polymyxin B</td><td>Colistin</td></tr><tr><td><i>Escherichia coli</i> ATCC 25922</td><td>2</td><td>2</td><td>1</td><td>2</td></tr><tr><td>Colistin-resistant <i>E. coli</i><sup>a</sup></td><td>2</td><td>2</td><td>16</td><td>16</td></tr><tr><td><i>E. coli</i> ATCC 25922 + 10% serum</td><td>2–4</td><td>2–4</td><td>1–2</td><td>2–4</td></tr><tr><td><i>E. coli</i> ATCC 25922 + Mg<sup>2+</sup> (21 mM)</td><td>>64</td><td>>64</td><td>>64</td><td>>64</td></tr><tr><td><i>E. coli</i> ATCC 25922 + LPS (1.0 mg mL<sup>−1</sup>)</td><td>>64</td><td>>64</td><td>>64</td><td>>64</td></tr><tr><td><i>E. coli</i> TOP10</td><td>2</td><td>2</td><td>2</td><td>2</td></tr><tr><td><i>Pseudomonas aeruginosa</i> PAO1</td><td>1</td><td>2</td><td>1</td><td>1</td></tr><tr><td><i>Acinetobacter baumannii</i></td><td>16</td><td>4</td><td>4</td><td></td></tr><tr><td><i>Klebsiella pneumoniae</i> NRRL-B-408</td><td>2</td><td>4</td><td>16</td><td></td></tr><tr><td><i>K. pneumoniae</i> NRRL-B-3521</td><td>4</td><td>4</td><td>2</td><td></td></tr><tr><td><i>Enterobacter cloacae</i> NRRL-B-413</td><td>2</td><td>2</td><td>8</td><td></td></tr><tr><td><i>E. cloacae</i> NRRL-B-425</td><td>2</td><td>2</td><td>64</td><td></td></tr><tr><td><i>Bacillus subtilis</i> 168</td><td>32</td><td>32</td><td>4</td><td></td></tr><tr><td><i>Candida albicans</i></td><td>>64</td><td>>64</td><td>>64</td><td></td></tr><tr><td><i>Saccharomyces cerevisiae</i></td><td>>64</td><td>>64</td><td>>64</td><td></td></tr><tr><td><i>Staphylococcus aureus</i> (MRSA)</td><td>>64</td><td>>64</td><td>32</td><td></td></tr></table> |
d5a64b19c6acc36908bbb33f16277f26fdbed901a34821fdc1eddb204d4dde81.png | complex | <table><tr><td>Studies (Author)</td><td>Year</td><td colspan="2">Chemotherapy regimen<sup>a</sup></td><td>Number (T/C)</td><td>Type of Assessable Outcomes</td><td>Jadad Scores<sup>b</sup></td></tr><tr><td></td><td></td><td>treatment</td><td>control</td><td></td><td></td><td></td></tr><tr><td>Hao XL[20]</td><td>2008</td><td>NP+SFI</td><td>NP</td><td>60/68</td><td>WBC/HB/PLT/nausea and vomiting toxicity, KPS</td><td>3</td></tr><tr><td>Wang K[21]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>18/18</td><td>tumor response, WBC/PLT toxicity, KPS</td><td>3</td></tr><tr><td>Kang GY[22]</td><td>2006</td><td>NP+SFI</td><td>NP</td><td>36/36</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS</td><td>2</td></tr><tr><td>Gong ZM[23]</td><td>2008</td><td>NP+SFI</td><td>NP</td><td>33/32</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS</td><td>2</td></tr><tr><td>Wang XY[24]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>35/34</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity,</td><td>4</td></tr><tr><td>Wang YZ[25]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>28/27</td><td>tumor response, KPS, WBC/PLT/HB toxicity</td><td>3</td></tr><tr><td>Li TW[26]</td><td>2009</td><td>NP+SFI</td><td>NP</td><td>36/33</td><td>tumor response, the KPS</td><td>4</td></tr><tr><td>Li Y[27]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>44/43</td><td>tumor response, WBC/PLT/nausea and vomiting toxicity,</td><td>4</td></tr><tr><td>Lv J[28]</td><td>2008</td><td>NP+SFI</td><td>NP</td><td>40/40</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS</td><td>4</td></tr><tr><td>Zhao ZY[29]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>35/34</td><td>tumor response, WBC/PLT/HB nausea and vomiting toxicity,</td><td>4</td></tr><tr><td>Geng L[30]</td><td>2004</td><td>NP+SFI</td><td>NP</td><td>25/15</td><td>tumor response, KPS</td><td>2</td></tr><tr><td>Yu QZ[31]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>30/32</td><td>tumor response, KPS</td><td>4</td></tr><tr><td>Liu CL[32]</td><td>2004</td><td>NP+SFI</td><td>NP</td><td>60/60</td><td>tumor response, WBC/PLT/HB toxicity</td><td>2</td></tr><tr><td>Liu PH[33]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>30/30</td><td>tumor response, KPS</td><td>1</td></tr><tr><td>Pan YK[34]</td><td>2008</td><td>NP+SFI</td><td>NP</td><td>45/45</td><td>tumor response, WBC/PLT/HB toxicity</td><td>2</td></tr><tr><td>Zheng JH[35]</td><td>2009</td><td>NP+SFI</td><td>NP</td><td>42/42</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity</td><td>4</td></tr><tr><td>Miao SR[36]</td><td>2010</td><td>NP+SFI</td><td>NP</td><td>38/41</td><td>tumor response, the KPS, WBC/PLT/nausea and vomiting toxicity</td><td>3</td></tr><tr><td>Li YQ[37]</td><td>2010</td><td>NP+SFI</td><td>NP</td><td>43/42</td><td>KPS</td><td>5</td></tr><tr><td>Geng D[38]</td><td>2007</td><td>NP+SFI</td><td>NP</td><td>42/26</td><td>tumor response, WBC/the nausea and vomiting toxicity</td><td>2</td></tr><tr><td>Zou Y[39]</td><td>2005</td><td>TP+SFI</td><td>TP</td><td>24/24</td><td>tumor response, KPS</td><td>3</td></tr><tr><td>Luo SZ[40]</td><td>2006</td><td>TP+SFI</td><td>TP</td><td>25/25</td><td>tumor response, KPS, WBC/PLT/nausea and vomiting toxicity</td><td>2</td></tr><tr><td>Luo SW[41]</td><td>2007</td><td>TP+SFI</td><td>TP</td><td>30/30</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS</td><td>2</td></tr><tr><td>Zhang FL[42]</td><td>2008</td><td>TP+SFI</td><td>TP</td><td>30/30</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS</td><td>3</td></tr><tr><td>Zhao YX[43]</td><td>2009</td><td>TP+SFI</td><td>TP</td><td>40/40</td><td>tumor response, KPS</td><td>2</td></tr><tr><td>Yu F[44]</td><td>2007</td><td>DC+SFI</td><td>DC</td><td>30/30</td><td>tumor response, WBC/PLT/HB toxicity</td><td>4</td></tr><tr><td>He WJ[45]</td><td>2008</td><td>GP+SFI</td><td>GP</td><td>35/35</td><td>tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS</td><td>3</td></tr><tr><td>Liang K[46]</td><td>2010</td><td>GP+SFI</td><td>GP</td><td>39/37</td><td>tumor response, KPS,</td><td>2</td></tr><tr><td>Chen J[47]</td><td>2007</td><td>TP/NP+SFI</td><td>TP/NP</td><td>41/39</td><td>tumor response, KPS</td><td>2</td></tr><tr><td>Wu L[48]</td><td>2004</td><td>TP/NP+SFI</td><td>TP/NP</td><td>30/30</td><td>tumor response, WBC toxicity</td><td>5</td></tr></table> |
f3643503b863acdf0daa7eb757bd73c1286aac163fd59752e84c29e2d14df065.png | complex | <table><tr><td></td><td></td><td colspan="6">Percentile (95% CI)</td><td></td></tr><tr><td></td><td>GM (95% CI)</td><td>10th</td><td>25th</td><td>50th</td><td>75th</td><td>90th</td><td>95th</td><td><i>n</i></td></tr><tr><td colspan="9">Overall population</td></tr><tr><td> μg/L</td><td>2.73 (2.50–2.98)</td><td>< LOD</td><td>1.40 (1.20–1.50)</td><td>2.70 (2.40–3.00)</td><td>5.30 (4.80–5.90)</td><td>10.2 (8.80–11.9)</td><td>17.5 (14.0–21.4)</td><td>2,548</td></tr><tr><td> μg/g creatinine</td><td>2.66 (2.43–2.91)</td><td>< LOD</td><td>1.47 (1.32–1.61)</td><td>2.48 (2.29–2.71)</td><td>4.48 (4.05–4.85)</td><td>8.67 (7.17–9.71)</td><td>13.2 (10.8–17.5)</td><td>2,548</td></tr><tr><td colspan="9">Age group</td></tr><tr><td colspan="9">6–11 years</td></tr><tr><td> μg/L</td><td>4.54 (3.94–5.24)</td><td>1.50 (0.90–2.00)</td><td>2.50 (2.20–3.10)</td><td>4.70 (4.00–5.60)</td><td>8.10 (6.80–9.60)</td><td>14.6 (10.8–19.1)</td><td>22.8 (16.7–35.3)</td><td>356</td></tr><tr><td> μg/g creatinine</td><td>5.00 (4.45–5.63)</td><td>1.67 (1.22–2.26)</td><td>3.01 (2.57–3.33)</td><td>5.06 (4.18–5.76)</td><td>7.48 (6.71–8.84)</td><td>16.1 (12.5–18.9)</td><td>23.5 (16.1–31.7)</td><td>356</td></tr><tr><td colspan="9">12–19 years</td></tr><tr><td> μg/L</td><td>3.18 (2.74–3.68)</td><td>0.700 (< LOD–1.10)</td><td>1.80 (1.50–2.10)</td><td>3.30 (2.90–3.80)</td><td>6.00 (4.70–7.20)</td><td>10.3 (7.60–13.7)</td><td>16.5 (11.5–21.5)</td><td>702</td></tr><tr><td> μg/g creatinine</td><td>2.37 (2.04–2.75)</td><td>0.894 (< LOD–1.09)</td><td>1.51 (1.23–1.72)</td><td>2.18 (1.91–2.52)</td><td>3.64 (2.94–4.55)</td><td>6.26 (5.15–8.70)</td><td>10.7 (7.57–14.1)</td><td>702</td></tr><tr><td colspan="9">20–59 years</td></tr><tr><td> μg/L</td><td>2.52 (2.22–2.85)</td><td>< LOD</td><td>1.20 (1.10–1.40)</td><td>2.50 (2.20–2.80)</td><td>4.90 (4.20–5.70)</td><td>9.40 (7.60–12.6)</td><td>17.0 (12.6–24.2)</td><td>1,040</td></tr><tr><td> μg/g creatinine</td><td>2.42 (2.17–2.69)</td><td>< LOD</td><td>1.34 (1.20–1.50)</td><td>2.21 (2.05–2.48)</td><td>3.95 (3.59–4.53)</td><td>7.46 (6.00–9.41)</td><td>11.2 (9.26–19.0)</td><td>1,040</td></tr><tr><td colspan="9">≥ 60 years</td></tr><tr><td> μg/L</td><td>2.51 (2.15–2.92)</td><td>0.700 (< LOD–0.80)</td><td>1.10 (0.90–1.40)</td><td>2.40 (1.90–2.70)</td><td>4.70 (3.90–5.80)</td><td>10.1 (7.40–12.5)</td><td>14.7 (12.1–26.3)</td><td>450</td></tr><tr><td> μg/g creatinine</td><td>2.92 (2.46–3.46)</td><td>0.913 (< LOD–1.11)</td><td>1.58 (1.35–1.88)</td><td>2.72 (2.41–3.03)</td><td>4.60 (3.72–5.22)</td><td>9.40 (6.43–12.5)</td><td>14.6 (11.2–19.2)</td><td>450</td></tr><tr><td colspan="9">Sex</td></tr><tr><td colspan="9">Male</td></tr><tr><td> μg/L</td><td>3.16 (2.82–3.54)</td><td>0.800 (< LOD–1.00)</td><td>1.70 (1.40–1.90)</td><td>3.00 (2.70–3.50)</td><td>5.90 (5.10–6.90)</td><td>11.0 (8.80–14.0)</td><td>19.5 (14.0–28.0)</td><td>1,270</td></tr><tr><td> μg/g creatinine</td><td>2.53 (2.28–2.82)</td><td>0.894 (< LOD–1.02)</td><td>1.40 (1.27–1.54)</td><td>2.36 (2.14–2.56)</td><td>4.38 (3.74–5.04)</td><td>7.42 (6.47–8.88)</td><td>13.0 (9.40–19.5)</td><td>1,270</td></tr><tr><td colspan="9">Female</td></tr><tr><td> μg/L</td><td>2.37 (2.13–2.65)</td><td>< LOD</td><td>1.10 (1.00–1.30)</td><td>2.30 (2.00–2.70)</td><td>4.80 (4.30–5.30)</td><td>9.30 (7.60–11.5)</td><td>14.7 (13.1–18.2)</td><td>1,278</td></tr><tr><td> μg/g creatinine</td><td>2.79 (2.47–3.15)</td><td>< LOD</td><td>1.52 (1.30–1.77)</td><td>2.65 (2.34–2.96)</td><td>4.51 (4.03–5.16)</td><td>9.41 (6.82–11.6)</td><td>13.5 (10.7–19.7)</td><td>1,278</td></tr><tr><td colspan="9">Race/ethnicity</td></tr><tr><td colspan="9">Non-Hispanic white</td></tr><tr><td> μg/L</td><td>2.67 (2.39–2.98)</td><td>< LOD</td><td>1.30 (1.10–1.50)</td><td>2.60 (2.30–2.90)</td><td>5.30 (4.70–6.10)</td><td>10.1 (8.20–12.6)</td><td>17.6 (12.6–24.3)</td><td>1,038</td></tr><tr><td> μg/g creatinine</td><td>2.81 (2.51–3.14)</td><td>< LOD</td><td>1.55 (1.36–1.75)</td><td>2.57 (2.34–2.85)</td><td>4.62 (4.10–5.19)</td><td>9.26 (7.00–10.8)</td><td>13.5 (10.3–23.5)</td><td>1,038</td></tr><tr><td colspan="9">Mexican American</td></tr><tr><td> μg/L</td><td>2.72 (2.40–3.08)</td><td>0.700 (< LOD–0.90)</td><td>1.50 (1.20–1.80)</td><td>2.70 (2.40–3.20)</td><td>4.90 (4.30–5.70)</td><td>9.00 (7.00–12.4)</td><td>14.4 (9.00–26.8)</td><td>637</td></tr><tr><td> μg/g creatinine</td><td>2.45 (2.13–2.81)</td><td>0.824 (< LOD–1.12)</td><td>1.38 (1.26–1.53)</td><td>2.32 (2.14–2.60)</td><td>4.04 (3.64–4.58)</td><td>6.97 (5.73–8.14)</td><td>11.0 (7.89–19.1)</td><td>637</td></tr><tr><td colspan="9">Non-Hispanic black</td></tr><tr><td> μg/L</td><td>3.18 (2.75–3.67)</td><td>0.700 (< LOD–1.10)</td><td>1.60 (1.30–2.00)</td><td>3.20 (2.70–3.80)</td><td>5.90 (4.90–7.30)</td><td>13.0 (9.50–14.6)</td><td>19.2 (14.6–30.5)</td><td>678</td></tr><tr><td> μg/g creatinine</td><td>2.24 (1.96–2.55)</td><td>0.752 (< LOD–0.925)</td><td>1.26 (1.06–1.41)</td><td>1.97 (1.78–2.37)</td><td>3.60 (3.25–4.24)</td><td>7.82 (6.38–10.4)</td><td>12.0 (10.1–17.4)</td><td>678</td></tr></table> |
39f1edc486990d9328655d140719e3e3f7e4935c7530639aa4e9e884eab36a22.png | simple | <table><tr><td>S. No </td><td>Reference </td><td>Gender </td><td>Lip Pits </td><td>Cleft lip (CL) </td><td>Cleft palate (CP) </td><td>CL & CP </td><td>Hypodontia </td><td>Ankyloglossia</td></tr><tr><td>1</td><td>Arangannal et al., (2002) [3] </td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td><i>✓</i></td><td> </td></tr><tr><td>2</td><td>Surasak et al., (2003) [6]</td><td>F </td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td></tr><tr><td>3</td><td>Moore and McCord (2004) [23]</td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td></tr><tr><td>4</td><td>Souissi et al., (2004) [7]</td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>5</td><td>Rizos and Spyropoulos (2004) [5]</td><td>F </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>6</td><td>Stanier and Moore (2004) [24]</td><td>F </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>7</td><td>King et al., (2004) [25]</td><td>M</td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>8</td><td>Karande and Patil (2005) [16]</td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td><i>✓</i></td><td> </td></tr><tr><td>9</td><td>Tokat et al., (2005) [14] </td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>10</td><td>Newman et al., (2005) [11] </td><td>F </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td><i>✓</i></td><td> </td></tr><tr><td>11</td><td>Ziai et al., (2005) [26]</td><td>M</td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>12</td><td>Kirzioglu and Ertürk (2006) [27]</td><td>M</td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>13</td><td>King et al., (2004) [25]</td><td>F </td><td><i>✓</i></td><td> </td><td><i>✓</i></td><td> </td><td><i>✓</i></td><td> </td></tr><tr><td>14</td><td>Klinische Padiatrie (2008) [28]</td><td>F </td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td></tr><tr><td>15</td><td>Etöz O. A. and Etöz A. (2009) [29]</td><td>M</td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>16</td><td>Nakano et al., (2010) [9]</td><td>M </td><td><i>✓</i> (UL) </td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>17</td><td>Lam et al., (2010) [30] </td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td> </td></tr><tr><td>18</td><td>Baghestani et al., (2010) [31]</td><td>M</td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>19</td><td>Moghe et al., (2010) [8]</td><td>F </td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td></tr><tr><td>20</td><td>Jobling et al., (2011) [15]</td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td></tr><tr><td>21</td><td>Manoharan et al., (2013) [10]</td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>22</td><td>Shweta et al., (2012) [2]</td><td>M </td><td><i>✓</i></td><td><i>✓</i></td><td> </td><td> </td><td> </td><td> </td></tr></table> |
2480343642b34f17a4311382870000afb0ee87fe13f43f2ed4fa9631f7523359.png | simple | <table><tr><td>Variables</td><td>Group 1</td><td>Group 2</td><td>Group 3</td><td>Group 4</td><td><i>F</i>/<i>χ</i><sup>2</sup> value</td><td><i>P</i></td></tr><tr><td>Cases</td><td>40</td><td>52</td><td>21</td><td>19</td><td>—</td><td>—</td></tr><tr><td>Age (year)</td><td>54.32 ± 10.14</td><td>58.31 ± 9.24</td><td>59.10 ± 7.55</td><td>60.37 ± 8.05</td><td>2.587</td><td>0.056</td></tr><tr><td>Sex (M/F)</td><td>24/16</td><td>31/21</td><td>12/9</td><td>11/8</td><td>0.064</td><td>0.996</td></tr><tr><td>Educational years</td><td>9.55 ± 3.37</td><td>10.37 ± 3.33</td><td>9.19 ± 2.87</td><td>8.63 ± 2.75</td><td>1.662</td><td>0.178</td></tr><tr><td>Etiology</td><td> </td><td> </td><td> </td><td> </td><td>7.148</td><td>0.711</td></tr><tr><td> B viral hepatitis cirrhosis</td><td>—</td><td>21</td><td>11</td><td>8</td><td> </td><td> </td></tr><tr><td> C viral hepatitis cirrhosis</td><td>—</td><td>1</td><td>1</td><td>1</td><td> </td><td> </td></tr><tr><td> Primary biliary cirrhosis</td><td>—</td><td>3</td><td>3</td><td>1</td><td> </td><td> </td></tr><tr><td> Autoimmune hepatitis cirrhosis</td><td>—</td><td>5</td><td>0</td><td>3</td><td> </td><td> </td></tr><tr><td> Schistosomiasis cirrhosis</td><td>—</td><td>6</td><td>1</td><td>1</td><td> </td><td> </td></tr><tr><td> Cryptogenic cirrhosis</td><td>—</td><td>16</td><td>5</td><td>5</td><td> </td><td> </td></tr><tr><td>Child-Pugh grading</td><td> </td><td> </td><td> </td><td> </td><td>7.229</td><td>0.124</td></tr><tr><td> Grade A</td><td>—</td><td>18</td><td>4</td><td>2</td><td> </td><td> </td></tr><tr><td> Grade B</td><td>—</td><td>21</td><td>8</td><td>7</td><td> </td><td> </td></tr><tr><td> Grade C</td><td>—</td><td>13</td><td>9</td><td>10</td><td> </td><td> </td></tr><tr><td>Child-Pugh scores</td><td>—</td><td>8.27 ± 2.36</td><td>9.19 ± 2.16</td><td>10.16 ± 2.27</td><td>4.965</td><td>0.009</td></tr><tr><td>Ammonia (<i>μ</i>mol/L)</td><td>—</td><td>37.12 ± 15.28</td><td>63.81 ± 19.22</td><td>106.21 ± 46.14</td><td>52.154</td><td><0.001</td></tr><tr><td>Cr (<i>μ</i>mol/L)</td><td>—</td><td>86.01 ± 22.80</td><td>83.35 ± 40.11</td><td>79.14 ± 43.92</td><td>0.318</td><td>0.728</td></tr><tr><td>TBil (<i>μ</i>mol/L)</td><td>—</td><td>45.78 ± 16.76</td><td>45.57 ± 14.51</td><td>42.81 ± 14.83</td><td>0.254</td><td>0.776</td></tr><tr><td>ALB (g/L)</td><td>—</td><td>29.62 ± 7.92</td><td>28.38 ± 5.36</td><td>31.05 ± 6.71</td><td>0.691</td><td>0.504</td></tr><tr><td>PT (sec)</td><td>—</td><td>3.14 ± 1.76</td><td>2.87 ± 1.74</td><td>3.25 ± 1.76</td><td>0.263</td><td>0.769</td></tr><tr><td>NCT-A (sec)</td><td>46.92 ± 11.80</td><td>51.31 ± 10.93</td><td>88.29 ± 9.38</td><td>—</td><td>108.840</td><td><0.001</td></tr><tr><td>DST (scores)</td><td>52.35 ± 10.69</td><td>49.98 ± 9.98</td><td>23.57 ± 4.04</td><td>—</td><td>72.476</td><td><0.001</td></tr></table> |
9acb8cdb6d73d0840e507814069a1749c2afdd2b9864c77bd0a64dbf22d0cc88.png | simple | <table><tr><td>Species</td><td>Origin</td><td>N</td><td>PCR + blood</td><td>Sensitivity of microscopy</td></tr><tr><td><i>M. nemestrina</i></td><td>West Java</td><td>4</td><td>4 (100 %)</td><td>NA</td></tr><tr><td><i>M. fascicularis</i></td><td>Lampung</td><td>30</td><td>6 (20 %)</td><td>3 (50 %)</td></tr><tr><td><i>M. fascicularis</i></td><td>Palembang</td><td>30</td><td>24 (80 %)</td><td>14 (58.3 %)</td></tr></table> |
50461b9f98a168a126e3f55c2563301f80c1d1fd891cb2b09f24a6f812877e11.png | simple | <table><tr><td>Inventory year</td><td>Stock change<sup>a </sup>(MgC yr<sup>-1</sup>)</td></tr><tr><td>1910</td><td>104,116</td></tr><tr><td>1920</td><td>97,021</td></tr><tr><td>1930</td><td>75,712</td></tr><tr><td>1940</td><td>16,051</td></tr><tr><td>1950</td><td>298,029</td></tr><tr><td>1960</td><td>591,785</td></tr><tr><td>1970</td><td>966,125</td></tr><tr><td>1980</td><td>437,628</td></tr><tr><td>1990</td><td>481,517</td></tr><tr><td>1995</td><td>59,764</td></tr><tr><td>2000</td><td>-184,812</td></tr><tr><td>2005</td><td>-151,437</td></tr><tr><td>2006</td><td>-135,679</td></tr><tr><td>2007</td><td>-200,187</td></tr><tr><td>2008</td><td>-198,821</td></tr><tr><td>2009</td><td>-191,391</td></tr><tr><td>2010</td><td>-173,214</td></tr></table> |
2427a0e65ea14caa6fb6b8cd58cab4ff64cce8441c430a0b48c9611e033f0a5f.png | simple | <table><tr><td></td><td>Pelvic obliquity (<i>r</i>)</td><td>Lumbar Cobb angle (<i>r</i>)</td><td>Thoracic curve Cobb angle (<i>r</i>)</td></tr><tr><td>Functional LLD</td><td>0.69*</td><td>0.44*</td><td>0.09</td></tr><tr><td>Structural LLD</td><td>0.51*</td><td>0.17</td><td>− 0.05</td></tr></table> |
c3e14db9fa106313f69b3ac25000a846fb849ea8996df91ca24170e453e21554.png | simple | <table><tr><td>Gene family</td><td>Gene</td><td>Description</td><td>References</td></tr><tr><td>MHC class I</td><td>ENSGALT00000028239, ENSGALT00000004115</td><td>Deletion of MHC class I antigen-presenting proteins in chicken was associated with Marek’s disease resistance</td><td>Luo et al. (2012)</td></tr><tr><td>MHC class II</td><td>CIITA</td><td>CIITA, a trans-activator of MHC II, was duplicated in cattle with nematode resistance</td><td>Liu et al. (2011)</td></tr><tr><td>Antimicrobial peptides</td><td>LAP, TAP, BSP30A</td><td>Cattle-specific, β-defensin family, antimicrobial peptides (AMPs) with high copy number</td><td>Bickhart et al. (2012)</td></tr><tr><td></td><td>PGN3, CATHL4</td><td>Cathelicidin family AMPs from pig and cattle, respectively, with high degrees of copy number variation</td><td>Paudel et al. (2013), Bickhart et al. (2012)</td></tr><tr><td>Endogenous retroviruses</td><td>enJSRV</td><td>A variant of the endogenous Jaagsiekte sheep retrovirus that is highly duplicated, protects individuals from the exogenous virus, which causes pulmonary adenocarcinoma</td><td>Viginier et al. (2012)</td></tr><tr><td>T cell receptors</td><td>WC1</td><td>CNVs of the cattle-specific WC1 gene have been identified</td><td>Liu et al. (2010), Chen et al. (2012)</td></tr></table> |
18ff4f57de8f0f29c8e03801c948953319b3e7b43239c39aefc6acb880b94b81.png | simple | <table><tr><td></td><td>RL</td><td>RL + 1</td><td>RL + 2</td><td>RL + 3</td><td>RL + 4</td><td>RL + 5</td><td>RL + 6</td><td>RL + 7</td></tr><tr><td>Galaxy S6</td><td>84.11</td><td>87.11</td><td>90.11</td><td>94.09</td><td>97.99</td><td>101.89</td><td><i>105.72</i></td><td>–</td></tr><tr><td>Galaxy Note 3</td><td>89.68</td><td>93.13</td><td>95.47</td><td>99.52</td><td>103.26</td><td><i>107.04</i></td><td>–</td><td>–</td></tr><tr><td>I-phone 5S</td><td>91.97</td><td>96.02</td><td>96.69</td><td>100.06</td><td>104.18</td><td>107.17</td><td>110.08</td><td><i>112.44</i></td></tr><tr><td>I-phone 6</td><td>88.25</td><td>92.05</td><td>98.32</td><td>101.44</td><td>104.49</td><td>107.76</td><td>110.21</td><td><i>113.11</i></td></tr><tr><td>LG G2</td><td>92.35</td><td>94.90</td><td>97.91</td><td>100.73</td><td>103.34</td><td>106.45</td><td><i>109.42</i></td><td>–</td></tr><tr><td>LG G3</td><td>89.60</td><td>92.62</td><td>95.60</td><td>98.43</td><td>101.16</td><td>104.27</td><td><i>107.25</i></td><td>–</td></tr></table> |
730eab02f824d5897e80a45e7a45217868d284bea7cea5814751612dc1517785.png | complex | <table><tr><td colspan="2">GeNorm<sup>PLUS</sup></td><td colspan="2">NormFinder</td><td colspan="2">BestKeeper</td><td colspan="2">Comparative delta-<i>C</i>t</td><td colspan="2">RefFinder</td></tr><tr><td>Gene</td><td>Stability Coeff.</td><td>Gene</td><td>Stability Coeff.</td><td>Gene</td><td>Stability Coeff.</td><td>Gene</td><td>Stability Coeff.</td><td>Gene</td><td>Stability Coeff.</td></tr><tr><td><i>Histone3</i></td><td>1.22</td><td><i>Histone3</i></td><td>0.812</td><td><i>Histone3</i></td><td>1.58</td><td><i>Histone3</i></td><td>1.678</td><td><i>Histone3</i></td><td>12</td></tr><tr><td><i>EF2</i></td><td>1.135</td><td><i>EF2</i></td><td>0.743</td><td><i>RAN</i></td><td>1.085</td><td><i>EF2</i></td><td>1.549</td><td><i>EF2</i></td><td>10.462</td></tr><tr><td><i>Actin</i></td><td>1.061</td><td><i>Tubulin</i></td><td>0.579</td><td><i>Tubulin</i></td><td>1.059</td><td><i>Actin</i></td><td>1.343</td><td><i>Actin</i></td><td>8.409</td></tr><tr><td><i>Cyclo</i></td><td>1.028</td><td><i>Cyclo</i></td><td>0.523</td><td><i>EF2</i></td><td>0.926</td><td><i>GAPDH</i></td><td>1.335</td><td><i>Cyclo</i></td><td>6.701</td></tr><tr><td><i>GAPDH</i></td><td>0.959</td><td><i>Actin</i></td><td>0.518</td><td><i>Clathrin</i></td><td>0.926</td><td><i>Clathrin</i></td><td>1.33</td><td><i>Clathrin</i></td><td>6.447</td></tr><tr><td><i>eTIF4E</i></td><td>0.857</td><td><i>Clathrin</i></td><td>0.504</td><td><i>eTIF4E</i></td><td>0.888</td><td><i>Cyclo</i></td><td>1.319</td><td><i>Tubulin</i></td><td>5.948</td></tr><tr><td><i>TIP41</i></td><td>0.798</td><td><i>TIP41</i></td><td>0.502</td><td><i>F-box</i></td><td>0.885</td><td><i>RAN</i></td><td>1.302</td><td><i>GAPDH</i></td><td>5.635</td></tr><tr><td><i>Tubulin</i></td><td>0.703</td><td><i>GAPDH</i></td><td>0.462</td><td><i>Actin</i></td><td>0.87</td><td><i>Tubulin</i></td><td>1.299</td><td><i>RAN</i></td><td>4.461</td></tr><tr><td><i>CDPK</i></td><td>0.599</td><td><i>RAN</i></td><td>0.453</td><td><i>Cyclo</i></td><td>0.718</td><td><i>TIP41</i></td><td>1.241</td><td><i>eTIF4E</i></td><td>3.742</td></tr><tr><td><i>RAN</i></td><td>0.503</td><td><i>Fbox</i></td><td>0.452</td><td><i>CDPK</i></td><td>0.699</td><td><i>F-box</i></td><td>1.234</td><td><i>TIP41</i></td><td>2.913</td></tr><tr><td><i>Clathrin</i></td><td>0.47</td><td><i>CDPK</i></td><td>0.272</td><td><i>GAPDH</i></td><td>0.681</td><td><i>eTIF4E</i></td><td>1.155</td><td><i>F-box</i></td><td>2.913</td></tr><tr><td><i>F-box</i></td><td>0.45</td><td><i>eTIF4E</i></td><td>0.257</td><td><i>TIP41</i></td><td>0.601</td><td><i>CDPK</i></td><td>1.091</td><td><i>CDPK</i></td><td>1.861</td></tr></table> |
c6bcfa75a8db1ad3e7b737841ce7738c0a38cee5943207f609edf2049a30e7f7.png | simple | <table><tr><td> </td><td>SOAPsnp</td><td>Atlas-SNP2</td><td>SAMtools</td><td>GATK-UGT</td></tr><tr><td>Quality score</td><td>Recalibrated</td><td>Raw</td><td>Recalibrated</td><td>Recalibrated</td></tr><tr><td>Machine cycle</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Allele type</td><td>Yes</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>Duplication level</td><td>Penalty in quality score</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Swap-base</td><td>No</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>MNP events</td><td>No</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>NQS</td><td>No</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Coverage variation</td><td>No</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Base dependency</td><td>Yes</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Strand independency</td><td>No</td><td>NO</td><td>Yes</td><td>No</td></tr></table> |
0124c249ac594e3bf806b192e4447ef6affe41cb32cd62c801d48f7cba170e8e.png | complex | <table><tr><td colspan="2"></td><td colspan="3">Individual Items</td><td colspan="3">Dimensions</td><td></td></tr><tr><td>LTC</td><td>PROM</td><td>N</td><td>% missing baseline</td><td>% missing follow-up</td><td>N</td><td>% missing baseline</td><td>% missing follow-up</td><td>% missing change score</td></tr><tr><td rowspan="3">Asthma</td><td>Mini-AQLQ</td><td>15</td><td>0-3.8</td><td>0.8-6.8</td><td>5</td><td>1.1-7.1</td><td>3.4-11.7</td><td>4.1-15.0</td></tr><tr><td>EQ-5D</td><td>5</td><td>0.4-0.8</td><td>0.8-1.9</td><td>1</td><td>1.1</td><td>3.0</td><td>4.1</td></tr><tr><td>EQ-5D VAS</td><td>1</td><td>3.4</td><td>3.8</td><td>N/A</td><td>N/A</td><td>N/A</td><td>6.8</td></tr><tr><td rowspan="3">COPD</td><td>CCQ</td><td>10</td><td>1.6-3.7</td><td>0-3.7</td><td>4</td><td>4.3-9.1</td><td>2.1-8.6</td><td>5.9-14.4</td></tr><tr><td>EQ-5D</td><td>5</td><td>0-1.1</td><td>1.1-2.1</td><td>1</td><td>2.1</td><td>4.8</td><td>5.3</td></tr><tr><td>EQ-5D VAS</td><td>1</td><td>5.0</td><td>4.4</td><td>N/A</td><td>N/A</td><td>N/A</td><td>7.8</td></tr><tr><td rowspan="3">Diabetes</td><td>DHP</td><td>18</td><td>0-2.8</td><td>1.2-3.1</td><td>3</td><td>1.6-6.2</td><td>2.8-7.5</td><td>4.4-12.1</td></tr><tr><td>EQ-5D</td><td>5</td><td>0.9-2.5</td><td>1.6-2.2</td><td>1</td><td>3.4</td><td>3.7</td><td>6.2</td></tr><tr><td>EQ-5D VAS</td><td>1</td><td>5.0</td><td>4.4</td><td>N/A</td><td>N/A</td><td>N/A</td><td>7.8</td></tr><tr><td rowspan="3">Epilepsy</td><td>QOLIE</td><td>31</td><td>0-27.9</td><td>1.0-30.8</td><td>8</td><td>0-42.3</td><td>2.9-50.0</td><td>2.9-61.5</td></tr><tr><td>EQ-5D</td><td>5</td><td>0-1.9</td><td>1.0-4.8</td><td>1</td><td>1.9</td><td>6.7</td><td>8.7</td></tr><tr><td>EQ-5D VAS</td><td>1</td><td>9.6</td><td>5.8</td><td>N/A</td><td>N/A</td><td>N/A</td><td>12.5</td></tr><tr><td rowspan="3">Heart failure</td><td>MLHFQ</td><td>21</td><td>0.6-11.0</td><td>3.2-21.3</td><td>3</td><td>5.8-28.4</td><td>9.0-36.1</td><td>14.8-48.4</td></tr><tr><td>EQ-5D</td><td>5</td><td>0-3.9</td><td>1.9-4.5</td><td>1</td><td>4.5</td><td>7.7</td><td>11.6</td></tr><tr><td>EQ-5D VAS</td><td>1</td><td>2.6</td><td>5.2</td><td>N/A</td><td>N/A</td><td>N/A</td><td>6.5</td></tr><tr><td rowspan="3">Stroke</td><td>SIS</td><td>60</td><td>2.9-23.5</td><td>2.0-22.5</td><td>10</td><td>5.9-36.3</td><td>5.9-38.2</td><td>9.8-52.9</td></tr><tr><td>EQ-5D</td><td>5</td><td>1.0-3.9</td><td>2.0-4.9</td><td>1</td><td>3.9</td><td>5.8</td><td>8.8</td></tr><tr><td>EQ-5D VAS</td><td>1</td><td>11.8</td><td>10.8</td><td>N/A</td><td>N/A</td><td>N/A</td><td>19.6</td></tr></table> |
883f6b707abaa5cd153a3199a11d14b605184e4e21b0943a5320a15ff351c513.png | simple | <table><tr><td>Characteristic</td><td>n = 52</td></tr><tr><td>Age, year (mean ± SD)</td><td>60 (±14)</td></tr><tr><td>Gender, number of patients (%)</td><td></td></tr><tr><td> Male</td><td>32 (61)</td></tr><tr><td> Female</td><td>20 [39]</td></tr><tr><td>Cause of benign rupture or leak, number of patients (%)</td><td></td></tr><tr><td> Anastomotic</td><td>32 (62)</td></tr><tr><td> Iatrogenic</td><td>13 [25]</td></tr><tr><td> Boerhaave's syndrome</td><td>4 [8]</td></tr><tr><td> Other</td><td>3 [5]</td></tr><tr><td>Location of benign rupture or leak, number of patients (%)</td><td></td></tr><tr><td> Distal esophagus</td><td>13 [25]</td></tr><tr><td> Mid-esophagus</td><td>24 (45)</td></tr><tr><td> Proximal esophagus</td><td>11 [21]</td></tr><tr><td> Unknown</td><td>4 [9]</td></tr><tr><td>Length of rupture or leak, cm (median (range))</td><td>2 (0.2-7)</td></tr><tr><td>Time interval between rupture and stent placement, number of patients (%)</td><td></td></tr><tr><td> Within 24 hours</td><td>5 [10]</td></tr><tr><td> After 24 hours</td><td>47 (90)</td></tr><tr><td>Prior treatment for benign rupture or leak, number of patients (%)</td><td></td></tr><tr><td> Stent placement in another hospital</td><td>3 [5]</td></tr><tr><td> Surgery</td><td>3 [5]</td></tr><tr><td> Clip placement</td><td>1 [2]</td></tr><tr><td> None</td><td>45 (88)</td></tr><tr><td>Antibiotic treatment, number of patients (%)</td><td></td></tr><tr><td> Yes</td><td>41.(79)</td></tr><tr><td> No</td><td>11 [21]</td></tr><tr><td>Concurrent fluid drainage, number of patients (%)</td><td></td></tr><tr><td> Yes</td><td>24 (46)</td></tr><tr><td> No</td><td>28 (54)</td></tr><tr><td>Total days of treatment with a stent, median (range)</td><td>39 (1-742)</td></tr></table> |
441a708c68ae521a0d5a03e7fd5d4e10c0f0a3bf5911efff238c32774e820115.png | simple | <table><tr><td>Tumor Grade</td><td>%</td></tr><tr><td>I</td><td>2.1</td></tr><tr><td>I B</td><td>8.5</td></tr><tr><td>II</td><td>27.6</td></tr><tr><td>II B</td><td>2.1</td></tr><tr><td>III A</td><td>19.2</td></tr><tr><td>III B</td><td>6.5</td></tr><tr><td>IV</td><td>34</td></tr></table> |
3f113929c37b18b84f84ec09d562dc29b4023f2308aa2c4516df40c6d634cf41.png | simple | <table><tr><td>Variables</td><td>Ever user (n = 11,013)</td><td>Nonuser (n = 3,055)</td><td><i>P</i>-value<sup>c</sup></td></tr><tr><td>Age, yrs</td><td>52.9 ± 15.0</td><td>33.2 ± 12.5</td><td>< 0.001</td></tr><tr><td> 18-29</td><td>842 (36.2)</td><td>1,481 (63.8)</td><td></td></tr><tr><td> 30-39</td><td>1,363 (61.7)</td><td>848 (38.3)</td><td></td></tr><tr><td> 40-49</td><td>1,898 (84.8)</td><td>340 (15.2)</td><td></td></tr><tr><td> 50-59</td><td>3,558 (93.3)</td><td>255 (6.7)</td><td></td></tr><tr><td> 60 ≥</td><td>3,352 (96.2)</td><td>131 (3.8)</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>5,053 (78.2)</td><td>1,410 (21.8)</td><td>0.01</td></tr><tr><td> Female</td><td>5,960 (78.4)</td><td>1,645 (21.6)</td><td>Reference</td></tr><tr><td>Education</td><td></td><td></td><td></td></tr><tr><td> Less than high school</td><td>5,248 (92.7)</td><td>413 (7.3)</td><td>< 0.001</td></tr><tr><td> High school</td><td>4,502 (74.2)</td><td>1,562 (25.8)</td><td>0.76</td></tr><tr><td> College or above</td><td>1,262 (53.9)</td><td>1,079 (46.1)</td><td>Reference</td></tr><tr><td>BMI<sup>a</sup>, kg/cm<sup>2</sup></td><td></td><td></td><td></td></tr><tr><td> ≥ 25.0</td><td>3,063 (85.1)</td><td>536 (14.9)</td><td>0.10</td></tr><tr><td> 18.5-24.9</td><td>7,342 (77.1)</td><td>2,183 (22.9)</td><td>0.76</td></tr><tr><td> < 18.5</td><td>577 (63.8)</td><td>328 (36.2)</td><td>Reference</td></tr><tr><td>Waist circumference<sup>b</sup>, cm</td><td></td><td></td><td></td></tr><tr><td> ≥ 80 (female) or 90 (male)</td><td>8,280 (81.8)</td><td>1,847 (18.2)</td><td>0.06</td></tr><tr><td> < 80 (female) or 90 (male)</td><td>2,665 (69.1)</td><td>1,180 (31.9)</td><td>Reference</td></tr><tr><td>Second-hand smoke</td><td></td><td></td><td></td></tr><tr><td> Never</td><td>2,149 (69.2)</td><td>957 (30.8)</td><td>< 0.001</td></tr><tr><td> Ever</td><td>8,862 (80.9)</td><td>2,098 (19.1)</td><td>Reference</td></tr><tr><td>Smoking</td><td></td><td></td><td></td></tr><tr><td> Current smoker</td><td>2,717 (84.5)</td><td>498 (15.5)</td><td>0.01</td></tr><tr><td> Ex-smoker</td><td>604 (92.8)</td><td>47 (7.2)</td><td>0.78</td></tr><tr><td> Never-smoker</td><td>7,383 (75.4)</td><td>2,408 (24.6)</td><td>Reference</td></tr><tr><td>Amount of smoking, pack-years</td><td>8.0 ± 23.1</td><td>2.4 ± 11.2</td><td>0.24</td></tr></table> |
fa78bdbda5f4fb22c7f4915d9526752ba9fb5082050f8b89dd8b1f9cc64fcab4.png | complex | <table><tr><td rowspan="2"></td><td colspan="4">Relative risk per SD increase in domestic usage</td></tr><tr><td colspan="2">Unadjusted (95% CI)</td><td colspan="2">Adjusted* (95% CI)</td></tr><tr><td>Respiratory</td><td></td><td></td><td></td><td></td></tr><tr><td> Chronic obstructive pulmonary disease</td><td>1.253</td><td>1.245 to 1.260</td><td>1.142</td><td>1.122 to 1.163</td></tr><tr><td> Asthma</td><td>1.199</td><td>1.176 to 1.223</td><td>1.093</td><td>1.032 to 1.158</td></tr><tr><td> Pneumonia</td><td>1.262</td><td>1.254 to 1.269</td><td>1.227</td><td>1.205 to 1.250</td></tr><tr><td> Tuberculosis</td><td>1.734</td><td>1.676 to 1.793</td><td>1.298</td><td>1.167 to 1.444</td></tr><tr><td>Cardiovascular</td><td></td><td></td><td></td><td></td></tr><tr><td> Ischaemic heart disease</td><td>1.141</td><td>1.138 to 1.143</td><td>1.102</td><td>1.095 to 1.110</td></tr><tr><td> Rheumatic heart disease</td><td>1.209</td><td>1.184 to 1.234</td><td>1.240</td><td>1.166 to 1.318</td></tr><tr><td> Stroke</td><td>1.137</td><td>1.133 to 1.141</td><td>1.114</td><td>1.101 to 1.127</td></tr><tr><td> Hypertension</td><td>1.204</td><td>1.196 to 1.212</td><td>1.112</td><td>1.089 to 1.135</td></tr></table> |
689315071b53abb8761bdc58ed7c253d598a2a35a948e60201cb865eac28f6e6.png | simple | <table><tr><td>Lively</td><td>Youthful</td><td>Exciting</td></tr><tr><td>More Sociable</td><td>More Spontaneous</td><td>More Active</td></tr><tr><td>More Natural/Down to earth</td><td>More Warm/Caring</td><td>More Self Confident</td></tr><tr><td>Enjoys the outdoors more</td><td>More Feminine</td><td>Pushy</td></tr><tr><td>More Modern</td><td>More Stylish</td><td>More Spirited/Fun</td></tr><tr><td>Higher income</td><td>More Sophisticated</td><td>Sensitive/caring</td></tr><tr><td>Friendly</td><td>Does things on the spur of the moment</td><td></td></tr></table> |
f357e9c5155451af2b7168ac1f5cdfd2f6cc41cdcaf70c28014c07532770e03d.png | complex | <table><tr><td>Population characteristics</td><td>Number</td><td>Unweighted, %</td><td>Weighted, %</td><td>Elaidic acid (C18:1 t9)Weighted mean (SE) μM</td><td>Vaccenic acid (C18:1 t11)Weighted mean (SE) μM</td><td>Palmitelaidic acid (C16:1 t9)Weighted mean (SE) μM</td><td>Linolelaidic acid (C18:2 t9, 12)Weighted mean (SE) μM</td></tr><tr><td colspan="8">Gender</td></tr><tr><td> Male (ref)</td><td>701</td><td>48.1</td><td>48.8</td><td>36.40(1.87)</td><td>43.12(1.96)</td><td>7.43(0.28)</td><td>3.04(0.15)</td></tr><tr><td> Female</td><td>755</td><td>51.9</td><td>51.2</td><td>37.99(1.41)</td><td>41.24(1.36)</td><td>7.67(0.15)</td><td>3.20(0.11)</td></tr><tr><td colspan="8">Age, y</td></tr><tr><td> 20–39 (ref)</td><td>509</td><td>35</td><td>42.8</td><td>34.98(1.27)</td><td>41.23(1.33)</td><td>7.30(0.19)</td><td>2.96(0.10)</td></tr><tr><td> 40–59</td><td>429</td><td>29.5</td><td>36.0</td><td>39.26(2.47) <sup>*</sup></td><td>43.62(2.27)</td><td>7.60(0.34)</td><td>3.26(0.19) <sup>*</sup></td></tr><tr><td> 60</td><td>518</td><td>35.5</td><td>21.2</td><td>38.27(1.36) <sup>*</sup></td><td>41.57(1.27)</td><td>7.97(0.22) <sup>*</sup></td><td>3.21(0.13) <sup>*</sup></td></tr><tr><td colspan="8">Race</td></tr><tr><td> Non-Hispanic White (ref)</td><td>695</td><td>47.7</td><td>75.0</td><td>38.97(1.75)</td><td>43.83(1.67)</td><td>7.97(0.19)</td><td>3.31(0.15)</td></tr><tr><td> Non-Hispanic Black</td><td>222</td><td>15.2</td><td>8.5</td><td>31.52(1.07) <sup>*</sup></td><td>37.80(1.19) <sup>*</sup></td><td>6.00(0.29) <sup>*</sup></td><td>2.39(0.08) <sup>*</sup></td></tr><tr><td> Mexican American</td><td>424</td><td>29.1</td><td>6.4</td><td>37.07(2.31)</td><td>41.76(2.39)</td><td>7.27(0.31) <sup>*</sup></td><td>2.94(0.18) <sup>*</sup></td></tr><tr><td> Other Hispanic</td><td>80</td><td>5.5</td><td>7.1</td><td>26.82(2.27) <sup>*</sup></td><td>33.41(2.26) <sup>*</sup></td><td>5.87(0.12) <sup>*</sup></td><td>2.43(0.08) <sup>*</sup></td></tr><tr><td> Other race / multiracial</td><td>35</td><td>2.5</td><td>3.0</td><td>34.49(5.04)</td><td>34.28(6.28)</td><td>6.05(0.75) <sup>*</sup></td><td>2.59(0.21) <sup>*</sup></td></tr><tr><td colspan="8">BMI, kg/m<sup>2</sup></td></tr><tr><td> Underweight (<18.5)</td><td>24</td><td>1.6</td><td>2.4</td><td>31.68(1.28)</td><td>40.01(1.96)</td><td>6.88(0.43)</td><td>2.28(0.14)</td></tr><tr><td> Normal weight (18.5–24.9) (ref)</td><td>459</td><td>31.5</td><td>36.3</td><td>33.98(1.60)</td><td>39.32(1.62)</td><td>7.04(0.20)</td><td>2.69(0.11)</td></tr><tr><td> Overweight (25–29.9)</td><td>490</td><td>33.7</td><td>31.6</td><td>36.21(1.52)</td><td>41.59(1.66)</td><td>7.36(0.27)</td><td>3.21(0.15) <sup>*</sup></td></tr><tr><td> Obese (>30)</td><td>483</td><td>33.2</td><td>29.7</td><td>42.67(1.88) <sup>*</sup></td><td>46.39(1.79) <sup>*</sup></td><td>8.43(0.21) <sup>*</sup></td><td>3.62(0.14) <sup>*</sup></td></tr><tr><td colspan="8">Alcohol use</td></tr><tr><td> No (ref)</td><td>454</td><td>31.2</td><td>26.1</td><td>39.41(1.22)</td><td>43.44(0.89)</td><td>8.12(0.16)</td><td>3.12(0.12)</td></tr><tr><td> Yes</td><td>1002</td><td>68.8</td><td>73.9</td><td>36.44(1.67) <sup>*</sup></td><td>41.71(1.71)</td><td>7.35(0.18) <sup>*</sup></td><td>3.12(0.13)</td></tr><tr><td colspan="8">Smoking status</td></tr><tr><td> Nonsmoker (ref)</td><td>720</td><td>49.5</td><td>46.8</td><td>35.58(1.82)</td><td>41.08(1.75)</td><td>7.53(0.22)</td><td>2.94(0.13)</td></tr><tr><td> Former</td><td>426</td><td>29.2</td><td>28.9</td><td>39.07(1.82) <sup>*</sup></td><td>43.70(1.71)</td><td>8.08(0.26)</td><td>3.29(0.16) <sup>*</sup></td></tr><tr><td> Current</td><td>310</td><td>21.3</td><td>24.3</td><td>38.16(1.92)</td><td>42.40(2.08)</td><td>6.97(0.32)</td><td>3.27(0.16) <sup>*</sup></td></tr><tr><td colspan="8">Hypertension<sup>a</sup></td></tr><tr><td> No (ref)</td><td>941</td><td>64.6</td><td>72.4</td><td>36.42(1.75)</td><td>42.09(1.76)</td><td>7.49(0.24)</td><td>3.02(0.13)</td></tr><tr><td> Yes</td><td>515</td><td>35.4</td><td>27.6</td><td>39.3(1.90)</td><td>42.35(1.36)</td><td>7.71(0.21)</td><td>3.38(0.13) <sup>*</sup></td></tr><tr><td colspan="8">Diabetes<sup>b</sup></td></tr><tr><td> No (ref)</td><td>1338</td><td>91.9</td><td>94.9</td><td>36.48(1.44)</td><td>41.57(1.34)</td><td>7.43(0.16)</td><td>3.09(0.12)</td></tr><tr><td> Yes</td><td>118</td><td>8.1</td><td>5.1</td><td>50.89(5.37) <sup>*</sup></td><td>53.12(3.89) <sup>*</sup></td><td>9.81(0.71) <sup>*</sup></td><td>3.79(0.20)<sup>*</sup></td></tr><tr><td colspan="8">Self-reported cardiovascular diseases history</td></tr><tr><td> No (ref)</td><td>1358</td><td>93.3</td><td>94.7</td><td>37.05(1.51)</td><td>42.16(1.40)</td><td>7.53(0.16)</td><td>3.11(0.12)</td></tr><tr><td> Yes</td><td>98</td><td>6.7</td><td>5.3</td><td>40.16(2.70)</td><td>42.03(2.97)</td><td>7.92(0.65)</td><td>3.31(0.19)</td></tr><tr><td colspan="8">Mortality status, n (%)</td></tr><tr><td> Assumed alive (ref)</td><td>1235</td><td>84.8</td><td>90.0</td><td>36.65(1.45)</td><td>41.82(1.39)</td><td>7.45(0.17)</td><td>3.12(0.12)</td></tr><tr><td> Assumed deceased</td><td>221</td><td>15.2</td><td>10.0</td><td>42.27(3.00) <sup>*</sup></td><td>45.25(2.86)</td><td>8.42(0.44) <sup>*</sup></td><td>3.18(0.15)</td></tr><tr><td>Overall</td><td>1456</td><td>100</td><td>100</td><td>37.22(1.44)</td><td>42.16(1.33)</td><td>7.55(0.15)</td><td>3.12(0.11)</td></tr></table> |
ea91c4494fabda097c46b9c3e967916139a83c9e9398e1109b3d379a16026f03.png | simple | <table><tr><td>Variable</td><td><i>n</i></td><td>Optical density</td></tr><tr><td><i>Sham-control </i></td><td>10</td><td>0.0008 ± 0.00143</td></tr><tr><td><i>CIA-control </i></td><td>10</td><td>0.0266 ± 0.01948<sup>*</sup></td></tr><tr><td><i>CIA-EA </i></td><td>10</td><td>0.0078 ± 0.00604<sup>*</sup></td></tr><tr><td><i>CIA-EA-SCH58261 </i></td><td>10</td><td>0.0493 ± 0.00482<sup>∗#</sup></td></tr><tr><td><i>CIA-SCH58261 </i></td><td>10</td><td>0.0507 ± 0.00965<sup>∗#</sup></td></tr></table> |
19f3c80ed2d4b8176ed7c6c7eef1e4ee4f0f6a496e130dbf4453e4a42272047c.png | simple | <table><tr><td>SVM</td><td>Sen</td><td>Spec</td><td>Acc</td><td>MCC</td><td>Prec</td><td>F1</td></tr><tr><td>1</td><td>34.64</td><td>96.77</td><td>79.62</td><td>0.4338</td><td>80.37</td><td>48.42</td></tr><tr><td>2</td><td>34.5</td><td>96.72</td><td>79.54</td><td>0.431</td><td>80.03</td><td>48.21</td></tr><tr><td>3</td><td>32.68</td><td>97.41</td><td>79.54</td><td>0.4316</td><td>82.78</td><td>46.86</td></tr><tr><td>4</td><td>34.75</td><td>96.81</td><td>79.68</td><td>0.4358</td><td>80.62</td><td>48.57</td></tr><tr><td>5</td><td>34.78</td><td>96.82</td><td>79.7</td><td><i>0.4363 </i></td><td>80.68</td><td>48.6</td></tr><tr><td>6</td><td>34.65</td><td>96.78</td><td>79.63</td><td>0.4339</td><td>80.39</td><td>48.43</td></tr><tr><td>7</td><td>34.51</td><td>96.72</td><td>79.55</td><td>0.4312</td><td>80.06</td><td>48.23</td></tr><tr><td>8</td><td>34.69</td><td>96.79</td><td>79.65</td><td>0.4347</td><td>80.48</td><td>48.48</td></tr><tr><td>9</td><td>34.77</td><td>96.83</td><td>79.7</td><td><i>0.4363 </i></td><td>80.69</td><td>48.6</td></tr><tr><td>10*</td><td>34.62</td><td>96.77</td><td>79.61</td><td>0.4334</td><td>80.32</td><td>48.39</td></tr><tr><td>1**</td><td>38.49</td><td>95.21</td><td>79.54</td><td>0.4334</td><td>75.75</td><td>50.93</td></tr><tr><td>2</td><td>40.61</td><td>94.77</td><td>79.8</td><td>0.4433</td><td>74.86</td><td>52.6</td></tr><tr><td>3</td><td>42.47</td><td>94.66</td><td>80.25</td><td>0.4577</td><td>75.24</td><td>54.26</td></tr><tr><td>4</td><td>41.79</td><td>95.6</td><td>80.74</td><td>0.4715</td><td>78.32</td><td>54.47</td></tr><tr><td>5</td><td>40.21</td><td>96.62</td><td>81.05</td><td><i>0.4809 </i></td><td>81.86</td><td>53.92</td></tr><tr><td>6</td><td>29.72</td><td>97.7</td><td>78.93</td><td>0.4107</td><td>83.06</td><td>43.76</td></tr><tr><td>7</td><td>28.86</td><td>98.12</td><td>79</td><td>0.414</td><td>85.21</td><td>43.1</td></tr><tr><td>8</td><td>28.3</td><td>98.33</td><td>79</td><td>0.4149</td><td>86.39</td><td>42.62</td></tr><tr><td>9</td><td>28.13</td><td>98.45</td><td>79.04</td><td>0.4167</td><td>87.12</td><td>42.52</td></tr><tr><td>10</td><td>27.72</td><td>98.66</td><td>79.08</td><td>0.4192</td><td>88.48</td><td>42.2</td></tr></table> |
1f58bfa60a1556966d180c4ac27205972431f6b998c212449a166f3dd60e323e.png | simple | <table><tr><td>Group</td><td>Taxon</td><td><i>N</i></td><td>Body mass (kg) range F-M<sup>a</sup></td><td>Locomotor behaviours</td></tr><tr><td>NWM</td><td><i>Lagothrix lagotricha</i></td><td>7</td><td>7.0-9.3</td><td>arboreal quadruped, with climbing and orthograde clambering<sup>b</sup></td></tr><tr><td> </td><td><i>Ateles</i> sp.</td><td>4</td><td>7.3-8.9</td><td>torso-orthograde suspensory; semi-brachiator<sup>c</sup></td></tr><tr><td> </td><td><i>Alouatta</i> sp.</td><td>13</td><td>5.4-7.2</td><td>arboreal quadruped, with climbing and orthograde clambering</td></tr><tr><td>Hominoids</td><td><i>Pongo pygmaeus</i></td><td>25</td><td>35.8-78.5</td><td>torso-orthograde suspensory<sup>d</sup></td></tr><tr><td> </td><td><i>Pongo abelii</i></td><td>9</td><td>35.6-77.9</td><td>torso-orthograde suspensory</td></tr><tr><td> </td><td><i>Pan troglodytes verus</i></td><td>14</td><td>41.6-46.3</td><td>knuckle-walker (arboreal and terrestrial) and climbing<sup>e</sup></td></tr><tr><td> </td><td><i>Pan troglodytes troglodytes</i></td><td>25</td><td>45.8-59.7</td><td>knuckle-walker (arboreal and terrestrial) and climbing</td></tr><tr><td> </td><td><i>Pan troglodytes schweinfurthii</i></td><td>6</td><td>33.7-42.7</td><td>knuckle-walker and climbing (proportion of arboreality varies from 33-68%)</td></tr><tr><td> </td><td><i>Pan paniscus</i></td><td>19</td><td>33.2-45.0</td><td>knuckle-walker (arboreal and terrestrial) and climbing, considered more arboreal than <i>P. troglodytes</i><sup>f</sup></td></tr><tr><td> </td><td><i>Homo sapiens</i></td><td>146</td><td>54.4-62.2</td><td>terrestrial biped</td></tr><tr><td> </td><td><i>Gorilla gorilla gorilla</i></td><td>40</td><td>71.5-170.4</td><td>terrestrial knuckle-walker (assumed to be less terrestrial than <i>G.b.beringei</i>)<sup>g</sup></td></tr><tr><td> </td><td><i>Gorilla beringei graueri</i></td><td>7</td><td>71.0-175.2</td><td>terrestrial knuckle-walker (assumed to be less terrestrial than <i>G.b.beringei</i>)</td></tr><tr><td> </td><td><i>Gorilla beringei beringei</i></td><td>9</td><td>97.5-162.5</td><td>terrestrial knuckle-walker (most terrestrial of all <i>Gorilla</i>, 93-98% terrestrial)</td></tr><tr><td> </td><td><i>Symphalangus syndactylus</i></td><td>5</td><td>10.7-11.9</td><td>brachiator<sup>h</sup></td></tr><tr><td> </td><td><i>Hylobates lar</i></td><td>27</td><td>5.4-5.9</td><td>brachiator</td></tr><tr><td>OWM</td><td><i>Presbytis</i> sp.</td><td>2</td><td>5.6-6.8</td><td>arboreal quadruped, capable of leaping and forelimb suspension<sup>i</sup></td></tr><tr><td> </td><td><i>Macaca mulatta</i></td><td>16</td><td>8.8-11.0</td><td>semi-terrestrial quadruped<sup>j</sup></td></tr><tr><td> </td><td><i>Macaca fascicularis</i></td><td>7</td><td>3.6-5.4</td><td>arboreal quadruped<sup>k</sup></td></tr><tr><td> </td><td><i>Papio Anubis</i></td><td>6</td><td>13.3-25.1</td><td>terrestrial quadruped<sup>l</sup></td></tr><tr><td> </td><td><i>Theropithecus gelada</i></td><td>5</td><td>11.7-19.0</td><td>terrestrial quadruped</td></tr><tr><td> </td><td><i>Chlorocebus aethiops</i></td><td>4</td><td>3.0-5.5</td><td>semi-terrestrial quadruped</td></tr><tr><td> </td><td><i>Erythrocebus patas</i></td><td>3</td><td>6.5-12.4</td><td>terrestrial quadruped</td></tr><tr><td> </td><td><i>Cercopithecus mitis</i></td><td>12</td><td>3.9-5.9</td><td>arboreal quadruped</td></tr></table> |
e0e4d2ded1940a91657806a09426164e23bec2bd978f7b3113f7de12e26f1869.png | simple | <table><tr><td>Primer Name</td><td>Primer Sequence (5’to 3’)</td></tr><tr><td>VHSCDNA</td><td>GTATCATAAAAGATGATGAGTTATGTTACAAGGG</td></tr><tr><td>VHSPCRF</td><td>GTTGAACACAGAGTCATATCTCATAATCG</td></tr><tr><td>VHSPCRR</td><td>GGTGGAGACACGGTCCTCATCATTGGACGTGAGG</td></tr><tr><td>PJETFOR</td><td>CGACTCACTATAGGGAGAGCGGC</td></tr><tr><td>PJETREV</td><td>AAGAACATCGATTTTCCATGGCAG</td></tr><tr><td>VHSNF</td><td>GATGACGACTACCCCGAGGACTCTGAC</td></tr><tr><td>SACPSIF</td><td>CTCCACCGCGGTAATACGACTCACTATAGG</td></tr><tr><td>SACPSIR</td><td>GCTTTGATCAAAGAGAAATTCTTATAATCGTGCCG</td></tr><tr><td>PSIMFEF</td><td>CGGCACGATTATAAGAATTTCTCTTTG</td></tr><tr><td>PSIMFER</td><td>GGCCTGCCACAATTGCCTTGACCACC</td></tr><tr><td>SPEMUTN</td><td>CGTTGAACAAAAGAACTCAGTACTAGTATGGAAGGAGGAATTCGTGCAGCG</td></tr><tr><td>SNABIMUTN</td><td>CGACTACCCCGAGGACTCTGACTAATACGTACTCCCGTCTCATAACCAACATAG</td></tr><tr><td>SPEMUTP</td><td>GACAAACACTGAGATACTAGTATGGCTGATATTGAGATGAGCGAGTCC</td></tr><tr><td>SNABIMUTP</td><td>CGATCAAGGCGGAGCTGGACAAGCTAGAGTAGTACGTACACAACGCATCACAC</td></tr></table> |
746cabf8f4b141489a0570a200e138d1af3c98d9998760c375e2c2045dd67ea2.png | simple | <table><tr><td></td><td>Indomethacin</td><td>Ibuprofen</td><td></td></tr><tr><td></td><td>(N = 161)</td><td>(N = 182)</td><td>p value</td></tr><tr><td>Day of Life at Start of Treatment (mean, SD)</td><td>3.3 ± 2.3</td><td>3.5 ± 2.7</td><td>NS</td></tr><tr><td>PDA Closed, n (%)</td><td>109 (68)</td><td>129 (71)</td><td>0.4</td></tr><tr><td>PDA Ligation, n (%)</td><td>45 (28)</td><td>38 (21)</td><td>0.1</td></tr><tr><td>BPD, n (%)</td><td>72 (45)</td><td>90 (49)</td><td>0.2</td></tr><tr><td>NEC-related conditions, any, n (%)</td><td>27 (17)</td><td>32 (18)</td><td>0.8</td></tr><tr><td>NEC, n (%)</td><td>6 (4)</td><td>15 (8)</td><td>0.08</td></tr><tr><td> NEC-Like Illness (%)</td><td>13 (8)</td><td>5 (3)</td><td>0.03*</td></tr><tr><td> Spontaneous Intestinal Perforations, n (%)</td><td>8 (5)</td><td>12 (7)</td><td>0.5</td></tr><tr><td>ROP, n (%)</td><td>65 (52)</td><td>41 (30)</td><td><0.001*</td></tr><tr><td>Severe ROP: Grades III-V</td><td>15 (12)</td><td>15 (11)</td><td>0.8</td></tr><tr><td>IVH, any, n (%)</td><td>58 (36)</td><td>57 (31)</td><td>0.4</td></tr><tr><td>Severe IVH: Grade III/IV</td><td>12 (8)</td><td>12 (9)</td><td>0.6</td></tr><tr><td>PVL</td><td>4 (2.4)</td><td>3 (1.6)</td><td>0.4</td></tr><tr><td>Death, n (%)</td><td>12 (7)</td><td>16 (9)</td><td>0.4</td></tr></table> |
40d57d6b7cec041c38bbaacee57f4eb9321b1662e69ffa2ee74a031a62b71f35.png | complex | <table><tr><td></td><td colspan="2">PDSS</td><td colspan="2">HAM-A</td><td colspan="2">Frequency</td></tr><tr><td></td><td>r</td><td>p value</td><td>r</td><td>p value</td><td>r</td><td>p value</td></tr><tr><td>Mesor</td><td>0.71</td><td>0.79</td><td>0.62</td><td>0.01</td><td>0.55</td><td>0.03</td></tr><tr><td>Amplitude(circadian)</td><td>0.22</td><td>0.41</td><td>0.35</td><td>0.19</td><td>0.16</td><td>0.55</td></tr><tr><td>Amplitude(12 hour harmonic)</td><td>0.00</td><td>1.00</td><td>0.42</td><td>0.10</td><td>0.46</td><td>0.08</td></tr><tr><td>Acrophase(circadian)</td><td>0.13</td><td>0.62</td><td>0.22</td><td>0.42</td><td>0.36</td><td>0.18</td></tr><tr><td>Acrophase(12 hour harmonic)</td><td>-0.27</td><td>0.31</td><td>-0.18</td><td>0.51</td><td>-0.18</td><td>0.49</td></tr></table> |
5c2c7c66b9f075cc830ab2659d1084148703179920c577f033f6b628dc8f2875.png | simple | <table><tr><td>Pair</td><td>Egg hatch rate</td><td>Number of progeny</td><td>Sex ratio (proportion male)</td><td>Status</td></tr><tr><td>PF 12.5.i</td><td>0.67</td><td>23</td><td>0.609</td><td>N</td></tr><tr><td>PF12.5.ii</td><td>0.88</td><td>34</td><td>0.412</td><td>N</td></tr><tr><td>PF12.6.i</td><td>0.92</td><td>56</td><td>0.446</td><td>N</td></tr><tr><td>PF12.6.ii</td><td>0.77</td><td>18</td><td>0.556</td><td>N</td></tr></table> |
4f146a1bf00b7b10ae75b3ef98f36b93a05df412d0f973a5912076c3b4a306dd.png | simple | <table><tr><td>Sample code</td><td>Type</td><td>Yield (mg)</td><td>Melting point (°C)</td><td>Physical state</td></tr><tr><td>IA/01/1</td><td>C-9154 analogue</td><td>90%</td><td>195-196</td><td>White powdery solid</td></tr><tr><td>IA/24/1/B</td><td>Methyl ester</td><td>160, (0.78 mmol)</td><td>74</td><td>Bright yellow crystalline solid</td></tr><tr><td>IA/21/1/B</td><td>Ethyl ester</td><td>100, (0.46 mmol)</td><td>63</td><td>Light brown crystalline solid</td></tr><tr><td>IA/22/1/B</td><td>n-propyl ester</td><td>170, (0.73 mmol)</td><td>55</td><td>Dark brown crystalline solid</td></tr><tr><td>IA/23/1/B</td><td>Isopropyl ester</td><td>105, (0.45 mmol)</td><td>70</td><td>Dark brown crystalline solid</td></tr><tr><td>IA/19/1/B</td><td>n-butyl ester</td><td>200, (0.81 mmol)</td><td>42</td><td>Yellow waxy solid</td></tr><tr><td>IA/20/1/B</td><td>2-butyl ester</td><td>150, (0.61 mmol)</td><td>40</td><td>Golden brown oil</td></tr><tr><td>IA/25/1/B</td><td>t-butyl ester</td><td>2, (~0.01 mmol)</td><td>Not determined</td><td></td></tr></table> |
ecc9002808de898f287e7b45249654e830880951e7af0743523a57d2815c27dc.png | simple | <table><tr><td></td><td>Plain radiograph (<i>n</i> = 30)</td><td>Bone scan (<i>n</i> = 30)</td><td>CT (<i>n</i> = 26)</td><td><i>P</i>-value</td></tr><tr><td>Sensitivity</td><td>0.0 (0.0–22.8)</td><td>100.0 (77.2–100.0)</td><td>76.5 (50.1–93.2)</td><td>0.045</td></tr><tr><td>Specificity</td><td>100.0 (55.5–100.0)</td><td>77.8 (40.0–97.2)</td><td>100.0 (55.5–100.0)</td><td>0.157</td></tr><tr><td>Accuracy</td><td>30.0 (14.7–49.4)</td><td>93.3 (77.9–99.2)</td><td>84.6 (65.1–95.6)</td><td>0.046</td></tr><tr><td>PPV</td><td>NaN</td><td>91.3 (72.0–98.9)</td><td>100.0 (66.1–100.0)</td><td></td></tr><tr><td>NPV</td><td>30.0 (14.7–49.4)</td><td>100.0 (47.3–100.0)</td><td>69.2 (38.6–90.9)</td><td></td></tr></table> |
55ca357150ed0bbd39a8ef5501623afeeb13c72749956f0297872b64a2788de5.png | complex | <table><tr><td>Gene</td><td>Primer</td><td>Enzyme</td></tr><tr><td rowspan="2"><i>GSTM1 </i></td><td>Forward: GAACTCCCTGAAAAGCTAAAGC</td><td rowspan="2"> </td></tr><tr><td>Reverse: GTTGGGCTCAAATATACGGTGG</td></tr><tr><td rowspan="2"><i>GSTT1 </i></td><td>Forward: TTCCTTACTGGTCCTCACATCTC</td><td rowspan="2"> </td></tr><tr><td>Reverse: CAGCTGCATTTGGAAGTGCTC</td></tr><tr><td rowspan="2"><i>GSTP1</i> (Ile105Val, rs1695)</td><td>Forward: GTAGTTTGCCCAAGGTCAAG</td><td rowspan="2">BsmAI</td></tr><tr><td>Reverse: AGCCACCTGAGGGGTAAG</td></tr><tr><td rowspan="2"><i>NQO1</i> (C609T, rs1800566)</td><td>Forward: AAGCCCAGACCAACTTCT</td><td rowspan="2">HinfI</td></tr><tr><td>Reverse: ATTTGAATTCGGGCGTCTGCTG</td></tr><tr><td rowspan="2"><i>EPHX1</i> (Tyr113His, rs1051740)</td><td>Forward: CTTGAGCTCTGTCCTTCCCATCCC</td><td rowspan="2">Tth111I</td></tr><tr><td>Reverse: AATCTTAGTCTTGAAGTGACGGT</td></tr><tr><td rowspan="2"><i>EPHX1</i> (His139Arg, rs2234922)</td><td>Forward: ACATCCACTTCATCCACGT</td><td rowspan="2">Rsa1</td></tr><tr><td>Reverse: ATGCCTCTGAGAAGCCAT</td></tr><tr><td rowspan="2"><i>HO-1</i> (5′-site GT repeats)</td><td>Forward: FAM-AGAGCCTGCAGCTTCTCAGA</td><td rowspan="2"> </td></tr><tr><td>Reverse: ACAAAGTCTGGCCATAGGAC</td></tr><tr><td rowspan="2"><i>XRCC1</i> (Arg280His, rs25489)</td><td>Forward: GGCTGGGACCACCTGTGTT</td><td rowspan="2">RsaI</td></tr><tr><td>Reverse: TTGACCCCCAGTGGTGCTAA</td></tr><tr><td rowspan="2"><i>XRCC1</i> (Arg399Gln, rs25487)</td><td>Forward: TCTCCCTTGGTCTCCAACCT</td><td rowspan="2">MspI</td></tr><tr><td>Reverse: AGTAGTCTGCTGGCTCTGG</td></tr><tr><td rowspan="2"><i>XPD</i> (C156A, rs238406)</td><td>Forward: TGGAGTGCTATGGCACGATCTCT</td><td rowspan="2">TflI</td></tr><tr><td>Reverse: CCATGGGCATCAAATTCCTGGGA</td></tr><tr><td rowspan="2"><i>hOGG1</i> (Ser326Cys, rs1052133)</td><td>Forward: ACTGTCACTAGTCTCACCAG</td><td rowspan="2">Fnu4HI</td></tr><tr><td>Reverse: TGAATTCGGAAGGTGCTTGGGGAAT</td></tr><tr><td rowspan="2"><i>ATM</i> (INV48 +238C>G, rs609429)</td><td>Forward: CCTGGTTATAAAATGAGAAGG</td><td rowspan="2">KpnI</td></tr><tr><td>Reverse: GCAGCAACTACCATTCATTGAG</td></tr></table> |
905237ea5ce7b52e9c6fd4d634e3633c45c6647b2373856b710ada67e924e044.png | simple | <table><tr><td>Target</td><td>Base URL extension</td></tr><tr><td>Homepage</td><td>fbcv</td></tr><tr><td>Term request tracker</td><td>fbcv/tracker</td></tr><tr><td>Pre-reasoned OBO version</td><td>fbcv/dpo-simple.obo</td></tr><tr><td>Full OWL version</td><td>fbcv/dpo-non-classified.owl</td></tr><tr><td>Full details of all available versions</td><td>fbcv/downloads</td></tr><tr><td>Individual term details for FBcv_0000423</td><td>FBcv_0000423</td></tr></table> |
7c3511a829f5e8ed8d371942a04f44d7091b6e1eeab0fa52fc87b725bec36ec3.png | complex | <table><tr><td rowspan="2">Subjects</td><td rowspan="2">Outcome</td><td rowspan="2">Number of events<sup>a</sup></td><td>Q2 versus Q1</td><td>Q3 versus Q1</td><td>Q4 versus Q1</td><td rowspan="2"><i>P </i>for linear trend</td></tr><tr><td>HR (95% CI)</td><td>HR (95% CI)</td><td>HR (95% CI)</td></tr><tr><td rowspan="4">All subjects</td><td>All-cause mortality</td><td>8.39</td><td>1.05 (0.77 to 1.43)</td><td>1.29 (0.96 to 1.73)</td><td>1.63 (1.22 –to 2.17)</td><td><0.001***</td></tr><tr><td>Cancer mortality</td><td>3.88</td><td>1.07 (0.69 to 1.68)</td><td>1.47 (0.96 to 1.25)</td><td>1.60 (1.04 to 2.43)</td><td>0.014*</td></tr><tr><td>CVD mortality</td><td>2.34</td><td>1.24 (0.67 to 2.29)</td><td>1.30 (0.71 to 2.36)</td><td>1.94 (1.09 to 3.42)</td><td>0.016*</td></tr><tr><td>Mortality from causes other than cancer and CVD</td><td>2.16</td><td>0.92 (0.50 to 1.68)</td><td>1.08 (0.60 to 1.93)</td><td>1.49 (0.86 to 2.60)</td><td>0.096</td></tr><tr><td rowspan="4">Men</td><td>All-cause mortality</td><td>11.14</td><td>0.98 (0.67 to 1.45)</td><td>0.98 (0.68 to 1.42)</td><td>1.50 (1.08 to 2.09)</td><td>0.020*</td></tr><tr><td>Cancer mortality</td><td>4.92</td><td>1.54 (0.86 to 2.75)</td><td>1.23 (0.68 to 2.21)</td><td>1.96 (1.15 to 3.35)</td><td>0.027*</td></tr><tr><td>CVD mortality</td><td>3.13</td><td>0.74 (0.34 to 1.61)</td><td>0.86 (0.43 to 1.72)</td><td>1.41 (0.76 to 2.60)</td><td>0.208</td></tr><tr><td>Mortality from causes other than cancer and CVD</td><td>3.09</td><td>0.65 (0.03 to 1.40)</td><td>0.86 (0.44 to 1.67)</td><td>1.15 (0.62 to 2.12)</td><td>0.557</td></tr><tr><td rowspan="4">Women</td><td>All-cause mortality</td><td>6.30</td><td>1.45 (0.86 to 2.46)</td><td>1.57 (0.91 to 2.71)</td><td>2.04 (1.22 to 2.34)</td><td>0.004*</td></tr><tr><td>Cancer mortality</td><td>3.13</td><td>1.51 (0.77 to 2.99)</td><td>1.25 (0.59 to 2.62)</td><td>1.62 (0.81 to 3.23)</td><td>0.295</td></tr><tr><td>CVD mortality</td><td>1.74</td><td>1.18 (0.36 to 3.86)</td><td>1.91 (0.61 to 6.00)</td><td>2.73 (0.93 to 8.06)</td><td>0.012*</td></tr><tr><td>Mortality from causes other than cancer and CVD</td><td>1.46</td><td>1.66 (0.52 to 5.25)</td><td>2.17 (0.68 to 6.96)</td><td>2.40 (0.78 to 7.38)</td><td>0.106</td></tr></table> |
441b11cb3a3f904e9a0d7eac51579afee519f28e0a15d74daa5ba6efc02a30d9.png | complex | <table><tr><td rowspan="2">Assay</td><td colspan="2">Coefficient of variation</td></tr><tr><td>Intra-assay (%)</td><td>Inter-assay (%)</td></tr><tr><td>OPG</td><td>3.53</td><td>5.78</td></tr><tr><td>sRANKL</td><td>9.38</td><td>12.00</td></tr><tr><td>sRAGE</td><td>4.00</td><td>7.15</td></tr><tr><td>esRAGE</td><td>5.20</td><td>8.50</td></tr></table> |
7ff9f48b87bbeaca04763bb5e5458e873809bbab91a578453a8dfe911a718d32.png | simple | <table><tr><td>Ingredients %</td><td>Basal diet </td><td>DPS2</td><td>DPS4</td><td>DPS6</td></tr><tr><td>Corn</td><td>67.58</td><td>65.54</td><td>63.64</td><td>61.55</td></tr><tr><td>SBOM (CP 44%)</td><td>23</td><td>23.09</td><td>23.20</td><td>23.35</td></tr><tr><td>Corn gluten (CP 62%)</td><td>3.0</td><td>3.0</td><td>3.0</td><td>3.0</td></tr><tr><td>Corn oil</td><td>3.4</td><td>3.36</td><td>3.27</td><td>3.17</td></tr><tr><td>Limestone</td><td>1.15</td><td>1.12</td><td>1.10</td><td>1.05</td></tr><tr><td>Dicalcium phosphate</td><td>1.27</td><td>1.30</td><td>1.30</td><td>1.30</td></tr><tr><td>L-lysine<sup><i>∗</i></sup></td><td>0.14</td><td>0.13</td><td>0.13</td><td>0.12</td></tr><tr><td>Dl-methionine<sup><i>∗∗</i></sup></td><td>0.01</td><td>0.01</td><td>0.01</td><td>0.01</td></tr><tr><td><i>P. dactylifera</i> seeds</td><td>0.0</td><td>2.0</td><td>4.0</td><td>6.0</td></tr><tr><td>Vitamin and mineral premix<sup><i>∗∗∗</i></sup></td><td>0.3</td><td>0.3</td><td>0.3</td><td>0.3</td></tr><tr><td>NaCl</td><td>0.15</td><td>0.15</td><td>0.15</td><td>0.15</td></tr><tr><td>Total</td><td>100</td><td>100</td><td>100</td><td>100</td></tr><tr><td>Calculated and analyzed composition</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> ME</td><td>3187.63</td><td>3189.41</td><td>3188.58</td><td>3188.10</td></tr><tr><td> CP %</td><td>18.14</td><td>18.13</td><td>18.12</td><td>18.14</td></tr><tr><td> Lysine %</td><td>0.96</td><td>0.96</td><td>0.96</td><td>0.96</td></tr><tr><td> Methionine %</td><td>0.32</td><td>0.32</td><td>0.32</td><td>0.32</td></tr><tr><td> Calcium %</td><td>0.80</td><td>0.80</td><td>0.80</td><td>0.80</td></tr><tr><td> Av. (P)</td><td>0.35</td><td>0.35</td><td>0.35</td><td>0.35</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.